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ABSTRACT
MhuD is a heme degrading enzyme found across mycobacteria. In the heme
uptake machinery of Mycobacterium Tuberculosis, MhuD is a heme oxygenase (HO)
involved in catalyzing the degradation of heme. Canonical HOs, such as human HO, have
been shown to degrade heme to non-heme iron, carbon monoxide (CO) and biliverdin.
However, MhuD has been demonstrated to degrade heme to non-heme iron and
mycobilin without the release of CO. Formation of a novel chromophore by MhuD
revealed that it follows a unique heme degradation mechanism compared to that of
canonical HOs. Binding of heme to MhuD is the first step in the degradation process and
previous studies have reported the binding affinity of heme to MhuD to be micromolar.
This would mean that MhuD may be an inefficient HO in vivo, especially at the recently
measured cytosolic labile heme concentration of 20-40 nM. Therefore, heme binding to
MhuD was re-investigated using fluorescence spectroscopy. Based on a recently
developed fluorescence-based assay, the Kd1 for heme-bound MhuD (MhuD—heme) was
determined to be 7.6 ± 0.8 nM. In addition, a UV/Vis absorption-based assay was
developed to measure the Kd2 for heme dissociation from diheme-bound MhuD (MhuD—
diheme), which was determined to be 3.3 ± 1.1 M. These data strongly suggest that
MhuD is a competent heme oxygenase in vivo.
Next, heme degradation by MhuD was investigated, which is shown to proceed
via formation of a meso-hydroxyheme intermediate. Time-resolved and tandem mass
spectrometry (MS) identified formation of both mycobilin (major product) and biliverdin
(minor product) by wild type (WT) MhuD. This interesting discovery warranted further
investigation. Heme bound to the MhuD active site undergoes a dynamic distortion
between two substrate conformations. Thus, we hypothesized that the conformation of
heme may be responsible for the product identity, and that both heme conformations may
be required for an efficient enzymatic activity of MhuD. To test these hypothesis,
different variants of MhuD were investigated. F23W MhuD has been shown to stabilize
more ruffled heme and W66F MhuD has been shown to stabilize less ruffled heme than
WT. MS studies of these variants identified mycobilin and biliverdin as the major
products for F23W and W66F MhuD, respectively. Thus, suggesting that the heme
confirmation plays a role in product identity. Also, the biliverdin formation by WT and
F23W MhuD lacked regioselectivity, which suggests that its formation proceeds via a
non-enzymatic pathway. In addition, UV/Vis study identified meso-hydroxyheme
intermediate for the heme degradation by F23W MhuD. Kinetic analysis of the reaction
catalyzed by F23W MhuD revealed that the meso-hydroxyheme dioxygenation rate is
considerably slower for this variant. In summary, these data strongly suggest that heme
degradation product of MhuD depends upon the degree of heme ruffling induced by the
active site and that dynamic heme is essential for MhuD.
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CHAPTER 1: HEME DEGRADATION CATABOLIZED BY MYCOBACTERIUM
TUBERCULOSIS MHUD
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1.1 GLOBAL TUBERCULOSIS IMPACT
Tuberculosis (TB) is one of the deadliest and most infectious diseases, which is
caused by an airborne pathogen called Mycobacterium Tuberculosis. In 2019, WHO
estimated that around 10 million people were infected with TB that resulted in about 1.2
million deaths worldwide.1 TB is the leading killer of people positive with HIV due to the
compromised immune system, and has a higher death rate compared to HIV negative
patients. In addition, drug-resistant TB is a serious public health threat. WHO reported
that in 2018, there were about half a million cases of rifampicin-resistant tuberculosis, of
which 78% were multidrug-resistant TB. Therefore, with the emergence of the drugresistant TB, the need to develop novel anti-TB therapeutics is critical.
1.2 IRON ACQUITISION PATHWAY OF MYCOBACTERIUM
TUBERCULOSIS
Iron is an essential nutrient that is utilized by M. tuberculosis (Mtb) for growth
and survival. Iron in the human body is found in the heme or nonheme (will be called just
“iron” hereafter) form.2, 3 The majority of the iron is in the ferric form and complexed
with transferrin and lactoferrin. The two siderophores; mycobactin and
carboxymycobactin are proposed to be involved in the iron uptake pathway of Mtb2, 4 by
scavenging iron from transferrin and lactoferrin. Mycobactin is insoluble in water and
thus is tethered to the Mtb outer membrane and the cell-wall environments. On the other
hand, carboxymycobactins are relatively soluble, thus, are involved in scavenging iron
from transferrin and lactoferrin. Also, they are imported into the Mtb cytoplasm by
IrtA/IrtB protein, where the iron in ferric carboxymycobactin is reduced and then
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released.3, 5 However, the most abundant form of iron in the human body is heme, and it
is mostly bound to hemoglobin. Thus, Mtb also contains a heme uptake pathway.6
1.3 HEME ACQUITISION PATHWAY OF MYCOBACTERIUM
TUBERCULOSIS
Several proteins have been identified for the acquisition of heme into the Mtb
cytosol. Rv0203 was identified and was proposed to be an extracellular heme binding

Figure 1. 1. Mtb heme uptake pathway. Two pathways involved in heme uptake are
colored orange and light orange. In the first pathway, Rv0203, MmPL3 and MmPL11 and
MhuD are identified to be involved in transport and degradation of heme. In the second
pathway, so far PPE36, PPE62 and FecB2 are proposed to be involved in binding and
shuttling heme through Mtb periplasm. Figure taken from reference 6.
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protein.7 The relatively weak ability of Rv0203 to bind heme8 suggested that another
unknown protein may be involved in stealing heme from hemoglobin through proteinprotein interaction. Thus, it was proposed that Rv0203 binds free heme and shuttles it
through the outer membrane to the inner membrane MmpL (mycobacteriual membrane
protein large) proteins: MmpL3 and MmpL11 (Figure 1.1).9 However, MmpL3 has been
shown to act as a flippase for mycolics acids10 and also to export tryhalose
monomycolate11, and MmpL11 has been shown to export lipids.12 Therefore, these
studies suggest MmpL3 and MmpL11 may have other roles beside transporting heme into
the cytosol. Mycobacterium heme utilization Degrader (MhuD) is the final enzyme
involved in the heme update pathway of Mtb, and it is involved in degradation of heme to
release iron (Figure 1.1).
Anti-TB drugs can be developed targeting these enzymes along the heme updake
pathway using a Trojan horse strategy. Previous study using Gallium Protoporphyrin IX
demonstrated that it was toxic against M. smegmatis.13 A study performed using Tin
Protoporphyrin IX (SnPPIX) showed that it inhibited human HO-1 and significantly
reduced bacterial load in Mtb infected mice when treated in combination with the anti-TB
medicine. However, the SnPPIX failed to inhibit MhuD or the Mtb growth in vitro.14 This
may seem like a viable strategy, but the problem with this is that all human and bacterial
heme dependent enzymes may incorporate the mismetallated heme, thereby inactivating
these enzymes in vivo. For MhuD, a potential inhibitor does not exist yet, but the
inhibitor needs to be selective enough to bind and disrupt the activity of MhuD and not of
human HO. Also, MhuD is an important enzyme that is found across mycobacteria,
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which means that development of a potential MhuD inhibitor may be utilized for other
nontuberculous mycobacteria as well.
1.4 HEME DEGRADATION MECHANISM
For developing a potential selective inhibitor, detailed understanding regarding
heme binding and its degradation by MhuD is essential. An original study has
demonstrated that MhuD binds heme with a micromolar affinity.20 This is in contrast with
the binding affinity calculated for other heme oxygenases,15-17 which are nanomolar. In
addition, cytosolic labile heme pool was determined to be 20-40 nM.18, 19 Based on these
data, it calls into question whether MhuD would be an efficient HO in vivo. An
interesting aspect of MhuD is that it can bind two hemes in its active site.20 However,
binding the second heme inactivates the enzyme itself.
Following heme binding, the next step in the heme acquisition process in MhuDmediated heme degradation. The canonical HO enzymes present in the bacterial
pathogens and in mammals have a very similar overall -helical structural fold.21-23 In the
active site of canonical HO, the heme is sandwiched in between proximal and distal
helices.24 The heme in the active site of these enzymes are coordinated through a
histidine residue on the proximal side and is observed to be in planar conformation. A
conserved and ordered water network is also present on the distal side of the heme
(Figure 1.2). In contrast, the non-canonical HOs, such as Staphylococcus aureus
IsdG/IsdI and Mycobacterium tuberculosis MhuD share high sequence and structural
homology with each other, however, they are quite distinct compared to canonical HOs.
The non-canonical HOs are homodimers that have ferredoxin like + fold, which form
a -barrel in between the homodimer.23, 25, 26 The heme in the active site makes
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interactions with various hydrophobic amino acids. Similar to HO, the heme is
coordinated through a histidine residue on the proximal side, however due to the presence
of hydrophobic amino acid residues, it lacks water network on the distal side.25, 26 The
heme in the active site of these enzymes features out-of-plane distortions, and the most
prominent distortion is ruffling. The degree of heme ruffling observed for IsdI, IsdG and
MhuD is 1.9, 2.3 and 1.4 Å, respectively.25, 27
The non-canonical HOs, such as Staphylococcus Aureus IsdG and
Mycobacterium tuberculosis MhuD, degrade heme to non-biliverdin products. IsdGmediated heme degradation releases iron and formaldehyde towards formation of
staphylobilin (Figure 1.2, bottom).28-30 While MhuD-mediated heme degradation releases
iron and mycobilin, where the meso-carbon is retained as an aldehyde group at the meso position (Figure 1.2, middle).31, 32 This is distinct from canonical HOs, which
degrade heme to biliverdin, by releasing iron and carbon monoxide (CO) (Figure 1.2,
top).33 This means that MhuD and IsdG carryout heme degradation through distinct
mechanistic pathways from canonical HOs. Therefore, detailed understanding of the
mechanistic steps towards formation of mycobilin by MhuD is essential.
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Figure 1. 2. HO degrades heme to for biliverdin by releasing iron and CO (top). MhuD
degrades heme to generate mycobilin, with the release of iron (middle). Staphylobilin is
generated, with the release of iron and formaldehyde during heme degradation by IsdG
(bottom).
A previous biochemical study investigating heme degradation by MhuD has
identified intermediates along the pathway.32 Initial monooxygenation during heme
degradation by MhuD occurs at the -meso-carbon to produce -meso–hydroxyheme
intermediate (Figure 1.2, middle). The Electron Paramagnetic Resonance (EPR) study of
the -meso–hydroxyheme bound to MhuD showed a radical species, probably due to its
ferrous neutral radical form. On the other hand, the regiochemistry of the initial
monooxygenation step is distinct in MhuD vs canonical HOs. The canonical HOs
degrade heme to biliverdin through an -meso–hydroxyheme intermediate (Figure 1.2,
top).34 A QM/MM study suggested that the ordered hydrogen bonding network present in
canonical HOs is responsible for guiding the transient HO radical to attack the -mesocarbon to produce an -meso–hydroxyheme intermediate.35 However, this water network
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is absent in the non-canonical HOs,27 such as MhuD.25 Thus, the initial monooxygenation
may proceed via a different mechanism. Next, the conversion of -meso–hydroxyheme
proceeds via dioxygenation and cleavage at -meso-carbon position and has been
proposed to proceed via a dioxetane intermediate (Figure 1.2, middle).32
Previous studies have suggested that dynamic ruffling of heme, which is absent in
canonical HOs, may be essential in conversion of heme to mycobilin by MhuD. As
mentioned above, the heme substrate is relatively planar for canonical HO; however, the
active site of non-canonical HOs induces an out-of-plane ruffling deformation of the
heme substrate. A spectroscopic study of MhuD, suggested that the heme substrate in
MhuD has a 2B2g ground state (ruffled) with a (dxz,dyz)4 (dxy)1 electronic configuration and
a thermally accessible 2Eg excited state (planar) with a (dxy)2 (dxz,dyz)3 electronic
configuration.25 A computational study predicted a double well potential along the heme
ruffling coordinate, which suggested that heme in MhuD can interchange between ruffled
and planar conformations.36 The ruffled heme conformation has been shown to place spin
density onto the meso carbons, which may direct a regiospecific attack on the meso
carbons for the conversion of heme to meso-hydroxyheme.37, 38 Indeed, the ruffling of
heme has been proposed to modulate the reactivity by changing the electronic
configuration of MhuD-meso-hydroxyheme complex, thus leading to CO suppressed
mechanism to produce mycobilin.29
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Crystallographic study has shown that the heme is ruffled for MhuD, and various
amino acids make several interactions with heme in its active site (Figure 1.3). Secondsphere amino acid residues Phe23 and Trp66 makes hydrophobic interaction with the
heme in the active site of MhuD (Figure 1.3). Site-directed mutagenesis study on Phe23
and Trp66 residue has shown that the heme ruffling deformation can be controlled by
altering the steric interaction of the residues at 23 and 66 position.36, 39 Increasing the
steric bulk of Phe23 to Trp resulted in increased heme ruffling compared to WT. On the
other hand, decreasing the steric bulk of Trp66 to Phe resulted in decreased heme ruffling
than WT. In addition, these substitutions also led to decreased enzymatic activity by

Figure 1. 3. Crystal structure of MhuD−heme−CN ( PDB ID 4NL5) showing active site
amino acid residue along with the heme substrate. Trp66 and Phe23 makes hydrophobic
interaction with heme. Asn7 is hydrogen bonded to the distal cyanide ligand, and Arg26
makes salt bridge interaction with propionate group of heme.
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MhuD. Moreover, Asn7 has a hydrogen bonding interaction with the distal cyanide (CN)
ligand, while Arg26 makes a salt bridge interaction with the propionate group (Figure
1.3). A study probing the role of Arg26 demonstrated that disrupting the salt-bridge
interaction through the mutation of Arg26 to Ser changed the product identity of heme
degradation from mycobilin to biliverdin.40
Various studies on MhuD have answered several questions regarding its
electronic structure, role of second-sphere amino acids on heme distortion and its
degradation, the presence of intermediates on the heme degradation mechanism, etc.
However, there are various questions that are still untested experimentally. First, the
ability of MhuD to be a competent HO in vivo is in question due to its weaker affinity
towards heme. Moreover, the MhuD has an ability to incorporate a dynamic heme in its
active site, which may be essential for its activity. Also, R26S MhuD has been
demonstrated to degrade heme to biliverdin, however a small amount of mycobilin was
also observed.40 Thus, it is possible that the presence of two different conformations of
heme in the active site of MhuD may lead to different products. These questions and
hypotheses will be explored in this dissertation. Initially, the binding affinity of MhuD to
heme and diheme will be reinvestigated. Next, the heme degradation mechanism by R26S
MhuD will be investigated utilizing various spectroscopic techniques to elucidate the
electronic structure of heme bound R26S MhuD. Also, kinetic studies will be performed
to elucidate the role of dynamic heme for the enzymatic activity of MhuD. Finally,
biochemical studies will be performed to assess the role of heme conformation on
product formation by MhuD.
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1.5 EXPERIMENTAL APPROACHES TO STUDY MHUD
A fluorescence assay had been developed previously to measure the heme
dissociation constant.17 Fluorescence spectroscopy takes advantage of intrinsic
fluorescence of tryptophan, which will be quenched with the addition of heme substrate
through Förster resonance energy transfer (FRET). MhuD has a Trp66 residue in the
active site within 4 Å of the heme substrate (Figure 1.3, PDB ID 4NL5).25 Thus, the
fluorescence assay developed for heme-bound S. aureus IsdG and IsdI can be used for
MhuD. The fluorescence spectroscopy is sensitive enough to work with proteins at
nanomolar concentrations, and thus the change in fluorescence intensity upon heme
addition can be quantified to extract the dissociation constant of first heme binding to
MhuD (Kd1). An interesting thing about MhuD is it can bind second heme in its active
site and will be investigated. Abs spectroscopy has been utilized previously to study
heme binding.16 The Abs spectra of heme, heme-bound and diheme-bound MhuD are
distinct. The different spectral feature of these species in solution can be utilized to study
the binding of second heme to the active site of MhuD. Titration of heme to the apo
protein can be monitored using Abs spectroscopy and the distinct spectral features of free
heme, heme-bound and diheme-bound MhuD can be quantified to extract the binding
constant for MhuD–diheme. Since, the binding constant for the first heme to MhuD can
be extracted using fluorescence spectroscopy, this value can be used as a constant to
extract the second dissociation constant (Kd2). However, Abs spectroscopy hasn’t been
previously utilized to study the binding of two heme substrates. Therefore, a new fitting
model will be developed to study the second binding event.
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Abs spectroscopy has been previously used to probe the electronic structure and
to subsequently determine the ruffling of the heme macrocycle compared to WT MhuD.39
The Abs spectra observed in porphyrins has been explained through Gouterman’s four
orbital (Figure 1.4a).41, 42 The Abs spectra arises from the  → * transition from the two
highest occupied molecular orbitals (HOMOs); a1u and a2u to the two lowest unoccupied
molecular orbitals (LUMOs); degenerate eg*. Transitions between these orbitals give rise
to two excited states, both with 1Eu character. Orbital mixing between the excited states
splits these states through configuration interaction, giving rise to a higher energy Soret
band and a lower energy Q-band (Figure 1.4b). Heme ruffling has been shown to alter the
energy gap between the filled a1u/a2u orbitals and the unoccupied eg* orbitals. A DFT
study has demonstrated that Q-band energy remains unchanged up to1.0 Å heme ruffling,
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Figure 1. 4. Gouterman’s four orbitals involved in the Abs spectra of a porphyrin (a) and
energy levels responsible for electronic transitions in the porphyrin system (b). Figure
taken from reference 38.43
however, the Abs spectra then red shifts with distortion above 1.0 Å. Similarly, the Soret
band energy is blue shifted up to 1.0 Å ruffling, then red-shifts from 1.0 – 2.3 Å.39 The
change in heme ruffling due to second-sphere amino acid substitution has been studied in
the past.36, 39, 44 Therefore, ruffling distortion of heme substrate due to Arg26 mutation to
Ser for MhuD and Phe23 mutation to Trp for IsdG will be investigated using Abs
spectroscopy.
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Magnetic Circular Dichroism (MCD) spectroscopy can be utilized to probe the
electronic structure changes caused by the second-sphere amino acid substitutions in the
heme bound enzyme.45 MCD measures the difference between the absorption of left- and
right-circularly polarized light. The MCD spectrum is taken as a function of the
wavelength in the presence of a magnetic field that is applied parallel to the direction of
propagation of the light beam. The MCD spectrum arises from the transition from a
ground to an excited state and depends on three Faraday terms: A, B and C-term. An Aterm arises from a transition from a non-degenerate ground state to orbitally degenerate
excited state. The degeneracy of the excited state is split in the presence of a magnetic
field due to Zeeman effect. Therefore, the transition would be temperature-independent,
and the spectrum would be a derivative shaped (Figure 1.5). The B-term arises from the
field-induced mixing between different states. The resulting MCD spectrum is
absorption-shaped and is temperature-independent. The C-term contribution to the MCD
spectrum arises due to the transition from the degenerate ground state to the nondegenerate excited state. Thus, resulting in absorption-shaped temperature-dependent
MCD spectrum (Figure 1.5).46 Optical transitions such as d→d charge transfer, metal to
ligand charge transfer and vice-versa, can be observed for a low spin ferric heme with an
unpaired electron in its ground state. The states arising from these configurations can mix
through spin-orbit coupling and give rise to temperature dependent C-terms, which
dominate the MCD spectra of heme proteins.
Variable field variable temperature (VTVH) MCD spectra can reveal information
regarding ground electronic state of paramagnetic systems. The Soret band is dominated
by the C-term, which at a fixed temperature increases linearly in the presence of low
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Figure 1. 5. A- and C-term MCD spectra origin. A-term arises from transition from nondegenerate ground state to degenerate excited state, whereas C-term arises from a
transition from degenerate ground state to non-degenerate excited state. In the presence
of a magnetic field, the degeneracy is lifted due to Zeeman Splitting. Adapted from
reference 42.47
field. However, at higher fields, the intensity starts to saturate due to Zeeman splitting, as
the lowest electronic state is populated due to Boltzmann distribution. In hemoproteins,
the Soret-Band is dominated by xy-polarized transitions, which means that the initial
slope of the saturation magnetization curves depends on the gz value. This will help
provide insights into the ground electronic state. Therefore, the change in the ground
electronic state due to second-sphere substitution can be probed using VTVH MCD.
Nuclear magnetic resonance (NMR) spectroscopy has been utilized for a low spin
ferric heme system to determine the ground electronic configuration. Generally, 1H NMR
spectra of a diamagnetic sample are observed from 0 – 10 ppm. However, in the
presence of an unpaired electron, these chemical shifts are hyperfine shifted either upfield
or downfield. Two electronic structures are possible for low spin ferric heme: (dxy)2 (dxz,
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dyz)3 and (dxz, dyz)4 (dxy)1. When the unpaired electron is in the dxy orbital, the mesoprotons will experience spin polarization through meso carbons and shift upfield. On the
other hand, when the unpaired electron is in the dxz or dyz orbital the spin density is
delocalized onto the pyrrole rings and spin polarization is experienced by the methyl
protons resuling in a downfield shift. Previous 1H NMR studies have determined the
ground state as (dxy)2 (dxz, dyz)3 for HO-heme-CN,48-50 and as (dxz, dyz)4 (dxy)1 for IsdGheme-CN51 and MhuD-heme-CN.25 1H NMR spectroscopy was also utilized to
investigate the change in ground electronic structure induced by the second-sphere amino
acid substitution in MhuD.36, 39 A Curie plot of the hyperfine-shifted resonances as an
inverse function of temperature can be plotted to investigate their linear dependence.52
Linear dependence would mean a Curie behavior, and would suggest presence of single
electronic state. However, non-linear dependence would mean a non-Curie behavior, and
would suggest presence of thermally accessible excited state. Therefore, 1H NMR
spectroscopy can be utilized to gain insights onto the ground electronic state and its
change induced by second-sphere amino acid substitution.
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CHAPTER 2: THE AFFINITY OF MHUD FOR HEME IS CONSISTENT WITH A
HEME DEGRADING FUNCTION IN VIVO.

Material in this dissertation chapter is an adaptation of the Metallomics manuscript
shown below:
Thakuri, B.; Graves, A. B.; Chao, A.; Johansen, S. L.; Goulding, C. W.; Liptak, M. D.,
The affinity of MhuD for heme is consistent with a heme degrading function in vivo.
Metallomics 2018, 10 (11), 1560-1563
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2.1 INTRODUCTION
Mycobacterial infections are responsible for a range of human diseases, including
two ancient ones: tuberculosis (Mycobacterium tuberculosis infection)1 and leprosy
(Mycobacterium leprae infection).2 This genus has a unique heme acquisition pathway
that is at least partially responsible for supplying a critical nutrient during infection by
harvesting iron from hemoglobin and perhaps other host heme-containing proteins.3, 4
Since bacteria require micromolar iron for growth,5 and the proteins of this pathway are
unique to mycobacteria, the proteins of the mycobacterial heme acquisition system are
promising drug targets.6, 7 Currently, this heme iron acquisition pathway is thought to
begin with Rv0203, a secreted heme binding protein that could transport extracellular
heme to the mycobacterial cell surface.8 Next, heme is transferred from Rv0203 to the
periplasmic domains of inner membrane proteins MmpL3 or MmpL11.9 Finally, heme is
degraded to non-heme iron and mycobilin by cytosolic MhuD.10-12 However, the precise
mechanism of mycobacterial heme acquisition and the identities of the protein
components are still poorly understood.
MhuD is a non-canonical heme oxygenase that is functionally distinct from both
eukaryotic heme oxygenases and IsdG heme oxygenases.13-15 This enzyme catalyzes the
monooxygenation of heme to meso-hydroxyheme, followed by dioxygenation of this
intermediate to the mycobilin product.11, 16 Detailed crystallographic and spectroscopic
characterization, coupled with computational modeling, have revealed that an out-ofplane ruffling distortion of the heme substrate is critical for the monooxygenation
reaction.17, 18 However, the dissociation constant for heme-bound MhuD (MhuD–heme)
has been reported to be in the micromolar range in the original study,10 which is
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inconsistent with the nanomolar values reported for four other heme oxygenases: HO-119,
HO-220, IsdG21 and IsdI.21 Furthermore, the reported heme dissociation constant for
MhuD–diheme is also micromolar,10 implying that there is only a narrow labile heme
concentration range where the enzymatically-active MhuD–heme species can be formed.
These observations call into question whether MhuD is a competent heme oxygenase in
vivo. In addition, two recent studies have established that the concentration of the
cytosolic labile heme pool in Homo sapiens and Saccharomyces cerevisiae is 20-40
nM,22, 23 and if the only source of heme for MhuD is this labile heme pool, the
micromolar heme affinity is insufficient as only 1% of MhuD would be heme loaded. A
recent reinvestigation of the heme dissociation constants for Staphylococcus aureus IsdG
and IsdI revealed that the previously reported values were two to three orders of
magnitude too large due to inherent sensitivity limitations of an assay that requires
micromolar protein samples.21 Thus, a reinvestigation of the MhuD–heme dissociation
constant previously measured in the original study using isothermal titration calorimetery
(ITC) and micromolar protein samples with a more sensitive spectroscopic technique is
warranted in order to determine whether MhuD is a competent heme oxygenase in vivo.
MhuD is unique among heme oxygenases in the fact that it can bind two heme
molecules per protein monomer. The X-ray crystal structure of diheme-bound MhuD
(MhuD–diheme, PDB ID 3HX9) revealed that the two hemes are stacked with nearly
parallel porphyrin planes (Figure 1.1).10 The MhuD–diheme form of the enzyme does not
degrade heme, which has led to speculation regarding the function of this species.
Initially, it was proposed that the MhuD–diheme form enables MhuD to function as a
heme storage protein, mitigating the toxicity of heme at high concentrations,24 and
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provide a heme reservoir under heme-deplete conditions. However, as noted above,
MhuD catalyzes a unique multi-step oxygenation of heme to mycobilin,11, 16 which
requires that MhuD has an active site distinct from other heme-dependent proteins (PDB
ID 4NL5).17 Thus, the MhuD–diheme form may be an in vitro artifact arising from the
combination of a unique active site and an excess of exogenous heme. For these reasons,
a reinvestigation of the dissociation constant for the second heme bound to MhuD–
diheme was also undertaken.

Figure 2. 1. MhuD is a non-canonical heme oxygenase found in mycobacteria (PDB IDs
3HX9 and 4NL5).10, 17 Heme-bound MhuD (MhuD–heme) is converted to iron and
mycobilin, but diheme-bound MhuD (MhuD–diheme) is enzymatically inactive.
Dissociation constants can be defined for dissociation of heme from MhuD–heme (Kd1)
and MhuD–diheme (Kd2).
This study reports dissociation constant measurements for heme dissociation from
MhuD–heme and MhuD–diheme based upon fluorescence and UV/Vis absorption (Abs)
spectroscopy-based assays. A previously described fluorescence assay was used to
measure the dissociation constant for MhuD–heme (Kd1),21 and an Abs assay was
developed to measure heme dissociation from MhuD–diheme (Kd2). Critical analyses of
the fits of these mathematical models to the experimental data suggested that the C-
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terminal His6 tag interferes with heme binding despite the fact that no interaction between
heme and the His6 tag was observed in the X-ray crystal structures of MhuD–heme (PDB
ID 4NL5) or MhuD–diheme (PDB ID 3HX9).10, 17 For this reason, a form of MhuD with
an enterokinase-cleavable N-terminal His6-tag was prepared. Fluorescence- and Absdetected titrations of heme into this form of MhuD were well fit by the mathematical
models yielding nanomolar and micromolar dissociation constants for MhuD–heme and
MhuD–diheme, respectively. The implications of these data for the biological functions
of MhuD–heme and MhuD–diheme are discussed.
2.2 EXPERIMENTAL
All materials were purchased from Fisher Scientific and used without further
purification unless otherwise noted. All water was obtained from a Synergy water
purification system (Millipore).
Cloning, Expression, and Purification. The cloning and expression of MhuD
(Rv3592) with a C-terminal His6 tag into pET-22b (Ampr, Novagen) has been previously
described.10 The MhuD gene was recloned into a pET30a vector to encode a protein with
an enterokinase cleavable N-terminal His6 tag, which results in encoded full-length
MhuD with an additional N-terminal Ala (MhuDCH). The M. tuberculosis MhuD gene
(Rv3592) was PCR amplified from the pET22a plasmid noted above using KOD-Hot
Start DNA Polymerase (Novagen) with primers (5’ – GGC CAT GGC CCC AGT GGT
GAA GAT CAA CGC AAT CGA GGT GCC CGC C – 3’) and (5’ – GGA AGC TTA
TTA TGC AGT CTT GCC GGT CCC ACC GAC GTC AAG CAC GAC – 3’)
containing the restriction sites NcoI and HindIII, respectively. The PCR product was gel
purified (Qiagen) and ligated into a linearized blunt vector, pCR-BluntII-TOPO
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(Invitrogen), and transformed into One-Shot TOP10 Escherichia coli cells (Invitrogen).
Restriction enzymes NcoI and HindIII were used to excise the MhuD insert from pCRBluntII-TOPO as well as cut the empty pET30a (Kanr) vector. The excised MhuD insert
and cut pET30a were ligated together using T4 DNA ligase (New England Biolabs). The
resulting DNA construct was verified by DNA sequencing (Retrogen).
Cells containing recombinant MhuD were lysed as described previously,17 and the
filtered supernatant was loaded onto a 5 mL Ni(II)-charged HiTrap chelating HP column
(GE Healthcare) equilibrated with 50 mM Tris pH 7.8, 350 mM NaCl using an ÄKTA
pure 25 L fast protein liquid chromatography (FPLC) system (GE Healthcare). The
column was washed with a 2 mM/mL linear gradient from 0 to 100 mM imidazole in 50
mM Tris pH 7.8, 350 mM NaCl at a flow rate of 5.0 mL/min. Pure MhuD eluted during a
subsequent 1.6 mM/mL linear gradient from 100 to 300 mM imidazole in 50 mM Tris pH
7.8, 350 mM NaCl at a flow rate of 5.0 mL/min (Figures A.1 - A.2). FPLC fractions
containing pure MhuD were pooled and the sample volume was reduced to 10 mL using
Amicon stirred cells with 10 kDa ultrafiltration membranes (Millipore). Following
overnight dialysis against 20 mM Tris pH 8.0, 50 mM NaCl, >99% pure MhuD was
obtained as assessed by SDS-PAGE gel electrophoresis (Figure A.3).
For recombinant expression of MhuDCH, the pET30a (Kanr) vector encoding
MhuDCH was transformed into BL21-GOLD (DE3) cells (Stratagene). DNA sequencing
at the Vermont Cancer Center DNA Analysis Facility confirmed the sequence of the
MhuDCH gene for all cell lines used at the University of Vermont (Table A.1). E. coli
cells containing pET30a were grown in Luria-Bertani medium containing 30 μg/μL
kanamycin at 37 °C using a MaxQ 5000 floor-model shaker (Thermo Scientific), and
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MhuDCH over-expression was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside
at an OD600 of 0.8 a.u. Cells were lysed in 50 mM Tris pH 7.8, 350 mM NaCl by
sonication following the addition of 2.5 mg lysozyme and 0.01 M phenylmethane
sulfonyl fluoride using a Branson S-450A Sonifier. The lysate was centrifuged at 15,000
x g for 45 mins using a Sorvall Legend XTR centrifuge (Thermo Scientific) and the
supernatant was filtered through a 0.45 μm membrane (Millipore). The filtered lysate was
loaded onto a 5 mL Ni(II)-charged HiTrap chelating HP column equilibrated with 50 mM
Tris pH 7.8, 350 mM NaCl using an ÄKTA pure 25 L FPLC system. The column was
washed with a 2.25 mM/mL linear gradient from 0 to 90 mM imidazole in 50 mM Tris
pH 7.8, 350 mM NaCl at a flow rate of 5.0 mL/min. Pure, uncleaved MhuDCH eluted
during a subsequent 1.48 mM/mL linear gradient from 90 to 275 mM imidazole in 50
mM Tris pH 7.8, 350 mM NaCl at a flow rate of 5.0 mL/min (Figures A.4 - A.5). FPLC
fractions containing pure, uncleaved MhuDCH were pooled and the sample volume was
reduced to 10 mL using Amicon stirred cells with 10 kDa ultrafiltration membranes.
Uncleaved MhuDCH was dialyzed overnight against 20 mM Tris pH 8.0, 50 mM NaCl, 2
mM CaCl2.
The His6 tag of MhuDCH was removed by adding enterokinase (New England
Biolabs) in a molar ratio of 1:250,000. The mixture was stirred for 36 h at 4 °C, then
loaded onto a 5 mL HiTrap Q HP column (GE Healthcare) equilibrated with 20 mM Tris
pH 8.0, 10 mM NaCl using an ÄKTA pure 25 L FPLC system. Pure, cleaved MhuDCH
eluted during a 1.0 mM/mL linear gradient from 50 to 250 mM NaCl in 20 mM Tris pH
8.0 at a flow rate of 5.0 mL/min (Figures A.6 - A.7). FPLC fractions containing pure,
cleaved MhuDCH were pooled and the sample volume was reduced to 2.5 mL using

29

Amicon stirred cells with 10 kDa ultrafiltration membranes. Following exchange into 50
mM Tris pH 7.4, 150 mM NaCl using a PD-10 desalting column (GE Healthcare), >95%
pure, cleaved MhuDCH was obtained as assessed by SDS-PAGE gel electrophoresis
(Figure A.8).
Electrospray ionization mass spectrometry (ESI-MS) was used to assess the
MhuDCH product. A 30 μM sample of cleaved MhuDCH in 50 mM Tris pH 7.4, 150 mM
NaCl was loaded onto a C18 guard column equilibrated with 2% acetonitrile with 0.1%
formic acid (v/v) in water (v/v) using a QTRAP 4000 LCMS/MS system (Sciex) with an
M/z from 600-2000. The column was washed using 2% acetonitrile with 0.1% formic
acid (v/v) in water (v/v) for 1 min at a flow rate of 100 μL/min. MhuDCH eluted during a
13.7%/min linear gradient from 2 to 98% acetonitrile with 0.1% formic acid (v/v) in
water (v/v) at a flow rate of 100 μL/min. The spectrum was deconvoluted using
BioAnalyst 1.5 software. The observed molecular weight of 11,327 Da was in perfect
agreement with the expected molecular weight of 11,327 Da (Figure A.9).
Spectroscopic characterization. The MhuD–heme extinction coefficient was
determined previously,17 and the extinction coefficients for MhuD–diheme, heme-bound
MhuDCH (MhuDCH–heme), and diheme-bound MhuDCH (MhuDCH–diheme) were
determined using a similar procedure. Samples of MhuD–diheme, MhuDCH–heme, and
MhuDCH–diheme were prepared in 50 mM Tris pH 7.4, 150 mM NaCl as described
previously,10 and their room temperature. Abs spectra were acquired from 900 to 200 nm
with a scan rate of 600 nm/min, a 1.0 nm data interval, and a 0.1 s integration time using
a Cary 100 Bio UV-Vis Spectrophotometer. The following extinction coefficients were
determined using the pyridine hemochrome assay:25 MhuD–diheme (ε410 = 165.3 mM30

1

cm-1), MhuDCH–heme (ε407 = 87.9 mM-1cm-1), and MhuDCH–diheme (ε395 = 162.3 mM-

1

cm-1).
Fluorescence-detected heme titrations into MhuD and MhuDCH were completed

by slightly modifying a previously described procedure.21 Briefly, 100 nM samples of
MhuD and MhuDCH, plus 17.5 μM heme solutions, were prepared in 50 mM Tris pH 7.4,
150 mM NaCl as previously described.17 Heme was titrated into MhuD and MhuDCH in
16 nM increments, and allowed to equilibrate for 5 min prior to fluorescence
characterization. Fluorescence emission spectra were acquired for 285 nm excitation
using a Photon Technology International QuantaMaster 4 spectrofluorometer equipped
with a Xenon arc lamp connected to an LPS-220b power supply, an ASOC-10 electronics
interface, an MD-4000 motor driver control, and a model 814 photomultiplier detection
system. Emission spectra were acquired in the 410 to 310 nm range with a step size of 1
nm, an integration time of 1 s, and slit widths of 3 nm.
Abs-detected titrations were carried out using similar protein samples. 5 μM
samples of MhuD and MhuDCH, and a 500 μM heme solution, were prepared in 50 mM
Tris pH 7.4, 150 mM NaCl as described before.17Heme was titrated into MhuD and
MhuDCH in 1 μM increments, and allowed to equilibrate until no further spectral changes
were observed. Abs spectra were acquired using the equipment and parameters described
above.
Spectral Analysis. The fluorescence-detected titrations of heme into MhuD and
MhuDCH were analyzed in order to determine Kd1 for MhuD and MhuDCH. The Trp66
fluorescence intensity for a mixture of MhuD, MhuD–heme, and heme depends upon
equation (2.1):
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𝐹
=

([𝑀ℎ𝑢𝐷𝑇 ] + [ℎ𝑒𝑚𝑒𝑇 ] + 𝐾𝑑1 ) − √([𝑀ℎ𝑢𝐷𝑇 ] + [ℎ𝑒𝑚𝑒𝑇 ] + 𝐾𝑑1 )2 − 4[𝑀ℎ𝑢𝐷𝑇 ][ℎ𝑒𝑚𝑒𝑇 ]
2

𝐹𝑚𝑖𝑛 − 𝐹𝑚𝑎𝑥
) + 𝐹𝑚𝑎𝑥
×(
[𝑀ℎ𝑢𝐷𝑇 ]
(2.1)
where [MhuDT] is the total MhuD concentration, [hemeT] is the total heme concentration,
Fmax is the fluorescence intensity in the absence of heme, and Fmin is the fluorescence
intensity for fully heme–bound MhuD. The emission intensity at 336 nm as a function of
[hemeT] was fit to equation (2.1) using GraphPad Prism 7.0 to determine Kd1 and its
standard error. The complete derivation of equation (2.1) has been reported previously for
Staphylococcus aureus IsdG,21 and a similar equation can be derived for MhuDCH.
The Abs-detected titrations were analyzed to extract Kd2 for MhuD and MhuDCH.
The Abs intensity at 410 nm for a mixture of MhuD, MhuD–diheme, MhuD–heme, and
heme depends upon equation (2.2):

𝐴410

𝜀𝑀ℎ𝑢𝐷−𝑑𝑖ℎ𝑒𝑚𝑒 [𝑀ℎ𝑢𝐷𝑇 ][ℎ𝑒𝑚𝑒]2 + 𝜀𝑀ℎ𝑢𝐷−ℎ𝑒𝑚𝑒 𝐾𝑑2 [𝑀ℎ𝑢𝐷𝑇 ][ℎ𝑒𝑚𝑒]
=
[ℎ𝑒𝑚𝑒]2 + 𝐾𝑑2 [ℎ𝑒𝑚𝑒] + 𝐾𝑑1 𝐾𝑑2
+

𝜀ℎ𝑒𝑚𝑒 ([ℎ𝑒𝑚𝑒]3 + 𝐾𝑑2 [ℎ𝑒𝑚𝑒]2 + 𝐾𝑑1 𝐾𝑑2 [ℎ𝑒𝑚𝑒])
[ℎ𝑒𝑚𝑒]2 + 𝐾𝑑2 [ℎ𝑒𝑚𝑒] + 𝐾𝑑1 𝐾𝑑2
(2.2)

where εMhuD–diheme, εMhuD–heme, and εheme are the molar extinction coefficients for MhuD–
diheme, MhuD–heme, and heme, respectively, at 410 nm. An equation for [heme] as a
function of only Kd1, Kd2, [MhuDT], and [hemeT] is derived in Appendix A. The Abs
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intensity at 410 nm as a function of [hemeT] was fit to equation (2.2) using Graph Pad
Prism 7.0 to determine Kd2 and its standard error. Kd1 was constrained to the value
determined above from analysis of the fluorescence-detected titrations. A similar
equation can be derived for MhuDCH. The complete derivation of equation (2.2) is
available in the Appendix A.
2.3 RESULTS
Heme binding to MhuD. Fluorescence spectroscopy was used to measure Kd1 for
heme dissociation from MhuD–heme. This was accomplished using an assay originally
developed for heme-bound S. aureus IsdG (IsdG–heme) and IsdI (IsdI–heme),21 which
can also be used for MhuD–heme because Trp66 is within 4 Å of the heme substrate
(PDB ID 4NL5).17 For MhuD, which can sequentially bind two heme substrates,10 the Kd
value extracted from this experiment will correspond to Kd1 because Trp66 fluorescence
will be fully quenched by Förster resonance energy transfer (FRET) to the first heme
molecule bound by the active site. The fluorescence-detected titrations of heme into 100
nM MhuD were fit to equation (2.1), yielding a Kd1 of 4.2 ± 1.4 nM (Figure 1.2). This
value is similar to those measured previously for IsdG–heme and IsdI–heme, but three
orders of magnitude lower than the ITC-based micromolar value previously reported for
MhuD–heme. However, it should be noted that the R2 value for this fit (0.908) is
significantly lower than those previously reported for IsdG–heme and IsdI–heme (0.960
and 0.955, respectively), suggesting an additional interaction between MhuD and heme is
not captured by our single-site binding model. Nevertheless, the fitted curve does pass
within the error bars of all experimental data points and, as a result, the MhuD
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fluorescence experiments suggest that the Kd value for MhuD–heme is in the low
nanomolar range.

Figure 2. 2. Fluorescence-detected titration of heme into 100 nM MhuD in 50 mM Tris
pH 7.4, 150 mM NaCl. The error bars represent the standard deviation of three
independent trials. The emission intensity was fit to equation (2.1) yielding a Kd1 of 4.2 ±
1.4 nM. Inset: Emission spectra with 0 (solid red), 4 (solid blue), and intermediate
(dashed gray) equivalents of heme.
Formation of MhuD–diheme. Following measurement of Kd1 for MhuD–heme
using fluorescence spectroscopy, Abs spectroscopy was used to measure Kd2 for MhuD–
diheme. Abs-detected titrations of heme into 5 μM MhuD were monitored at 410 nm and
fit to equation (2.2), which has been derived here as an analytical expression for
sequential binding of two substrates to a single protein. As the Kd1 for MhuD–heme
measured at 100 nM is expected to be more accurate than any value measured at 5 μM,
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Kd1 was held constant at its fluorescence-measured value when fitting the Abs-detected
heme titration into equation (2.2). These fits yielded a Kd2 of 4.4 ± 7.2 nM (Figure 2.3).
As was the case for the Kd1 measured here for MhuD–heme, the Kd2 measured for MhuD–

Figure 2. 3. Abs-detected heme titration into 5 μM MhuD in 50 mM Tris pH 7.4, 150
mM NaCl. The spectra represent MhuD with 0 (solid blue), 3 (solid red), and
intermediate (dashed gray) equivalents of heme. Inset: The error bars represent the
standard deviation of three independent trials. The Abs-detected heme titration was fit to
equation (2.2) yielding a Kd2 of 4.4 ± 7.2 nM.
diheme is significantly lower than that previously measured using ITC.10 But, careful
inspection of the fit to equation (2.2) reveals that the best fit line falls outside the
experimental error bars for several data points. Furthermore, the Soret band initially blueshifts by 6 nm to 401 nm upon addition of up to two equivalents of heme, then red-shifts
to 410 nm upon addition of a third equivalent of heme (Table A.2). As was the case for
the fluorescence-detected heme titration (Figure 2.2), these data suggest that there is an
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additional interaction between MhuD and heme that is not captured by our binding
models. These issues with the extraction of Kd1 and Kd2 values from analyses of heme
titrations into MhuD motivated preparation of a His6 tag-free version of MhuD.
Heme binding to MhuDCH. A His6 tag-free version of MhuD (MhuDCH) was
prepared and the Kd1 for heme dissociation from MhuDCH–heme was measured using
fluorescence spectroscopy. A tag-free version of M. tuberculosis MhuD was obtained
from E. coli by designing a recombinant gene for MhuD with an enterokinase cleavable
N-terminal His6 tag. A fluorescence experiment similar to that described above for
MhuD–heme was used to determine Kd1 for heme dissociation from MhuDCH–heme.
Analysis of these data resulted in a Kd1 of 7.6 ± 0.8 nM with an R2 of 0.985 (Figure 2.4).
Thus, the Kd1 values for heme dissociation from MhuD–heme and MhuDCH–heme are
similar, suggesting that the His6 tag of MhuD minimally interferes with formation of the
MhuD–heme complex. As noted above for MhuD–heme, the Kd1 for MhuDCH–heme is
three orders of magnitude lower than the value previously reported for this complex
based upon ITC,10 but similar to those previously reported two other non-canonical heme
oxygenases.21 Nevertheless, since there has been an issue in the literature with the
accuracy of Kd values extracted from heme titrations into heme oxygenases,21, 26 the
accuracy of the fit was further assessed.
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Figure 2. 4. Fluorescence-detected titration of heme into 100 nM MhuDCH in 50 mM Tris
pH 7.4, 150 mM NaCl. The error bars represent the standard deviation of three
independent trials. The emission intensity was fit to equation (1) yielding a Kd1 of 7.6 ±
0.8 nM. Inset: Emission spectra with 0 (solid red), 4 (solid blue), and intermediate
(dashed gray) equivalents of heme.
In order to assess the goodness of fit, simulated titration curves for Kd1 values one
order of magnitude smaller and larger than the best fit were compared to the experimental
data for MhuDCH–heme (Figure 2.5). Decreasing the Kd1 value from the best fit of 7.6 nM
to 0.76 nM lowered R2 from 0.985 to 0.911 and resulted in a simulated titration curve
that misses the error bars for six data points. Increasing Kd1 to 76 nM decreased R2 to
0.398 and produced a simulated curve that missed all but one of the experimental error
bars. Thus, these data indicate that the nanomolar value measured here for Kd1 is
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Figure 2. 5. Best fit of the fluorescence-detected heme titrations for MhuDCH using
equation (2.1) (solid blue). The error bars represent the standard deviation of three
independent trials. Titration curves simulated using equation (1) and Kd1 values one order
of magnitude larger (dashed red) or smaller (dashed green) than the best fit, are
inconsistent with experiment.
accurate, and the micromolar value measured previously is actually an upper limit due to
the micromolar protein concentration required for ITC.10 Based upon the data presented
in this manuscript, and that reported previously for IsdG–heme and IsdI–heme,21 it is
reasonable to conclude that the Kd for heme dissocation from non-canonical heme
oxygenases is nanomolar.
Formation of MhuDCH–diheme. The Kd2 value for heme dissocation from
MhuD–diheme was also reinvestigated for a form of MhuD without a His6 tag (MhuDCH).
As was the case for MhuD–diheme, Kd2 for heme dissociation from MhuDCH–diheme
was extracted from an Abs-detected heme titration monitored at 395 nm. Unlike the case
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for the Abs-detected titration of heme into MhuD (Figure 2.6), the Soret band steadily
blue-shifts from 408 nm to 394 nm upon addition of up to three equivalents of heme
(Figure 2.6, Table A.3). Since no interaction between the His6 tag and the active site of
MhuD was observed in the X-ray crystal structure of this species (PDB ID: 3HX9),10

Figure 2. 6. Abs-detected titration of heme into 5 μM MhuDCH in 50 mM Tris pH 7.4,
150 mM NaCl. The spectra represent MhuDCH with 0 (solid blue), 3 (solid red), and
intermediate (dashed gray) equivalents of heme. Inset: The error bars represent the
standard deviation of three independent trials. The Abs-detected heme titration was fit to
equation (2.2) yielding a Kd2 of 3.3 ± 1.1 μM.
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Figure 2. 7. Best fit of the Abs-detected heme titrations for MhuDCH using equation (2.2)
(solid blue). The error bars represent the standard deviation of three independent trials.
Titration curves simulated using equation (2.2) and Kd2 values one order of magnitude
larger (dashed red) or smaller (dashed green) than the best fit are inconsistent with
experiment.
this band shift may be derived from loss of a weak interaction between the His6 tag and
labile heme. Analysis of the heme titration data following the methodology outlined
above for MhuD–diheme resulted in a Kd2 of 3.3 ± 1.1 μM for MhuDCH–diheme. This
value is three orders of magnitude higher than that reported here for MhuD–heme, but
similar to the 5.0 ± 0.8 μM value reported previously based upon ITC. The discrepancies
between the two Kd2 values reported in this work, and the one reported in the literature,
motivated a careful assessment of the accuracy of the values reported here.
Similar to the strategy described above to assess the accuracy of the fluorescence
analysis, the Abs data was compared to simulated titration curves for Kd2 values one
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order of magnitude smaller and larger than the best fit (Figure 2.7). The R2 value for the
fit decreased from 0.985 to 0.975 and 0.969 when titration curves were simulated for Kd2
values of 0.33 and 33 μM, respectively. Furthermore, the best fit titration curve passes
through all experimental error bars for MhuDCH–diheme, whereas the fits for Kd2 values
one order of magnitude smaller or larger than the best fit do not. In addition, it is worth
restating that the best fit curve for heme dissociation from MhuD–diheme also does not
fall within all experimental error bars (Figure 2.3). These analyses strongly suggest that
the Kd2 value reported here for MhuDCH–diheme is accurate, and the His6 tag interferes
with measurement of this value. The fact that the Kd2 value reported previously for
MhuD–diheme based upon ITC is consistent with the accurate Kd2 value reported here for
MhuDCH–diheme suggests that the interaction between the His6 tag and the heme
substrate has a minimal impact on the thermodynamics of heme binding. In summary, the
data presented here indicate that Kd1 for heme dissociation from MhuDCH–heme is 7.6 ±
0.8 nM and Kd2 for heme dissociation from MhuDCH–diheme is 3.3 ± 1.1 μM.

2.4 DISCUSSION
Accuracy of the Kd1 value. The data presented here strongly suggest that MhuD
is a competent heme oxygenase in vivo with a nanomolar binding affinity to heme. This is
however, three orders of magnitude lower than the reported value in both the original
study using ITC,10 and a recent study using MS.27 Similar to the original study,10 a recent
MS study also employed micromolar protein concentration to extract the binding
constant. The issue with this is that when nanomolar dissociation constant is measured
using micromolar protein concentration, it becomes very hard to extract an accurate
dissociation constant, as most of the heme would be bound to protein prior to
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measurements. Based on the published literature, the concentration of the cytosolic labile
heme in Saccharomyces cerevisiae and humans is in nanomolar range (20-40 nM).22, 23 In
addition, the Kd1 value extracted in our study is consistent with those reported in the
literature for the heme bound heme oxygenases.19-21 Moreover, a recent study has
reported the Kd1 of heme binding to MhuD to be in nanomolar range.28 Similarly, the
statistical analysis of the fitting curve shown above for heme binding to MhuD (Figure
2.5) demonstrated that the fitting got worse even with an order of magnitude higher value
of the fitted Kd1. Therefore, these observations strongly suggest that the Kd1 for heme
binding to MhuD is nanomolar and accurate.
Expected in vivo functions of MhuD. The relevance of the Kd values can perhaps
be best understood by considering several scenarios. At sub-nanomolar concentrations of
labile heme, the measured Kd values imply that MhuD–heme and MhuD–diheme
complexes are not stable and will dissociate prior to enzymatic turnover (Figure 2.8),
which means that any excess heme biosynthesis or acquisition relative to heme protein
loading will increase the labile heme concentration.2, 3, 29 Once nanomolar concentrations
of labile heme are reached, a stable MhuD–heme complex will be formed resulting in
heme degradation and a reduction of the heme concentration by one molecule per
turnover.10 In a sense, this means that MhuD can buffer the labile heme concentration at
a nanomolar level within M. tuberculosis. As mentioned earlier, two recent studies have
established that the concentration of the cytosolic labile heme pool in Homo sapiens and
Saccharomyces cerevisiae is 20–40 nM,22, 23 and notably in human IMR90 lung
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fibroblasts and HEK293 cells the labile heme pool is 400–600 nM,30 so a nanomolar
concentration of labile heme within M. tuberculosis is conceivable implying that MhuD–

Figure 2. 8. Fractionation of MhuD as a fuction of heme concentration. The curves
represent the fraction of MhuD (dotted blue), MhuD–heme (dashed red), and MhuD–
diheme (solid green) present for heme concentrations between 1 nM and 100 M. Under
typical conditions, the primary form of MhuD is MhuD-heme, but significant amounts of
MhuD-diheme can be formed under heme replete conditions.
heme is a competent heme oxygenase in vivo. Despite the buffering capability of MhuD,
it is conceivable that the labile heme concentration within M. tuberculosis could increase
to micromolar levels if an inadequate amount of MhuD is present to buffer heme and/or if
there is a high flux of heme into the organism via the heme acquisition system resulting
in formation of a stable MhuD–diheme complex.
The biological function of MhuD–diheme is currently unknown, but here we
speculate that MhuD may have a secondary function in its diheme form as a heme storage
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or heme sensor/regulatory protein. The diheme form of MhuD is unique among heme
oxygenases and is one feature that distinguishes the MhuD enzyme found throughout
mycobacteria from the IsdG enzymes found in Gram-positive bacteria and eukaryotic
green algae.10, 26, 31-35 Mycobacteria are a diverse genus that encounter a wide range of
heme replete and deplete conditions, and any one of these conditions may be the origin of
the MhuD–diheme function. For example, Mycobacterium haemophilum can only utilize
heme as its sole exogenous iron source and has no siderophore-dependent iron uptake
mechanism;36, 37 this is also the case for M. leprae.38, 39 It is compelling to speculate that
these two mycobacterial strains utilize MhuD to harbor a second heme molecule as a
storage mechanism when faced with an abundance of host heme. Over the 100 nM to 100
μM labile heme concentration range a significant mixture of MhuD–heme and MhuD–
diheme would be present, and the storage function may act to slow the rate of heme
degradation in order to accommodate the rate of MhuD product utilization by
downstream enzymes. Alternatively, the MhuD–diheme form may act as a
sensor/regulator, as many bacterial heme uptake systems have been shown to be
regulated. In fact, both the Pseudomonas aeruginosa and S. aureus heme uptake systems
are regulated by their heme degrading proteins albeit through different mechanisms.40, 41
Thus, these observations suggest that MhuD may have a dual function throughout
mycobacteria, heme degradation and, possibly, heme storage or regulation.
Development of general assays to quantify tetrapyrrole binding by proteins.
This work, and a recent publication,21 describe the development of two assays that could
be used to measure dissociation constants for a wide range of tetrapyrroles from a protein
site. The fluorescence-based assay employed here to measure Kd1 for MhuD–heme could
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be used to measure Kd for any protein–tetrapyrrole interaction where the protein has a
binding site tryptophan and the molecule is a d1-d9 metal tetrapyrrole. A large number of
protein–cofactor interactions meet these criteria, including heme binding by a number of
heme-dependent peroxidases and cytochromes P450.42-44 The assay relies upon
measuring intrinsic Trp fluorescence, which is quenched in close proximity to a d1-d9
metal tetrapyrrole be-cause the tetrapyrrole Abs spectrum promotes efficient FRET and
the d1-d9 transition metal center provides efficient non-radiative relaxation pathways, as a
function of tetrapyrrole con-centration. One important limitation of the fluorescencebased assay is spectral interference arising from non-binding site Trp residues and Raman
scattering. Fortunately, these limitations can be overcome by subtracting the background
fluorescence observed upon complete tetrapyrrole binding and adjusting the detection
wavelength, respectively. In summary, this fluorescence assay can be used to quantify
binding of heme, vitamin B12, cofactor F430, and their unnatural analogues to any protein
with an active site Trp.
The Abs-based assay used here to measure Kd2 for MhuD–diheme could be used
for any protein site that binds two tetrapyrroles sequentially. This assay takes advantage
of the intense Abs spectrum of tetrapyrroles,45 but the mathematical model used for
analysis must correct for the relatively unusual situation in protein-ligand binding assays
where the free ligand concentration contributes directly to the experimental observable.
An approximation-free model for Abs spectroscopy monitored binding of a single
tetrapyrrole to a protein site has been described previously,46 which involves solution of a
quadratic polynomial. Here, an approximation-free model for sequential binding of two
tetrapyrroles to a single protein site is described, which involves solution of a cubic
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polynomial. A range of applications for this assay can be envisaged, including
determination of whether heme stacking observed at protein dimer interfaces in several
proteins involved in heme uptake by pathogens is physiologically-relevant.9, 47-50 An
important caveat is that the mathematical model described here was explicitly derived for
sequential binding, and deviations of the experimental data from this model are indicative
of a second binding site or non-sequential binding. In the future, approximation-free
models for additional tetrapyrroles or binding sites could be derived in a manner
analogous to that described here or by scripting the appropriate mechanism for a software
package such as DynaFit.51, 52
2.5 CONCLUSION
In conclusion, a comprehensive study of heme binding by M. tuberculosis MhuD
has been completed. Following removal of the His6-tag, it was determined that the Kd1 for
heme dissociation from MhuD–heme is 7.6 ± 0.8 nM using a previously described
fluorescence-based assay.21 An Abs assay was developed here to measure Kd2 for heme
dissociation from MhuD–diheme, which was revealed to be 3.3 ± 1.1 M. The low
nanomolar Kd1 value for MhuD–heme, coupled with the in vitro function of MhuD,
establishes this protein as a competent heme oxygenase in vivo. Based upon the
micromolar Kd2 value for MhuD–diheme, we speculate that MhuD may have a secondary
function as a heme storage or regulatory protein, but the biological function of MhuD–
diheme remains an open question that merits further investigation. Finally, it is expected
that the assays described here can be used to measure accurate dissociation constants for
a wide range of tetrapyrrole-dependent proteins.
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CHAPTER 3: THE HEME DEGRADATION PRODUCT OF MYCOBACTERIUM
TUBERCULOSIS MHUD DEPENDS UPON THE DEGREE OF HEME SUBSTRATE
RUFFLING INDUCED BY THE ACTIVE SITE.
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3.1 INTRODUCTION
At physiologically relevant temperatures, proteins vibrate around their
equilibrium structure and these dynamic motions are often essential for their function.
Sometimes dynamic motion is dramatic, as is the case for the domain rearrangements of
cobalamin-dependent methionine synthase during enzymatic turnover.1 Other times, more
subtle structural changes have important functions as is the case with the allosteric
changes to hemoglobin following binding of molecular oxygen.2 In heme proteins, a
source of dynamic motion is out-of-plane deformations of the heme substrate.3 For
clarity, these motions are described based upon the normal coordinates for distortion
from a D4h symmetric tetrapyrrole: waving (eg), propelling (a1u), doming (a2u), ruffling
(b1u), and saddling (b2u).4 Mycobacterium tuberculosis MhuD is an example where a
protein active site can induce a dynamic ruffling distortion of a heme substrate. A
prominent example of a protein that hosts a dynamic heme is Mycobacterium
tuberculosis MhuD.5 MhuD is a non-canonical heme oxygenase (HO) whose heme
substrate undergoes a dynamic ruffling deformation, but it has not you been ascertained
whether the substrate dynamics have a functional role.
It has been shown that MhuD binds a dynamic heme and that MhuD degrades
heme to a unique product, but a connection between heme ruffling and mycobilin
production has been elusive. Magnetic measurements have shown that the large ruffling
deformation observed in the X-ray crystal structure of cyanide-inhibited MhuD (MhuD–
heme–CN, PDB ID 4NL5) arises from a dynamic heme substrate that is present in
solution as an equilibrium mixture of planar and ruffled heme.5, 6 The populations of
these conformations can be tuned by the F23W and W66F substitutions because these
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residues act like a vice on the heme substrate (Figure 3.1).7 As alluded to above, MhuD is
a non-canonical HO that degrades heme to mycobilin via a meso-hydroxyheme
intermediate.8, 9 Canonical HOs, which degrade heme to biliverdin, also have a mesohydroxyheme intermediate, suggesting the mechanisms of the two enzymes diverge after
the first oxygenation reaction.10 These observations suggest that heme ruffling induced by
the MhuD active site may be responsible for the novel trioxygenated product of this
enzyme. However, no clear correlation between heme ruffling and HO degradation
product has been reported.
To assess whether heme dynamics are correlated with heme degradation, we
measured rate constants and identified isomeric products for MhuD-catalyzed heme
trioxygenation as a function of substrate conformation. The enzyme catalyzed conversion
of heme to meso-hydroxyheme is formally a monooxygenation,9 and the influence of
ruffling on the rate of this reaction had previously been assessed using an established
assay.11 Decreased heme ruffling in W66F MhuD is correlated with a decreased rate of
MhuD-catalyzed heme monooxygenation.7 The further oxygenation of mesohydroxyheme to mycobilin is formally a dioxygenation reaction.9 The rate of this reaction
was assessed here by a novel enzyme assay. Finally, we determined the isomeric products
of MhuD-catalyzed heme degradation for enzyme variants that stabilize one of two
substrate conformations.5 These experiments have provided important insight into the
role of dynamic heme ruffling in the enzymatic mechanism of MhuD.
This article describes a mechanistic study of MhuD-catalyzed heme
trioxygenation carried out using UV/Vis absorption (Abs) spectroscopy and mass
spectrometry (MS). Using a previously described UV/Vis Abs-based assay,11 the rates of
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WT, F23W, and W66F MhuD-catalyzed heme monooxygenation were measured by
monitoring the disappearance of the Soret band. Next, the rate of meso-hydroxyheme
oxygenation was quantified by analyzing the time course of a UV/Vis Abs band in the

Figure 3. 1. MhuD is a non-canonical heme oxygenase whose heme degradation
products and active site structure differ from canonical enzymes. MhuD produces a
trioxygenated mycobilin product, whereas canonical heme oxygenases generate
dioxygenated biliverdin (top). His75 is a first-sphere ligand to the heme substrate. Asn7,
Phe23, and Trp66 are second-sphere ligands that perturb the heme substrate via nonbonding interactions (bottom).
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red region of the spectrum. The heme degradation products of WT, F23W, and W66F
MhuD were identified using electrospray ionization (ESI)-MS. Each reaction produced
multiple heme degradation products, and the major product for each enzyme variant was
determined by monitoring the product ratio over a 2 h time course. Finally, tandem liquid
chromatography (LC)-MS was employed to determine the product isomer(s) for each
reaction. These data have provided significant new insight into the enzymatic mechanism
of MhuD and revealed a new example of protein function derived from protein dynamics.
3.2 EXPERIMENTAL
All reagents were purchase from Fisher Scientific and used without further
purification unless noted otherwise.
Protein expression and purification. WT, F23W, and W66F MhuD were
expressed as described previously. Briefly, a pET-22b (Ampr) plasmid encoding WT
mhuD was a gift from Prof. Celia Goulding (University of California-Irvine).11 The
F23W and W66F mutations were introduced using QuikChange site-directed mutagenesis
kits (Agilent).5, 7 All three MhuD variants were overexpressed in BL21-GOLD (DE3)
cells, grown aerobically in Luria-Bertani (LB) medium, as described previously.11
WT, F23W, and W66F MhuD were purified in a manner similar to that previously
described for WT enzyme. WT MhuD was purified using an ÄKTA pure 25 L fast
protein liquid chromatography (FPLC) system.12 F23W MhuD was purified similarly, but
a 1.3 mM/mL elution gradient was employed (Figure B.1). This procedure yielded 17.6
mg of >99% pure F23W MhuD per liter of LB medium (Figure B.2). W66F MhuD was
also purified similarly to WT enzyme, but with an elution gradient of 3.3 mM/mL from
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125 to 325 mM imidazole (Figure B.3). Purification of W66F MhuD yielded 14.8 mg of
>99% pure protein per liter of growth medium (Figure B.4), as assessed by SDS-PAGE.
UV/Vis Abs spectroscopy. Heme degradation by MhuD variants was assayed in
a manner similar to previously described experiments. WT, F23W, and W66F hemebound MhuD (MhuD–heme) were prepared as previously described.6, 11 UV/Vis-detected
heme degradation assays were performed in a manner similar to that previously
described,3 with several exceptions. Briefly, 50 M MhuD–heme in 50 mM potassium
phosphate (KPi) pH 6.0 was reacted with 5 mM ascorbic acid, 10 mM
ethylenediaminetetraacetic acid (EDTA), 840 U/mL bovine catalase (Sigma-Aldrich),
and 167 U/mL bovine superoxide dismutase at 37 oC and protected from light. For each
enzyme variant, UV/Vis Abs spectra were acquired between 700 and 300 nm with a scan
rate of 600 nm/min, a 1.0 nm data interval, and a 0.1 s integration time using a Cary 100
Bio UV-Vis spectrophotometer at 0, 5, 10, 20, 30, 60, and 120 min after mixing.
In addition, the decrease of the Soret band (412 nm) and the growth of the 620 nm
feature for heme degradation by F23W MhuD was monitored by acquiring an Abs
spectra of 20 M F23W MhuD–heme in 50 mM KPi pH 6.0 reacted with 2 mM ascorbic
acid, 5 mM EDTA, 840 U/mL bovine catalase (Sigma-Aldrich), and 167 U/mL bovine
superoxide dismutase at room temperature protected from light. The spectra were taken
every 60 s for 120 min at 600 nm/min, using a 0.1 s digital integration time, 2 nm
bandwidth, and 1.0 nm data interval.
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Kinetic information was extracted from the UV/Vis Abs data via non-linear least
squares fitting to kinetic models. The decrease of the MhuD–heme Soret band as a
function of time was fit to a pseudo-first order kinetic model:
𝐴𝑆𝑜𝑟𝑒𝑡 = (𝐴𝑆𝑜𝑟𝑒𝑡,0 − 𝐴𝑆𝑜𝑟𝑒𝑡,∞ )𝑒 −𝑘1𝑡 + 𝐴𝑆𝑜𝑟𝑒𝑡,∞

(3.1)

where ASoret,0 is the absorbance at 0 min, ASoret,∞ is the absorbance at ∞ min, and k1 is the
rate constant for heme monooxygenation. The decrease of the Soret band absorption
intensity versus time was fit to equation 3.1 using GraphPad Prism 8.0 in order to extract
k1 and its standard error for each MhuD variant. For F23W MhuD, the increase of 620
nm UV/Vis Abs feature was described by the following kinetic model:
𝐴620 = 𝐴620,0 [𝑒 −𝑘1𝑡 + (

𝜀𝑚ℎ
𝜀ℎ

) (𝑘

𝑘1
2 −𝑘1

) (𝑒 −𝑘1𝑡 − 𝑒 −𝑘2𝑡 )]

(3.2)

where A620,0 is the absorbance at 0 min, k1 is the rate constant for F23W MhuD-catalyze
heme monooxygenation determined from fitting the Soret band decrease to equation 3.1,
mh is the molar extinction coefficient for meso-hydroxyheme, h is the molar extinction
coefficient for heme, and k2 is the rate constant for heme dioxygenation. h was
determined based upon the pyridine hemochrome assay.13 The change in absorbance at
620 nm versus time was fit to equation 3.2 using GraphPad Prism 8.0 to extract k2, mh,
and their standard errors. Complete derivations of equations 3.1 and 3.2 are available in
the Appendix B.
ESI-MS. ESI-MS was also used to monitor heme degradation for WT, F23W, and
W66F MhuD as a function of time. WT, F23W, and W66F MhuD samples with partially
degraded heme were prepared as described above and flash frozen in liquid nitrogen
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(Airgas) after 0, 5, 10, 20, 30, 60 and 120 min of reaction time. In addition, a control
experiment was performed where 50 M hemin chloride in 50 mM KPi pH 6.0 was
reacted with 5 mM ascorbic acid, 10 mM EDTA, 840 U/mL bovine catalase (SigmaAldrich), and 167 U/mL bovine superoxide dismutase at 37 oC for 120 min before flash
freezing the sample in liquid nitrogen. ESI-MS data was acquired using a system
composed of a Shimadzu Prominence HPLC coupled to an ABI Sciex 4000 QTrap Pro
hybrid triple-quadrupole/linear ion trap. All 22 reactions were loaded onto a C18 column
equilibrated with 2% acetonitrile (MeCN) with 0.1% formic acid (v/v) in water (v/v), and
eluted with a linear gradient from 2% to 98% MeCN with 0.1% formic acid (v/v) in water
(v/v) over 50 min. ESI-MS data for 600-1500 m/z was acquired in positive ion mode.
The ESI-MS data were analyzed in order to determine the heme degradation
products of WT, F23W, and W66F MhuD as a function of time. Ions with m/z of 583,
611, and 616 m/z eluted after 20.8, 22.8, and 23.8 min of the linear MeCN gradient
described above. Ion chromatograms (EIC) of the target ions (m/z 583, 611 and 616)
were extracted from the total ion chromatogram from each ESI-MS run using BioAnalyst
1.5. The averaged background spectra from the baseline of the chromatogram preceding
each chromatographic peak in each EIC were subtracted from the averaged spectra of the
chromatographic peak to produce background subtracted spectra for each target ion. The
integrated peak area for each EIC of the target ions was used to calculate the relative
abundances of the target ions for each time-point.
Tandem LC-MS. Tandem LC-MS experiments were employed to further
characterize each of the major ions produced by the WT, F23W, and W66F MhuDcatalyzed reactions. Tandem LC-MS data were obtained for the 583, 611 and 616 m/z
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parent ions with a collision energy of 44 mV using the same system described above. A
third quadrupole was used as a linear ion trap to scan the fragmentation products of these
parent ions. To improve chromatographic resolution of four 583 m/z isomers, ESI-MS
data for a WT, F23W and W66F MhuD sample with a 120 min reaction time was eluted
with a modified linear gradient from 2% to 82% MeCN with 0.1% formic acid (v/v) in
water (v/v) over 38 min. The tandem LC-MS data was analyzed in order to determine the
product isomer(s) for each enzyme-catalyzed reaction. Finally, tandem LC-MS data was
also acquired 50 M hemin chloride in 50 mM KPi pH 6.0. Background subtracted
tandem LC-MS chromatograms were extracted using BioAnalyst 1.5 as described above
for the ESI-MS data.
3.3 RESULTS
Second-sphere substitutions alter MhuD reaction mechanism. Abs
spectroscopy was used to monitor the heme degradation by WT MhuD at 0, 5, 10, 15, 20,
30, 60 and 120 mins. After 0 min time-point, the intensity of the Soret band at 407 nm
decreased until 30 min without the observable band shift. After 30 mins, the intensity of
the Soret band further decreased, and blue shifted to 399 nm. The intensity of the Q-band
peaks also decreased with time, and a peak at 540 nm was observed. As expected, these
data suggest that the heme is being degraded by WT MhuD to possibly mycobilin (Figure
B.5). This is similar to what has been observed in the past studies.8
Next, using similar reaction conditions, heme degradation by F23W MhuD was
monitored using the Abs spectroscopy. During the heme degradation, the Soret band at
412 nm (0 min) decreased in intensity and blue-shifted to 407 nm (120 min) (Figure 3.2).
The relative decrease of the Soret band intensity in smaller for F23W compared to WT
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(Figure B.5). Also, a previous study has shown that the mycobilin bound MhuD has less
intense peak in the violet region compared to the meso-hydroxyheme bound MhuD.9 The
Q-band at 537 and 560 nm decreased in intensity, however, the intensity of a peak at 620
nm slowly started to increase over time (Figure 3.2). The peak at 620 nm has been
attributed to MhuD complexed with meso-hydroxyheme.9 The 620 nm peak started to
form immediately and saturated with time. Thus, this suggest a possible mesohydroxyheme intermediate building up with time during the heme degradation by F23W
MhuD.

Figure 3. 2. Abs monitored heme degradation by F23W MhuD (50 M F23W MhuD‒
heme, 50 mM KPi pH 6.0, 37oC) monitored at 0 (red trace), 5 - 60 (dotted gray) and 120
mins (blue trace). Peak at 620 nm gradually increases with time.
Finally, using Abs spectroscopy, heme degradation by W66F MhuD was
monitored. The heme degradation reaction featured a decrease in the Soret band coupled
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with a red shift from 402 to 405 nm (from 0 to 120 mins) (Figure 3.3). The Soret band
further red-shifted to 408 nm at 180 mins. Multiple changes were observed at the Q-band
region; the 560 nm peak with a shoulder at 601 nm disappeared with time, as the peak at
536 nm with a shoulder at 560 nm grew. Most importantly, a feature at ~690 nm grew
over the same time period (Figure 3.3). This would suggest a possible biliverdin
formation.14 Thus, ESI-MS study will be performed to identify possible intermediates and
products of heme degradation by WT MhuD and its variants.

Figure 3. 3. Abs monitored heme degradation by W66F MhuD (50 M W66F MhuD‒
heme, 50 mM KPi pH 6.0, 37oC) monitored at 0 (red trace), 5 - 60 (dotted gray), 120
mins (blue trace). Inset: Maximized spectra from 620 - 760 nm.
WT MhuD produces a mixture of mycobilin and biliverdin. The heme
degradation sample by WT MhuD was analyzed using ESI-MS. The mass spectrum of
the 30 min sample revealed the presence of 3 peaks with m/z 583, 611 and 616, eluting at
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20.8, 22.8, and 23.8 mins respectively (Figure B.6). These peaks likely correspond to
biliverdin (m/z 583), mycobilin (m/z 611) and heme (m/z 616). However, to confirm this,
tandem LC-MS study on each of these peaks were performed. For, m/z 616, hemin
chloride solution was analyzed. The fragmentation pattern of the m/z 616 is the same as
the one observed for hemin chloride (Figure 3.4 and B.7). Major fragments observed are
m/z 557 and m/z 498, corresponding to the loss of CH2COOH and (CH2COOH)2
respectively. This implies that the m/z 616 is the undegraded heme molecule.

Figure 3. 4. MS/MS spectrum of m/z 616. Two major daughter fragments of m/z 557 and
m/z 498 is observed corresponding to loss of CH2COOH (red dotted line) and
(CH2COOH)2 (blue dotted line) respectively. Fragment ions of m/z 616 matches up with
that of hemin chloride (Figure B.7.).
Similarly, tandem LC-MS on the m/z 611 was also performed for the 30 min
sample of heme degradation by WT MhuD. The m/z 611 likely corresponds to mycobilin,
which has been observed in previous studies as well.8 The fragment ions observed for
MS/MS of m/z 611 are shown in the supplemental section (Figure B.8). Each of the
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fragment ions are color matched to where the fragmentation occurs in the mycobilin
structure. For example, the largest fragment ion corresponding to m/z 476 results from
the cleavage below the -meso carbon (red dashed line, Figure B.8). In a similar way,
other fragment ions can be traced back to the mycobilin structure. Therefore, the m/z 611
peak is most likely mycobilin. As expected, it has the highest relative intensity compared
to other peaks (Figure B.6).
Finally, tandem LC-MS was performed on the m/z 583 peak, and a single
fragment ion of m/z 297 was observed (Figure B.9). The m/z 297 is due to the
fragmentation at the -meso carbon position. This likely suggests that m/z 583 peak
corresponds to biliverdin. This is a surprising and an interesting find as biliverdin is a
major product formed during the heme degradation by canonical heme oxygenase.15 A
recent study has identified biliverdin as the major product of R26S MhuD.16 However, it
is the first time it has been observed for WT MhuD. Therefore, to investigate whether this
peak arises from enzymatic turnover or coupled oxidation, a control degradation assay
was performed using just hemin chloride instead of heme bound MhuD. 120 min of this
sample injected onto the ESI-MS showed the presence of m/z 583 in a miniscule amount
(Figure B.10). The relative abundance of m/z 583 compared to the heme peak (m/z 616)
is ~2%. This value is significantly lower than the value observed for the heme
degradation by WT MhuD (Figure B.6). This implies that the m/z 583 peak arises from
the enzymatic turnover. Therefore, these data suggest that WT MhuD is degrading heme
to produce a mixture of mycobilin and biliverdin.
Second-sphere substitutions alter identity of primary reaction product. Next,
to analyze the formation of mycobilin and biliverdin during the heme degradation by WT
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MhuD, the reaction mixtures were monitored as a function of time using ESI-MS to get a
better understanding of the product distribution (Figure 3.5). Similar to the Abs assay, the
reaction was monitored at 0, 5, 10, 20, 30, 60 and 120 mins. Initially, the ratio of
mycobilin to biliverdin was small but with time, the major product is clearly identified as
mycobilin, and biliverdin is observed as the minor product. The amount of biliverdin
formation stays consistent after 60 mins, however, the amount of mycobilin formation
increases with time. One explanation on the biliverdin formation can be rationalized from
the fact that MhuD can accommodate dynamic heme in its active site. Thus, the ruffled
and planar heme conformation may be important in formation of different heme
degradation products.

Figure 3. 5. Time-resolved ESI-MS study on heme degradation by WT MhuD.
Formation of mycobilin and biliverdin is plotted as relative abundance (%) against heme
as a function of time. Sample at each time-point has 4 mins delay taken up by thawing
and injecting process. Thus, 0 min time-point sample is 50 M WT MhuD‒heme (50 mM
KPi pH 6.0, 37oC).
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Time-dependent MS study was performed on the heme degradation sample by F23W
MhuD, because it has been shown that the F23W substitution induces more ruffled
conformation of heme compared to WT MhuD.5 The heme degradation study by F23W
MhuD was similar to the one performed for WT MhuD. Like WT MhuD, the study on
heme degradation by F23W MhuD showed mycobilin as the major product and biliverdin
as the minor product (Figure 3.6). However, as expected, the enzymatic activity is slower
than WT MhuD. UV/Vis assay suggested a possible meso-hydroxyheme intermediate
being observed during the heme degradation by F23W MhuD. This may explain why
there is a noticeably lag in mycobilin formation. Thus, the increased ruffling, did not
change the product identity, but may have considerably slowed down the conversion of
meso-hydroxyheme to mycobilin.

Figure 3. 6. Time-resolved ESI-MS study on heme degradation by F23W MhuD.
Formation of mycobilin and biliverdin is plotted as relative abundance (%) against heme
as a function of time. Sample at each time-point has 4 mins delay taken up by thawing
and injecting process. Thus, 0 min time-point sample is 50 M F23W MhuD‒heme (50
mM KPi pH 6.0, 37oC).
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Next, a time-dependent MS study was performed to monitor heme degradation by
W66F MhuD, as it has been shown to house more planar heme in its active site than WT
MhuD.6 Unlike, WT and F23W MhuD, heme degradation by W66F MhuD showed
biliverdin as the major product and mycobilin as the minor product (Figure 3.7). This
confirms the earlier observation (Figure 3.3), where the increase of the feature at ~690
nm suggested biliverdin formation. The biliverdin formation also becomes more apparent
at higher timepoints. R26S MhuD is the only variant that has shown to degrade heme to
biliverdin.16 It should also be noted that the enzymatic inefficiency W66F MhuD
compared to WT can be clearly observed. Therefore, the decrease in ruffling completely

Figure 3. 7. Time-resolved ESI-MS study on heme degradation by W66F MhuD.
Formation of mycobilin and biliverdin is plotted as relative abundance (%) against heme
as a function of time. Sample at each time-point has 4 mins delay taken up by thawing
and injecting process. Thus, 0 min time-point sample is 50 M W66F MhuD‒heme (50
mM KPi pH 6.0, 37oC).
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altered the product identity, and biliverdin is observed as the major product for W66F
MhuD.
Second-sphere substitutions alter biliverdin isomer. Tandem LC-MS on the
120 min sample of heme degradation by WT MhuD was performed to identify the
biliverdin isomers. Careful inspection of the Mass Ion Chromatogram (MIS) for m/z 583
(biliverdin) in all the runs revealed that multiple peaks correlating to m/z 583 was
present. Optimized ESI-MS run revealed four peaks corresponding to m/z 583 eluted at
38.7, 39.0, 39.4 and 40.2 mins for WT MhuD (Figure B.11). Tandem LC-MS performed
on all the four m/z 583 peaks showed distinct fragmentation pattern (Figure 3.8). The
fragment ions typical for ,  and -biliverdin is m/z 297, 343 and 402 respectively, and
the fragment ions corresponding to each of the biliverdin isomers except -biliverdin has
previously been assigned.17, 18 Therefore, the m/z 583 peak having the major MS/MS
fragment ion of m/z 555 was assigned to -biliverdin (Figure 3.9). By identifying the
major MS/MS fragment ions of each peak, the biliverdin isomers for the eluted peaks
were assigned in the following order: , ,  and  (Figure 3.8, Figure B.11). Also, the
elution order for the biliverdin isomers remained same as observed in previous studies.
The presence of all the biliverdin isomers as the minor product during heme degradation
by WT MhuD is very interesting, and thus, similar tandem LC-MS study was performed
to identify the biliverdin isomers formed during heme degradation by F23W and W66F
MhuD.
Tandem LC-MS on the heme degradation sample at 120 min by F23W MhuD was
performed. Using the similar analysis performed for WT MhuD, the largest observed
fragment ions were matched with their corresponding biliverdin isomer. Thus, ,  and 70

biliverdin isomers were identified and labeled (Figure B.12). Unlike WT MhuD, biliverdin isomers was not observed. The mutation of Phe23 to Trp may sterically hinder
the oxygenation at the -meso-carbon. Therefore, the lack of regioselectivity observed for
the formation of the biliverdin isomers by WT and F23W MhuD questions whether this
reaction is proceeding enzymatically.

Figure 3. 8. MS/MS spectra of each chromatographic peak corresponding to m/z 583 ran
for 120 min heme degradation sample by WT MhuD. Spectra A-C were assigned as  
and -biliverdin respectively, based on their assignment from previous studies.17, 18
Spectra D has major fragments (m/z 555 and m/z 297) that hasn’t been assigned before
and is assigned to -biliverdin. Spectra A-D is put here according to their elution order
(Figure B.11).
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Finally, the heme degradation sample at 120 min by W66F MhuD was analyzed
using tandem LC-MS. It should be noted that the retention time observed for the ESI-MS
chromatogram involving biliverdin isomers did not stay consistent between WT, F23W
and W66F runs. However, this would not affect the identity of biliverdin isomers as they
were identified using the fragment ions from tandem LC-MS run. Tandem LC-MS
reveled that W66F MhuD degrades heme to -biliverdin predominantly (Figure B.12),
with a very small amount of -biliverdin. To date, this is the second MhuD variant after
R26S to have been able to degrade heme to -biliverdin. Also, the presence of
predominantly one biliverdin isomer suggests that the formation of biliverdin by W66F
MhuD is regioselective and is formed enzymatically.
Second-sphere amino acid substitution effect the rate of heme degradation. A
kinetic study was done due to the observed 620 nm peak during the Abs-monitored heme
degradation by F23W MhuD (Figure 3.2). This was performed to extract the rate constant
of the monooxygenation of heme by monitoring the Soret band, and of the dioxygenation
of meso-hydroxyheme by monitoring the 620 nm peak, at RT. The decreased Soret band
monitored as a function of time was fit to a pseudo-first order kinetic model using
equation (3.1) (Figure B.13). A heme monooxygenation rate constant (k1) of 0.0253 ±
0.0002 min-1 was extracted from the fit with a R2 value of 0.9931. Next, the increase of
the Q-band at 620 nm was monitored as a function of time and fit to a kinetic model
described by equation (3.2) to extract the rate constant for the dioxygenation reaction.
The dioxygenation rate constant (k2) was extracted to be vanishingly small with R2 of
0.9950 (Figure 3.9). Comparing the two rate constants, the initial monooxygenation is
observed to be 13 orders of magnitude faster process than the dioxygenation.
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Figure 3. 97. 620 nm peak was monitored during the heme degradation by F23W MhuD
as a function of time and fitted using a kinetic model described in equation (3.2). The
fitting gave a rate of 1.645 x 10-15 ± 3.618 x 10-7 min-1 for dioxygenation reaction (k2),
with a R2 of 0.9950. Black dots represent the experimental data and the purple line
represents the fitted data.
To further understand the impact of heme ruffling on the heme monooxygenation,
kinetic analysis was performed to extract the rate of heme monooxygenation by WT,
W66F and F23W MhuD at 37oC. The data was analyzed using equation (3.1) by
monitoring the disappearance of the Soret band of each variants. The rate of heme
monooxygenation observed for W66F is much slower than observed for WT and F23W
MhuD (Figure B.14, Table 2.1). It is 16 times slower than WT and 31 times slower than
F23W MhuD.
Next, the observed rate of heme monooxygenation by F23W is twice as observed
for WT MhuD. However, the kinetic fitting graph (Figure B.14) shows that the
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disappearance of the Soret band in F23W is not as efficient as observed in WT MhuD.
This may be explained by the difference between the Abs intensity of the mycobilin
bound vs the meso-hydroxyheme bound MhuD.
Table 3. 1. The pseudo first order rate of monooxygenation by WT, F23W and W66F
MhuD extracted by monitoring the decrease of Soret band as a function of time at 37oC.
The data was fit into equation (3.1), the resulting rate with standard error and R2 is shown
below.
Variant

Rate with standard error (min-1)

R2

W66F

0.00481 ± 0.00362

0.9889

WT

0.07956 ± 0.00520

0.9937

F23W

0.15072 ± 0.01882

0.9661

3.4 DISCUSSION
Implication of heme conformation on product formation. The significance of
heme conformations on the enzymatic mechanism by MhuD is poorly understood. The
spectroscopic investigation revealed that MhuD has a ruffled ground state, and thermally
accessible planar excited state. Planar heme conformation is observed in the active site of
the canonical HO, such as HO-119 and C. diphtheriae-HO,20 whereas, IsdI from
Staphylococcus aureus induces one of the largest ruffling deformations known in the
biochemical literature (PDB ID 3QGP).21 The magnitude of heme ruffling induced by
MhuD can be tuned by the F23W and W66F substitutions because these residues act like
a vice on the heme substrate (Figure 1). Thus, F23W MhuD has increased population of
the ruffled comformation7 compared to wild-type (WT) enzyme, and W66F MhuD5 has
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increased population of planar conformation compared to WT enzyme. UV/Vis and MS
studies on heme degradation by MhuD variants presented here suggested that the secondsphere substitution influences the enzymatic mechanism. ESI-MS and tandem LC-MS
study provided insights on the role of heme conformation on the formation of the final
product by variants of MhuD. Decreased heme ruffling in W66F MhuD completely
altered the product identity to -biliverdin. This would mean that W66F MhuD alters the
heme degradation mechanism in a way to afford biliverdin formation. On the other hand,
increased heme ruffling did not change the product identity, as mycobilin was identified
as the major product for F23W-mediated heme degradation. However, the presence of
highly ruffled heme significantly altered the dioxygenation pathway, evidenced by the
meso-hydroxyheme observation.
Kinetics study was performed by monitoring the Soret and the 620 nm peak to
gain insights into the rate of heme monooxygenation and the rate of meso-hydroxyheme
dioxygenation by F23W MhuD. The 620 nm peak suggests formation of mesohydroxyheme intermediate. Thus, the ruffled heme may have influenced the heme
degradation pathway of F23W MhuD to afford the observation of an intermediate. The
rate of heme monooxygenation (k1) was extracted using a pseudo first order kinetic
model (equation 3.1) and then was added into the derived kinetic model (equation 3.2) to
calculate the rate of dioxygenation of meso-hydroxyheme (k2). The extracted k2 value is
considerably slower than the k1 value, which means that the formation of heme to mesohydroxyheme is a much faster process than the formation of meso-hydroxyheme to
mycobilin. Thus, the increased heme ruffling induced by the substitution to bulkier Trp
residue at the 23 position seem to slow the dioxygenation reaction. Therefore, these data
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would strongly suggest that the heme conformation can play a role in altering the heme
degradation mechanism and can also tune the final product formation.
ESI-MS and tandem-MS study identified all the biliverdin isomers as a minor
product for WT, whereas,   and -biliverdin isomers was identified as a minor product
for F23W MhuD. This would suggest that there is lack of regioselectivity on biliverdin
formation by WT and F23W MhuD. Since miniscule amount of -biliverdin is observed,
the oxygenation reactions seem to be regioselective to -meso carbons for W66F MhuD
and is proceeding enzymatically. All the isomers of biliverdin are observed when heme is
degraded through a coupled oxidation pathway in the presence of O2 and a reductant.22, 23
In the presence of catalase, the coupled oxidation of myoglobin was inhibited, leading
authors to conclude that exogenous peroxide is required for coupled oxidation of
myoglobin. However, this study was performed in the presence of catalase and
superoxide dismutase. Thus, it is unlikely that MhuD heme degradation reaction produces
exogenous peroxide or superoxide. However, it is likely that the reactive oxygen species
(ROS) being produced in the active site of MhuD may be causing the coupled oxidation
of heme to biliverdin isomers. Therefore, biliverdin formation by WT and F23W MhuD
may be proceeding via a non-enzymatic pathway, however, -biliverdin is being
produced enzymatically by W66F MhuD.
Importance of dynamic heme in the conversion of heme to mycobilin. MhuD
houses a dynamic heme in its active site, which may be essential for its catalytic activity.
UV/Vis and ESI-MS assay suggested that the heme conformation plays a role its
degradation mechanism by MhuD. It can be clearly observed that when heme is tuned
into a single conformation (ruffled or planar) by the second-sphere amino acid
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substitution, the enzymatic activity of MhuD is altered. Thus, to investigate these changes
in the enzymatic activity, the rate of change in Soret peak was monitored and fit using a
pseudo first order kinetic model (equation 3.1). Surprisingly, the rate of change in Soret
peak for F23W is twice as fast compared to WT MhuD. But the decrease in Soret band is
more pronounced in WT compared to F23W MhuD (Figure B.14). As mentioned
previously, the Soret peak observed for MhuD-meso-hydroxyheme complex is much
intense than for MhuD-mycobilin complex.9 Thus, these observations suggest that F23W
MhuD is producing meso-hydroxyheme instead of degrading heme fully to mycobilin.
This result is consistent with the above kinetic study performed for F23W MhuD (Figure
3.10.). On the other hand, W66F is observed to degrade heme very slowly compared to
F23W and WT MhuD. The slower rate observed may be due to the decreased heme
ruffling induced by the active site of W66F MhuD. The decreased ruffling is altering the
enzymatic pathway of W66F MhuD to afford biliverdin formation, and thus it is not
surprising that the rate of heme oxidation is slowed down significantly. These
observations strongly suggest that the initially ruffled heme may be necessary for the
conversion of heme to -meso-hydroxyheme by MhuD. Finally, the inefficient
enzymatic pathway that was observed in the absence of either of the heme conformations
would strongly suggest that dynamic heme is essential for an efficient conversion of
heme to mycobilin by MhuD.
Possible heme degradation mechanism by W66F MhuD. Formation of biliverdin proceeds via -meso-hydroxyheme intermediate in the heme degradation
mechanism by canonical HO.10 The initial oxygenation happens at the -meso-carbon
through a ferric-hydroperoxo intermediate.24-26 The ordered hydrogen bonding network is
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proposed to act like a OH radical trap and help guide it to the -meso carbon.27 This is
followed by a subsequent conversion of -meso-hydroxyheme to -verdoheme
intermediate.28-30 The final oxygenation and the ultimate ring cleavage to form biliverdin
is proposed to be initiated by binding of either O2 or H2O2 to ferrous verdoheme.31-33
However, MhuD does not have the water cluster present in its active site as the canonical
HOs, which can guide the initial oxygenation to occur at the -meso-carbon. Thus, it is
likely that the heme degradation may proceed via a distinct mechanism. It is possible that
it may follow a similar mechanism as proposed for R26S MhuD,16 to proceed via a diol
intermediate.34 Thus, identifying the C1 product of W66F MhuD-mediated heme
degradation would help elucidate the mechanism. But, the enzymatic activity in W66F is
not as efficient as compared to R26S MhuD (Chapter 4) and may pose difficulties in
identifying the C1 product. Therefore, a comprehensive study to characterize the C1
product of W66F MhuD is warranted.
3.5 CONCLUSION
In conclusion, Abs and MS study suggest that heme degradation by MhuD
depends on the heme distortions induced by the active site. Highly ruffled heme altered
the mechanism by affording a meso-hydroxyheme intermediate, and the kinetics study
confirmed that the conversion of meso-hydroxyheme to mycobilin is very inefficient.
Increased ruffling was observed to enhance the initial monooxygenation of heme to
meso-hydroxyheme. In contrast, planar heme slowed down the degradation of heme by
MhuD and completely changed the mechanism to afford biliverdin as the major product.
Therefore, dynamic heme substrate is required for the heme degradation by MhuD.
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CHAPTER 4: INVESTIGATING THE ELECTRONIC STRUCTURE OF THE HEME
SUBSTRATE INDUCED BY R26S SUBSTITUTION IN MYCOBACTERIUM
TUBERCULOSIS MHUD.
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4.2 INTRODUCTION
Heme oxygenases (HO) are a group of protein that are responsible for the
degradation of heme to release non-heme iron, and produce biliverdin and carbon
monoxide (CO) as a side product.10, 15 This heme degradation process plays an essential
role in various organisms, such as: iron homeostasis, cell signaling and protection against
oxidative stress.35-37 The HO enzymes in the bacterial pathogens degrade heme as a
source of iron for their growth, survival and pathogenicity, and predominantly produce
biliverdin and CO.14, 38 However, some bacterial pathogens have evolved the heme
degradation pathways to produce different heme degradation products.11, 39, 40
Staphylococcus aureus heme degrading enzyme, IsdG and IsdI has been studied to
catabolize heme to produce non-heme iron, formaldehyde and staphylobilin isomers.41, 42
On the other hand, Mycobacterium heme utilization degrader (MhuD) is a heme
degrading enzyme from Mycobacterium Tuberculosis, that has been shown to degrade
heme to release non-heme iron and mycobilin as an organic byproduct.8, 9 The unique
degradation product by MhuD means that it degrades heme through a mechanistically
different pathway than the canonical HO.
The regiochemistry of the first oxygenation step for forming meso-hydroxyheme
intermediate during the heme degradation by the canonical HO differs from the noncanonical HO. Canonical HOs from bacteria to mammals have similar alpha helical fold,
where the heme is sandwiched in between.19, 43, 44 They also contain ordered hydrogen
bonding network responsible for guiding the transient OH radical to regioselectivity
attack the -meso position of the porphyrin ring.27 This hydrogen bonding network is
absent in non-canonical HOs such as IsdG/I and MhuD.6, 21, 45, 46 The heme in the active
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site of such enzymes is significantly distorted or ruffled compared to canonical HOs.
Crystal structure of MhuD-heme-CN (PDB: 4NL5) shows that the heme is ruffled in the
active site of MhuD in such a way that  and −meso carbons are more accessible to
reactive radical oxygen species to attack.6 However, recent study suggests that formation
of mycobilin proceeds via -oxygenation of  or -hydroxyheme.9 This would mean that
significant electronic contribution is very likely for the regioselectivity of heme cleavage
by MhuD. Ruffling has been suggested to stabilize 2B2g electronic state which puts
significant spin density into the meso carbon positions,21, 47, 48 and this makes irondioxygen attack more favorable. WT MhuD has been suggested to stabilize 2B2g [(dxz, dyz
)4 (dxy)1] ground electronic state with thermally accessible 2Eg [(dxz, dyz )3 (dxy)2] excited
electronic state.6 Since, the  or -meso carbon positions are ruffled away from the distal
position, there may be an electronic driving force responsible for initial oxygenation at
the  or -meso carbon positions.
Recent study on R26S MhuD has shown that the mutation causes changes in the
product identity upon heme degradation, resulting in formation of -biliverdin with the
release of non-heme iron and formaldehyde (Figure 4.1).16 Arg26 in the active site of
MhuD is hydrogen bonded with one of the propionates of heme (between  and -meso
carbons). Therefore, Arg26 was initially proposed to play a role in orienting the heme at
the active site of MhuD. It is well known that MhuD can bind two heme per monomer in
its active site.11 Thus, MhuD has two distinct binding sites for each heme molecule.
Based on the crystal structure of MhuD–diheme (PDB: 3HX9), Arg26 is involved in
forming a salt bridge with the propionate group (between  and  meso carbons) of the
solvent exposed heme but has no interaction with the solvent protected heme. Thus,
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Arg26 may also be important in orienting the heme in this distinct solvent exposed
binding pocket. The formation of biliverdin is similar to canonical HO, however a
different C1 product suggest unique heme degradation mechanism. In addition, ~24% of
the product observed during the heme degradation by R26S MhuD is mycobilin. Thus,
the R26S substitution might have altered the active site in a way to accommodate
different heme degradation pathways to produce biliverdin and mycobilin, and the
formation of these products may proceed via different electronic structure of the heme
substrate.

Figure 4. 1 WT MhuD degrades heme to mycobilin and releases non-heme iron. R26S
MhuD has been shown to degrade heme to biliverdin while releasing non-heme iron and
formaldehyde.16
In this study, the change in electronic structure of heme and its reactivity induced
by the R26S substitution in MhuD, as well as the possible of role of Arg26 is investigated
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using various spectroscopic techniques. UV-Vis absorbance spectroscopy was used to
observe if substitution of Arginine 26 to Serine changes the ruffling of heme in the active
site of MhuD. Cryogenic Magnetic Circular Dichroism (MCD) and Variable Field
Variable Temperature (VTVH) MCD spectroscopic techniques were used to provide
insights on the ground electronic states of cyanide inhibited R26S MhuD–heme. Other
spectroscopic techniques such as, 1H NMR and temperature dependent 1H NMR were
utilized to investigate the electronic states of the cyanide inhibited R26S MhuD–heme–
CN at room temperature. Temperature dependent 1H NMR was used to investigate the
presence of more than one electronic state with the use of Curie plot. Finally, LC-MS was
utilized to monitor the heme degradation activity by R26S MhuD. The results of these
techniques are reported here in the results section and their implications has been
discussed in the discussion section.
4.2 EXPERIMENTAL
Unless otherwise noted, all materials in this work were purchased from Fisher Scientific
and used without further purification.
Protein Expression and Purification: A gene encoding R26S MhuD on a pET22a
vector was transformed into BL21 gold cells. DNA sequencing at Vermont Cancer Center
(VCC) confirmed the sequence of R26S MhuD gene (Table C.1). Expression of R26S
MhuD was performed as previously described for WT MhuD.11 R26S MhuD was purified
using an Äkta pure 25 L fast protein liquid chromatography (FPLC) system (GE
Healthcare) as previously described.16 Fractions containing purified R26S MhuD were
pooled and the sample volume was reduced to 10 mL using Amicon stirred cells with 10
kDa ultrafiltration membranes. Following overnight dialysis against 50 mM Tris, 50 mM
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NaCl pH 7.4, 10 mg/L of >99% pure MhuD were obtained as assessed using a Bradford
assay and SDS-PAGE (Figure C.1 and C.2).
Spectroscopic Characterization: Absorbance spectra at room temperature were
acquired for R26S MhuD–heme and R26S MhuD–heme–CN in 50 mM Tris pH 7.4, 50
mM NaCl, by scanning from 900 to 200 nm at 600nm/min with a 1.0 nm data interval
and 0.1 s integration time using Cary 100 Bio spectrophotometer. Preparation of hemebound R26S MhuD has been described previously.6 R26S MhuD–heme and R26S
MhuD–heme–CN extinction coefficient for the Soret band was determined to be 66.9
mM-1 cm-1 and 85.6 mM-1 cm-1 respectively using the pyridine hemechrome assay as
described previously.49
1

H NMR spectra was acquired on cyanide inhibited R26S MhuD–heme–CN in 50 mM

Tris pH 7.4, 50 mM NaCl as previously described for WT MhuD.6 Buffer was exchanged
into 20mM NaPi pH 7.4 using a PD-10 column. Volume of R26S MhuD–heme–CN was
reduced to 615 µL using Amicon stirred cells with 10 kDa ultrafiltration membranes. This
was followed by lyophilization of the R26S MhuD–heme–CN for at least 24 hrs on a
VirTis lyophilizer. The powder was dissolved using 615 µL of 100% D2O, to give final
concentration of 1 mM R26S MhuD–heme–CN . 1H NMR Spectra of R26S MhuD–
heme–CN were acquired using Super Water Eliminating Fourier Transform (SuperWEFT) pulse sequence technique as previously described.6, 50 1H NMR super WEFT
spectra at 11, 25, 35 and 42 oC were collected on a Varian Unity Inova 500 MHz NMR
spectrometer using 50 ms -delay and 50 ms acquisition time. The NMR data was
analyzed and processed using MestreNova 14.0.4.
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Cryogenic Magnetic Circular Dichroism (MCD) were acquired for 10 M R26S MhuD–
heme–CN in 50 mM KPi pH 7.4, 50 mM NaCl, 60% (v/v) glycerol using Jasco J-815
spectropolarimeter and an Oxford SM4000-8T Spectromag controlled by a Mercury iTC
temperature controller and a Mercury iPS power supply. Spectral data were acquired with
a 1.0 nm bandwidth, 0.25 s integration time, 0.5 nm data pitch, and 200 nm/min scanning
speed. The MCD spectra was processed by removing the CD contribution from the final
MCD spectrum. This was done by subtracting the negative field data from the positive
field data and dividing by 2. Variable Field Variable Temperature (VTVH) MCD
saturation magnetization curve were acquired at 2, 5 and 10 K for the Soret band at 422
nm by ramping the magnetic field at 0.7 T/min, with a 1.0 nm bandwidth, 0.25 s
integration time, and a data pitch of 0.5 nm. Simulations for Model 2 and Model 3 were
used as previously described.6
Heme Degradation Assay. Heme catalyzed reaction by R26S MhuD were analyzed.
Degradation of 50 uM R26S MhuD‒heme in 50 mM KPi pH 6.0, 150 mM NaCl at 37oC
was performed in the presence of 5 mM ascorbate, 10 mM EDTA, 840 U/mL of catalase
and 167 U/mL of Superoxide Dismutase (SOD). Liquid Chromatography-Mass
Spectrometry (LC-MS) was used to determine the composition of products formed as a
function of time. LC-MS was performed on Shimadzu Prominence HPLC system coupled
to an AB Sciex 4000 QTrap Pro hybrid triple-quadrupole/linear ion trap liquid
chromatograph-mass spectrometer operated in position ion mode. Heme degradation
samples of R26S MhuD at 0, 5, 10, 20, 30, 60 and 120 mins we injected on the LC-MS
equilibrated with 2 % Acetonitrile (MeCN) with 0.1% formic acid (v/v) in water (v/v).
The m/z 583, 611 and 616 peaks eluted with a linear gradient from 2% MeCN to 98%
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with 0.1% formic acid (v/v) in water (v/v) over 50 mins using 1 mm C18 LC column
scanning from m/z 600-1500. Ion chromatograms (EIC) of the target ions (m/z 583, 611
and 616) were extracted from the total ion chromatogram from each ESI-MS run using
BioAnalyst 1.5. The averaged background spectra from the baseline of the chromatogram
preceding each chromatographic peak in each EIC were subtracted from the averaged
spectra of the chromatographic peak to produce background subtracted spectra for each
target ion. The background subtracted spectra of each target ion was then integrated to get
the peak area, which was used to calculate the relative abundances of the target ions for
each time-point.
4.3 RESULTS
Spectroscopic Characterization: Using UV/Vis absorption spectroscopy,
ruffling of R26S MhuD–heme–CN was assessed. Previous study has demonstrated that
up to 1.0 Å ruffling there is no change in energy in the Q band region whereas the Soret
band energy is blue shifted.7 However, beyond 1.0 Å ruffling, both Q-band and Soret
band are red-shifted. Q band feature of the Cyanite inhibited R26S MhuD–heme did not
change (18,000 cm-1) but the Soret band blue shifted from 23,900 cm-1 to 24,000 cm-1
(Figure 4.2) compared to WT MhuD–heme–CN. However, since 100 cm-1 is about the
experimental error of the UV-Vis spectrophotometer that we use, this suggests that the
substitution of arginine 26 to serine does not significantly affect the ruffling of the heme
in the MhuD’s active site.
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Figure 4. 2. UV/Vis absorption spectra of WT (blue) and R26S (red) MhuD–heme–CN
in 50 mM Tris pH 7.4, 50 mM NaCl. The Q-band did not change but the Soret band blueshifted by 100 cm-1
Previous studies via MCD spectroscopy have provided insights on the electronic
structures of MhuD–heme–CN species. Correlation between the population of the 2Eg
electronic state and the area under the of the Soret band has been previously established.7
For the 2Eg [(dxz, dyz )3 (dxy)2] electronic ground state, spin-orbit coupling exists between
ground state and low lying excited state.51 This would lead to increased C- term MCD
intensity as compared to 2B2g [(dxz, dyz )4 (dxy)1] electronic ground state, where the spinorbit coupling may not exist or is not as strong. MCD spectra of R26S MhuD– heme–CN
was collected and compared to F23W and WT MhuD–heme–CN. The area
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Figure 4. 3. 5K, 7T MCD spectra of R26S MhuD–heme–CN (dotted red), WT MhuD–
heme–CN (solid purple), F23W MhuD–heme–CN (dotted blue). Inset: Magnified MCD
spectra from 500-650 nm.
under the curve for the Soret band observed for R26S is larger than WT and F23W
MhuD–heme–CN (Figure 4.3, Table C.2). Previous study has suggested that the state
populations are proportional to the area under the curve, as such that, higher area under
the curve means higher 2Eg electronic state population. Therefore, MCD spectra suggests
that the more population of 2Eg electronic state is observed for R26S MhuD–heme–CN
compared to F23W and WT MhuD–heme–CN.
VTVH MCD spectroscopy was performed to identify the ground state of R26S
MhuD–heme–CN. Analysis of the VTVH MCD saturation magnetization curves for the
Soret band of R26S MhuD–heme–CN revealed that the slope of the curves increases with
increasing temperature. In other words, nesting is being observed because of the presence
of a thermally accessible excited state. Comparison of the saturation magnetization curve
92

of R26S MhuD–heme–CN was made to the model complexes known to have pure 2Eg
and 2B2g electronic ground states (Figure 4.4). This suggested that R26S MhuD–heme–
CN has a 2B2g [(dxz, dyz )4 (dxy)1] electronic ground state and with increasing temperature,

Figure 4. 4. VTVH MCD saturation magnetization curve for R26S MhuD–heme–CN
(top) in 50 mM KPi, pH 7.4, 50 mM NaCl, 60% (v/v) glycerol at 2 (red), 5 (black) and 10
K (blue). VTVH MCD saturation magnetization curve for WT MhuD–heme–CN is
adapted from ref 22 and shows the curve at 2 (red), 5 (black) and 10 K (blue). The
simulated magnetization curves for the ferric heme model complexes with 2Eg (dashed
purple) and 2B2g (dashed green) electronic ground states are used for comparisons.
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2

Eg [(dxz, dyz )3 (dxy)2] electronic state is populated (Figure 4.4). However, the saturation

magnetization curves of R26S is less nested when compared to WT MhuD–heme–CN
(Figure 4.4)6. Decreased nesting observed R26S MhuD–heme–CN can be attributed to
the increased energy gap between 2Eg and 2B2g for compared to WT MhuD–heme–CN.
This implies that heme in the active site of the R26S MhuD may be less dynamic than in
the native enzyme (WT). Interestingly, VTVH and MCD data may suggest that there may
be a mixture of two species of R26S MhuD–heme–CN with different electronic states
present in the solution. These spectroscopies along with UV/Vis cannot distinguish
between the species, as the data collected from them will be due to the equilibrium
mixture of these states.
Next, 1H NMR experiments were employed to further investigate and identify the
electronic states influenced by R26S substitution in MhuD–heme–CN. Previous studies
have suggested 2Eg electronic states of cyanide inhibited heme oxygenase are associated
with downfield hyperfine-shifted 1H resonances52 and 2B2g electronic states are associated
with upfield hyperfine-shifted 1H resonances.21 Downfield hyperfine shifted resonances
are retained in 1H NMR spectra of R26S substituted MhuD–heme–CN , and the furthest
is observed at 20.0 ppm (Figure 4.5), suggesting that 2Eg electronic state is populated at
room temperature. Upfield hyperfine- shifted resonances are also observed for R26SMhuD–heme–CN , and the furthest one is observed at -16.2 ppm, which suggest the
presence of a 2B2g electronic state as well. However, the upfield resonances are less
paramagnetically shifted than F23W and WT MhuD–heme–CN.53 This suggests that less
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populated 2B2g electronic state is observed for R26S compared to F23W and WT MhuD.
It seems that at room temperature, 2Eg is more populated than 2B2g electronic state for

Figure 4. 5. 1H NMR spectra of 1mM R26S MhuD–heme–CN (top), F23W MhuD–
heme–CN (middle) and WT MhuD–heme–CN (bottom) in 20mM NaPi pH 7.4, 50mM
NaCl (100% D2O) at 25 oC. 1H NMR spectra of F23W MhuD–heme–CN and WT
MhuD–heme–CN adapted from ref 5 and 6 respectively.
R26S MhuD–heme–CN. To further study the presence of more than one S=½ electronic
states, temperature dependent NMR study was performed.
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1

H NMR super-WEFT spectra of R26S MhuD–heme–CN was acquired at 11, 25,

35 and 42 oC (Figure 4.6). The chemical shifts of resonances from A-G are monitored

Figure 4. 6. 1H NMR super-WEFT spectra of 1mM MhuD–heme–CN in 20mM NaPi,
50mM NaCl pH 7.4 at 11 oC, 25 oC, 35 oC and 42 oC as labeled above. The chemical
shifts of resonances A-G are labeled and monitored as a function of temperature.
and reported as a function of temperature. These resonances are then plotted and fitted to
the Curie Law as a function of inverse temperature (1/T in K-1) (Figure 4.7). Two of the
four downfield shifted resonances (A-B) have linear dependence close to the typical 0-10
ppm range and hence exhibit Curie behavior.54 However other resonances (C-G) does not
show linear dependence with increasing temperature, exhibiting a non-Curie behavior.
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This means that the downfield shifted resonances showing Curie behavior suggest the
presence of pure 2Eg electronic state, indicating a planar heme in the active site. On the
other hand, the paramagnetically shifted resonances from C-G does not exhibit Curie
behavior as the temperature approaches infinity, implying that a mixture of two different
S=½ electronic states are present. This would suggest presence of two different species

Figure 4. 7. Curie plot of 1H resonance from A-G of R26S MhuD–heme–CN . Solid
circles represent the experimental data at 11, 25, 35 and 42 oC. The lines are the fit to the
Curie law drawn linearly with increasing temperature.
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of R26S MhuD–heme–CN in solution. MCD, VTVH and Abs studies cannot distinguish
between these species, as the spectra collected will be due to the equilibrium mixture
between these states in solution. However, temperature dependent 1H NMR spectroscopy
can and was able to identify these species.

Heme degradation Assay. Time-resolved MS study on heme degradation by
R26S MhuD showed biliverdin as the major product and mycobilin as the minor product
(Figure 4.7). With the increasing time, it becomes clearer that the heme degradation

Figure 4. 8. Time-resolved LC-MS study on heme degradation by R26S MhuD.
Formation of mycobilin and biliverdin is plotted as relative abundance (%) against heme
as a function of time. Sample at each time-point has 4 mins delay taken up by thawing
and injecting process. Thus, 0 min time-point sample is 50 M R26S MhuD‒heme (50
mM KPi pH 6.0, 150 mM NaCl, 37oC).
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by R26S MhuD yields biliverdin as the major product. This is in line with the results
published by Goulding and co-workers, where they observed -biliverdin as the major
product and very small amount of mycobilin isomers as the minor product.16

4.4 DISCUSSION
Electronic structure of R26S MhuD–heme–CN : 1H NMR spectra of R26S
MhuD–heme–CN showed the presence of two different electronic states as WT MhuD–
heme–CN,6 but 1H NMR alone cannot distinguish between the presence of two different
species. Thus, the temperature dependence of the paramagnetically shifted resonances
were investigated through a temperature dependent 1H NMR study (Figure 4.6). This
study revealed the likelihood of two species of R26S MhuD–heme with different
electronic states. The Curie plot (Figure 4.7) suggested that a single electronic state is
populated by resonances having a linear dependence with temperature (2Eg), and mixture
of two electronic states (2Eg and 2B2g) are present for the resonances having non-linear
dependence with temperature.
The MCD, VTVH and Abs spectra arises from the equilibrium mixture between
the two species in solution. Due to the nature of these techniques, they cannot distinguish
between these species (2Eg and mixture of 2Eg and 2B2g). Thus, a conclusive statement
cannot be made from the Abs data in order to understand the effect of Arg26 substitution
on heme ruffling. As for the MCD spectra, it is dominated by the C-term intensity (2Eg).
Hence, it is almost impossible to analyze the data in order to extract information on 2B2g
electronic state or distinguish between the two species. However, the VTVH curve for
R26S MhuD–heme–CN suggested a 2B2g electronic ground state with 2Eg excited state.
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Based on the temperature dependent 1H NMR and the cryogenic VTVH data, the 2B2g
electronic ground state can be assigned for the species with a mixture of 2Eg and 2B2g
electronic states.
Interestingly, these observations could be explained by a mixture two species with
varied heme conformations that is present in active site of R26S MhuD. One species has
a planar heme conformation (2Eg) and the other species have a ruffled heme conformation
(2B2g and 2Eg) with 2B2g ground state. The presence of the two different species of R26S
MhuD–heme–CN with different electronic structure will certainly have implications on
the reactivity of MhuD by Arg26 substitution. This is further supported by a recent study
where biliverdin is observed as the major and mycobilin as the minor product of heme
degradation by R26S MhuD.16 The implication of this is further discussed in detail
below.
Implication of the electronic structure on heme degradation by R26S MhuD.
Recent studies have highlighted -biliverdin as the product of heme degradation by R26S
MhuD.16, 55 The C1 product of the heme degradation by R26S MhuD is also different
from WT MhuD, as formaldehyde is released instead of CO.16 This suggest that heme
degradation might be proceeding through a pathway different from that of canonical HO.
Time-dependent MS study on the heme degradation by R26S MhuD showed biliverdin as
the major product. The spectroscopic data collected illustrated the possibility of two
different species of R26S MhuD–heme–CN. One housing planar heme in the active site
and the other housing more ruffled heme in the active site. Thus, we propose that the
R26S MhuD with planar heme having 2Eg electronic ground state may be responsible for
degrading heme to biliverdin. In addition, R26S MhuD with dynamic heme having a
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mixture of 2B2g and 2Eg electronic states may be responsible for degrading heme to
mycobilin.
Role of Arginine 26. Since R26S MhuD degrades heme with a different
mechanism than canonical HO and WT MhuD, a recent study proposes that the role of
Arg26 is more than just properly orienting heme within the active site.16 A recent
computational study on heme degradation by R26S MhuD suggested that after the
mutation, the salt bridge formed between Arg26 and one of the propionate group
(between  and -meso carbons) is broken, which allowed for that propionate group to
form hydrogen bond with Asn7 instead.56 It is then proposed that this allows the hydroxyl
radical to attack -meso position since  and -meso positions are ruffled towards the
proximal His75, and -meso position is sterically hindered by the Ile9. This would mean
the salt bridge between Arg26 and the propionate needs to be stabilized for Asn7 to guide
the hydroxyl radical to  or -meso carbon positions, suggesting that Asn7 may play a
role in regioselective oxygenation during the first step. This may explain the formation of
biliverdin but formation of mycobilin (~24%) during the heme degradation by R26S
MhuD challenges this proposal.16
Since the presence of two different species of R26S MhuD–heme–CN with varied
electronic structure may explain the formation of biliverdin and mycobilin during the
heme degradation by R26S MhuD, it is reasonable to suggest that Arg26 not only
stabilizes the heme orientation but may also stabilize the heme conformation in the active
site of MhuD. The salt bridge interaction between the Arg26 and the propionate group of
the heme substrate allows for placing the heme in a prime location where it can attain the
required conformation induced by second sphere amino acids interaction. In addition,
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MhuD has two distinct binding sites for heme in its active site, where Arg26 forms a salt
bridge interaction with the solvent exposed heme molecule. Without such interaction, we
can speculate that the heme in the active site of R26S MhuD will not be locked into a
position, and the large active site pocket of MhuD along with the presence of two distinct
binding sites may allow for some flexibility on heme binding. This would mean that
R26S MhuD loses its control on guiding heme towards the correct binding pocket,
allowing heme to bind to either of the binding site. Presence of two different
conformation of heme in the active site of R26S MhuD, as suggested in this
spectroscopic study, may be the result of binding of heme at two different binding sites.
However, it is worth noting that current study is insufficient in understanding how
different conformation of heme is controlled in the active site of R26S MhuD. Therefore,
further investigation regarding this hypothesis is necessary.
4.5 CONCLUSION
In summary, a single mutation of Arginine 26 to Serine in MhuD induced a
drastic change in its electronic structure. Through the spectroscopic investigations
performed in this study, the possibility for the presence of a pure 2Eg and a mixture of
2

B2g and 2Eg electronic states is proposed. This would then suggest that more than one

conformation of heme may be present in the active site of R26S MhuD. These
conformations may be thus be responsible for formation of biliverdin as the major
product and mycobilin as a very minor product. However, additional spectroscopic
characterization may be necessary to fully elucidate the role of R26 and the electronic
structure induced by its substitution.
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CHAPTER 5: INVESTIGATING THE EFFECT ON HEME RUFFLING AND
DEGRADATION BY F23W SUBSTITUTION IN STAPHYLOCOCCUS AUREUS
ISDG.

110

5.1 INTRODUCTION
Staphylococcus aureus is a Gram-positive pathogen involved with staph
infections. People with chronic conditions such as diabetes, cancer etc., are at greater risk
from this infection. The drug resistant strain such as Methicillin-Resistant S. aureus
(MRSA) has a high mortality rate1 and according to CDC, the untreated MRSA can
become severe and cause sepsis. The rates of MRSA related infections compared to other
developed countries is higher in the United States.2 Due to increased infection, the
clinical researches are being done to treat the conditions caused by MRSA, such as
Pneumonia, Osteomyelitis, etc.3 However, the mortality rate has stayed high even with
the antibiotics in the market that are effective against MRSA. In addition, the vaccine
development has also been unsatisfactory.3 Therefore, more extensive research on
discovering better insights between the host and the S. aureus pathogen is necessary.
Like most organisms, S. aureus also needs iron to grow and survive inside the
human host. However, most of the iron in human body is in the form of heme and it is
also the preferred iron source for S. aureus during the early infection period.4 The heme
acquisition from the host by S. aureus utilizes the iron-regulated surface determinant
(Isd) system, where several Isd proteins and enzymes are involved in the iron
acquisition.5-8 IsdG and IsdI enzymes in the Isd system are involved in cleaving the heme
to release iron, formaldehyde and an organic byproduct called staphylobilin.9-11 These
enzymes are a viable drug target for the future development of therapeutic strategies
against S. aureus and thus, understanding the mechanism behind the cleavage of heme by
IsdG/I to sequester iron is essential.

111

Similar to IsdG/I, our body also have heme degrading enzymes known as human
heme oxygenase (hHO), which falls within canonical heme oxygenase (HO) family. Like
all the canonical HO, the hHO degrades heme to release iron, carbon monoxide (CO) and
biliverdin.12, 13 Bacterial pathogens consisting of similar heme degrading enzyme
predominantly degrades heme to produce biliverdin and CO.14, 15 The ordered hydrogen
bonding network present in the active site of these enzyme has been proposed to be
responsible for guiding the OH radical to selectively attack -meso position of heme
substrate.16, 17 Such water cluster is absent in active site of non-canonical HO such as

F23

H76
W67

Figure 5. 1. Active site of heme bound N7A IsdG is shown to have hydrophobic
interaction with secondary sphere amino acids F23 and W67. Substitution of W67 to Ala
completely stopped the IsdG-mediated heme degradation. While F23A substitution did
not alter the heme degradation by IsdG.18
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Mycobacterium tuberculosis MhuD and Staphylococcus aureus IsdG/I.19-22 Both IsdG/I
and MhuD has been shown to degrade ruffled heme in the active site, which is proposed
to be one of the reasons for their distinct enzymatic mechanism.18, 19, 21, 23, 24 The IsdGcatalyzed heme degradation has been proposed to go through a bridged transition state
with concerted O-O bond cleavage and C-O bond formation, resulting in oxygenation at
the /-meso carbons to form /-meso-hydroxyheme intermediate on its way to towards
staphylobilin formation.25
The heme substrate in the active site of IsdG hydrophobically interacts with
several amino acid residues such as Leu9, Phe23, Trp67, Val80 etc.19 (His76, Phe23 and
W67 is shown in Figure 5.1). Roles of second-sphere amino acids in the IsdG/I catalyzed
heme degradation has been studied in the past.18, 25, 26 Most specifically the roles of Asn7
and Trp67 in the heme degradation mechanism seems to be important. The Asn7 is
responsible for rotating the hydrogen bonded hydroperoxo ligand towards - and -meso
carbons, and the hydrophobic interaction between heme and the Trp67 leads to the
pushing of - and -meso carbons towards the distal hydroperoxo ligand.20, 24, 25 Also,
recent study has proposed that Asn7 and Trp67 work together towards a unique heme
degradation chemistry by IsdG.26
Another residue that makes hydrophobic interaction with the substrate is Phe23.
Surprisingly, the role of Phe23 has not been widely studied. Previous study on this
residue on Phe23 substitution to Ala, showed that the heme degradation mechanism was
not affected.18 Conversely, the conserved Phe23 residue in MhuD has been shown to alter
the electronic structure of heme, thereby affecting the enzymatic activity of F23W
MhuD.23 The F23W variant showed increased heme substrate ruffling compared to WT
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MhuD. The Phe23 in IsdG makes steric contact on the distal side of heme and thus its
substitution to a bulkier Trp amino acid is hypothesized to alter the heme ruffling and
consequently its electronic structure and the enzymatic activity.
In this study, Phe23 was substituted to Trp to gain insights on its role in the
enzymatic pathway by S. aureus IsdG. Circular Dichroism (CD) spectroscopy was
utilized to analyze the secondary structure of the F23W variant. UV/Vis (Abs)
spectroscopy was utilized to gain information on the F23W induced heme ruffling. The
activity assay by this variant was studied using Abs spectroscopy and Liquid
Chromatography-Mass Spectrometry (LC-MS). The results for this study are reported
and their implication has been discussed below.
5.2 EXPERIMENTAL
Unless otherwise noted, all materials in this work were purchased from Fisher Scientific
and used without further purification.
Protein Expression and Purification: The cloning of WT IsdG from pET-15b (Ampr,
Novagen)9, 25-27 and S219V tobacco etch virus (TEV)28 protease from PRK793 (Ampr),
have been previously described. A short-linker F23W variant of IsdG was prepared by
site-directed mutagenesis using the QuickChange Lightning Kit (Agilent). The DNA
primers to be used for mutagenesis were purchased from Midland Certified Reagent
Company (Table D.1). DNA sequencing performed at the Vermont Integrative Genomics
Resource at the University of Vermont confirmed the mutation of Phe23 to Trp (Table
D.2). Plasmids encoding F23W IsdG were transformed in BL21-GOLD (DE3) cells
(Stratagene).
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Short-linker F23W IsdG was expressed as described previously for WT IsdG.27 The
purification of F23W IsdG was performed as previously described for WT IsdG with
some modifications.9, 25, 27 Cell pellets from 1 L of cell growth were lysed as previously
described.26 This was performed two more times and the filtered lysate were pooled
before loading onto a 5 mL, nickel(II)-charged HiTrap Chelating HP column (GE
Healthcare) equilibrated with 50 mM Tris pH 7.4, 150 mM NaCl using an ÄKTA Pure 25
L fast protein liquid chromatography (FPLC) system (GE Healthcare). After loading the
filtered lysate onto the nickel(II)-charged HiTrap Chelating HP column, the column was
washed with a 1.3 mM/mL linear gradient from 0 – 80 mM imidazole in 50 mM Tris pH
7.4, 150 mM NaCl at a flow rate of 5.0 mL/min. Pure, uncleaved F23W IsdG eluted
during a subsequent 2.2 mM/mL linear gradient from 80 mM – 300 mM imidazole in 50
mM Tris pH 7.4, 150 mM NaCl at a flow rate of 5.0 mL/min (Figure D.1). FPLC
fractions containing pure uncleaved F23W IsdG were assessed by SDS-PAGE gel
electrophoresis (Figure D.2). The N-terminal His6 tag was removed as previously
described for WT IsdI.23, 27, 29 The purity of the resulting pure untagged, short-linked
F23W IsdG was >99%, as assessed by SDS-PAGE gel electrophoresis (Figure D.2).
Circular Dichroism(CD) spectroscopy. CD spectroscopy was utilized to analyze the
secondary structure of short-linker F23W IsdG. F23W IsdG was exchanged onto 10 mM
potassium phosphate (KPi) pH 7.4 buffer using PD-10 desalting columns (GE Healthcare)
and loaded onto 2mm path length quartz cuvettes (Starna). CD spectra were acquired
from 260 – 185 nm with a scan speed of 20 nm/min, 1.0 nm bandwidth, 0.5 nm data pitch
and a digital integration time of 8s using a Jasco J-1500 spectropolarimeter. A total of 6
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spectra were collected and averaged, then subtracted from the CD spectra of blank buffer
(10 mM KPi pH 7.4) to get the final CD spectrum of F23W IsdG.
Electrospray Ionization Mass Spectrometry (ESI-MS). ESI-MS was used to assess
His6 tagged and untagged F23W IsdG. 25-uM samples of His6 tagged and untagged
F23W IsdG in 50 mM Tris pH 7.4, 150 mM NaCl were loaded onto C18 guard columns
equilibrated with 2% acetonitrile with 0.1% formic acid (v/v) in water (v/v) using a
QTRAP 4000 LCMS/MS system (Sciex) with an M/z from 600-2000. The samples were
run on a linear gradient from 2 to 98% acetonitrile with 0.1% formic acid (v/v) in water
(v/v) at a flow rate of 100 μL/min. The spectrum was deconvoluted using BioAnalyst 1.5
software. The observed molecular weights of His6 tagged and untagged F23W IsdG are
consistent with their calculated molecular weights (Figure D.3 and D.4)
Abs Spectroscopy. Short-linker heme-bound F23W IsdG (F23W IsdG–heme) and
cyanide-inhibited F23W IsdG (F23W IsdG–heme–CN) were prepared as described
previously for long-linker WT IsdG.25, 27 The molar extinction coefficients were assessed
for both of these species using the pyridine hemochrome method.30 The molar extinction
coefficients for F23W IsdG–heme and F23W IsdG–heme–CN were calculated as 412 =
92.6 mM-1 cm-1 and 420 = 90.3 mM-1 cm-1 respectively.
Room temperature Abs spectroscopy was used to assess heme ruffling byF23W IsdG.
Abs spectra were collected for F23W IsdG–heme–CN samples in 50 mM Tris pH 7.4,
150 mM NaCl. The Abs spectra was collected on a Cary 100 Bio spectrophotometer from
800 – 200 nm with a scan rate of 600 nm/min, 0.1 s digital integration time, 2 nm
bandwidth, and 1.0 nm data interval.
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Abs Assay. The activity of heme catalyzed by F23W IsdG were analyzed by Abs
spectroscopy. Degradation of 25 M of F23W IsdG–heme in 50 mM Tris pH 7.4, 150
mM NaCl was performed in the presence of 2.5 mM ascorbate, 1 mM
Ethylenediaminetetraacetic acid (EDTA), 1 K units of bovine liver catalase (Sigma
Aldrich). Assays were run at room temperature and the Abs spectra of the reaction
mixture were acquired every 2.5 mins between 800 – 200 nm for 60 mins with a scan rate
of 600 nm/min, 0.1 s digital integration time, 2 nm bandwidth, and 1.0 nm data interval.
Liquid Chromatography-Mass Spectrometry (LC-MS) Assay. Using the same
reaction condition as above, LC-MS was used to determine the composition of products
formed as a function of time for the degradation of heme by F23W IsdG. LC-MS was
performed on a system composed of a Shimadzu Prominence HPLC system coupled to an
ABI Sciex 4000 QTrap Pro hybrid triple-quadrupole mass spectrometer operated in
positive ion mode. Heme degradation sample of F23W IsdG at 10 and 60 mins were
injected onto the LC-MS equilibrated with 2% acetonitrile with 0.1% formic acid (v/v) in
water (v/v). The m/z 599, 611 and 616 peaks eluted with a linear gradient from 2 to 98%
acetonitrile with 0.1% formic acid (v/v) in water (v/v) over 50 mins using a C4 LC
column in a positive ESI scanning from m/z 600-1500. Ion chromatogram (EIC) of the
target ions (m/z 599, 611 and 616) were extracted from the total ion chromatogram (TIC)
from each LC-MS run.
5.3 RESULTS
CD Spectroscopy. CD spectroscopy was used to gain insights into the secondary
structures of apo IsdG due to the F23W substitution. Fitted CD spectra of F23W IsdG
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gave 10% -helices and 35% -sheets (Figure D.5 and Table D.3).31-34 This is close to
the observed secondary structure of WT IsdG (9% -helices and 35% -sheets) by CD
spectroscopy (Figure 5.2, Table D.3). Comparing these values, there isn’t significant
change in the secondary structure of IsdG induced by F23W mutation. Therefore, any
changes in the spectroscopic data moving forward can be attributed to the change in the
interactions within the enzyme active site.

Figure 5. 2. UV CD spectra of the short-linker apo F23W IsdG (solid blue) in 10 mM
potassium phosphate (KPi) pH 7.4 was compared to that of WT IsdG35 (solid red) (Figure
D.5 and Table D.3).
Abs Spectroscopy Characterization: Using Abs spectroscopy, ruffling of the
heme substrate within F23W MhuD–heme–CN was assessed. In the previously reported
Abs spectrum of cyanide inhibited WT IsdG–heme, the lower energy Q-band is observed
at 18,000 cm-1 and the higher energy Soret band is observed at 23,800 cm-1. As compared
to WT, there is no change in the the Q-band and the Soret band energy in the Abs
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spectrum of F23W IsdG–heme–CN (Figure 5.3). The absorbance spectrum of porphyrin
arises from the transition between two HOMOs (a1u and a2u) and two LUMOs (two eg*),
which give rise to two excited states.36 Mixing of these states create a higher and a lower
energy states corresponding to the Soret and the Q-bands, respectively. Effect of the
second-sphere amino acid residue substitution on the heme macrocycle distortion has
been studied in the past for M. tuberculosis MhuD23, 37 and IsdG.35 This can alter the

Figure 5. 3. UV/Vis absorption spectra of F23W IsdG–heme–CN (solid green) compared
to that of WT IsdG–heme–CN (solid red).35 The Soret and the Q-band energy remain
unchanged after F23W substitution at 23,800 cm-1 and 18,000 cm-1 respectively.
Abs spectra of the heme bound enzyme by altering the energy gap between the filled
a1u/a2u orbitals and the unoccupied eg* orbitals. Previous DFT study has demonstrated
that up to 1.0 Å ruffling of heme, there is no change in energy in the Q-band region,
which then undergoes a red shift with increasing ruffling distortion.37 However, up to 1.0
Å ruffling, the Soret band energy is blue shifted, and then red-shifts with larger degrees
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of ruffling.37 Since both the Soret and the Q-band energy did not change from WT to
F23W, the mutation to bulkier Trp residue did not affect the heme ruffling, meaning that
the filled a1u/a2u orbitals and the unoccupied eg* orbitals stayed the same. This would also
suggest that the heme is ruffled by ~2.04 Å in F23W IsdG–heme–CN, as observed for
WT.26
Abs Assay. The heme degradation by F23W IsdG was monitored using Abs
spectroscopy to understand the influence of Phe23 on the enzymatic efficiency (Figure
5.4). Previous studies have shown that Trp67 substitution to Ala completely stops the
heme degradation activity by IsdG.18 However, Trp67 substitution by less bulkier Phe in
IsdG retained a decreased heme degradation activity compared to the WT enzyme.35 On
the other hand, effect of Phe23 substitution on the IsdG-mediated heme degradation has
been studied previously by mutating Phe23 to smaller Ala residue.18 The influence of
Phe23 substitution to bulkier Trp residue is investigated here. Since heme can be
degraded to biliverdin through the coupled oxidation pathway in the presence of
hydrogen peroxide and a reductant, the heme degradation reaction by F23W
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Figure 5. 4. UV/Vis monitored heme degradation by F23W IsdG (25 M F23W IsdG‒
heme, 50 mM Tris pH 7.4, 150 mM NaCl) monitored every 2.5 mins for 60 mins at room
temperature. Abs spectra at 0 min (blue trace), 2.5 – 57.5 mins (Dashed grey), and 60
mins (solid red) are shown. Vertical downward arrow at the Soret (412 nm) and the Qband (563 nm) shows the direction of spectral change as a function of time.
IsdG was performed in the presence of catalase to avoid the degradation of heme through
the coupled oxidation pathway.38, 39 As a result, Abs monitored heme degradation spectral
change would be due to the enzymatic heme degradation by F23W IsdG. Abs monitored
activity assay by F23W IsdG showed decreased of the Soret band and the Q-band
intensity at 412 nm and 563 nm respectively, as a function of time. This suggests that the
degradation of heme is being carried out by F23W IsdG, which means that Phe23
substitution to bulkier Trp residue does not affect the enzymatic activity of IsdG. This
observation agrees with the previous study, where the F23A substitution did not alter the
heme degradation activity of IsdG.18 However, previous study monitored the degradation
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of heme but not the formation of products. Thus, in this study, the product identity of the
heme degradation by F23W IsdG was monitored by LC-MS.

LC-MS assay. LC-MS was used to determine the composition of the products
formed during the heme degradation reaction catalyzed by F23W IsdG. The F23W
substitution does not seem to affect the enzymatic activity of IsdG, as demonstrated by
the Abs monitored activity assay. Thus, to investigate if the heme degradation by IsdG is
proceeding through similar mechanism after the Phe23 substitution to Trp, LC-MS was
utilized. Like the Abs activity assay above, the heme degradation assay utilizing LC-MS
was performed in the presence of catalase, to identify the products formed through the
enzymatic degradation of heme by F23W IsdG. The heme degradation by F23W IsdG
was monitored at two different time-points (10 and 60 mins) to understand the evolution
of products being formed with time (Figure 5.5). At the initial 10 mins time-point, the
MS spectra revealed three peaks of m/z 599, 611 and 616. These peaks correspond
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Figure 5. 5. LC-MS spectra of heme degradation by F23W IsdG at 10 mins (A, top) and
60 mins (B, bottom). Three peaks of m/z 599, 611 and 616 is observed at both time-points
with different relative intensity. These peaks correspond to staphylobilin, formyl-oxobilin and heme, respectively.
with molar mass of staphylobilin, formyl-oxo-bilin, and heme, respectively.40 The m/z
616 peak has the highest intensity compared to other peaks, which is expected as the
heme degradation reaction is in its initial time-point. LC-MS performed at 60 min timepoint again revealed the same three peaks, but their relative intensity changed as a
function of time. As expected, m/z 599 peak at 60 mins has a higher intensity than at 10
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mins. The peak intensity of m/z 611 also noticeably increased during the same time
interval. As the heme degradation reaction proceeds forward, heme is degraded to form
the final product staphylobilin along with the intermediate formyl-oxo-bilin. Formyl-oxobilin has been observed in the past as an intermediate on the way towards formation of
staphylobilin during the heme degradation by IsdG.40 The LC-MS data for the heme
degradation by F23W IsdG suggests that the Phe23 substitution to larger amino acid does
not significantly alter the enzymatic mechanism of IsdG. The heme degradation by WT
IsdG is proposed to proceed via 2B2g electronic ground state where the heme substrate is
observed to be more ruffled than in MhuD.19, 21, 25 Therefore, this lack of change in the
enzymatic mechanism is consistent with the Abs data that suggested lack of observed
structural changes in heme due to F23W substitution.

5.4 DISCUSSION
Implication of F23W substitution on heme ruffling. The F23W substitution
induced effect on heme ruffling of IsdG was accessed using Abs spectroscopy. The heme
substrate in the active site of IsdG/I enzymes are more ruffled (1.9 – 2.3 Å)19, 21 compared
to that of MhuD.21 Ruffling has been shown to change the electronic ground state from
2

Eg [(dxy)2 (dxz, dyz)3] to 2B2g [(dxz, dyz)4 (dxy)1]. Less ruffled heme is observed for the

canonical HO, however, more ruffled heme in the active site of non-canonical HO is
observed and is proposed to be important for their enzymatic activity. Substitution of
Phe23 to larger Trp residue was hypothesized to alter the amount of ruffling onto the
heme macrocycle through the hydrophobic steric interaction. However, the Abs data of
cyanide inhibited F23W IsdG–heme is unchanged when compared to the Abs spectrum of
WT IsdG–heme–CN. This would suggest a minimal effect on the heme ruffling by F23W
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substitution. In addition, a previous computational study has shown that the energy cost
related to ruffling of increases rapidly for ruffling above 1.8 Å.23 Thus, it is possible that
the ruffling distortion ceiling might have already been reached for the heme bound IsdG,
and that increasing the steric bulk at the second-sphere amino acid residues such as
F23W, does not increase heme ruffling. This is because the energy cost becomes very
high to attain a higher degree of ruffling. Therefore, we can speculate this as the reason
behind lack of spectral change observed for F23W IsdG–heme–CN compared to WT
IsdG–heme–CN. Based upon this Abs data, it is likely that the electronic structure of
F23W IsdG–heme–CN remained unchanged from the WT variant.
Implication of F23W substitution on heme degradation. Heme degradation
reaction mediated by F23W substitution in IsdG does not seem to significantly alter the
enzymatic activity of the mechanism. The Abs monitored heme degradation by F23W
MhuD showed a constant decrease of Soret and Q-band features as a function of time.
The LC-MS data showed the formation of formyl-oxo-bilin and staphylobilin consistent
with this Abs study and a previous heme degradation study40, suggesting that the
enzymatic mechanism of IsdG remained unchanged with the F23W substitution. This
further implies that the increasing steric bulk at the residue 23 does not affect the heme
degradation mechanism of IsdG and is consistent with the lack of structural change of
heme substrate by the F23W substitution. This result is different from the heme
degradation study performed for MhuD where the conserved Phe23 residue was mutated
to Trp (Chapter 2).23 In the study, it was observed that the increased steric bulk
significantly altered the enzymatic mechanism of MhuD. The heme degradation became
less efficient, which gave rise to an observation of the meso-hydroxyheme intermediate,
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as investigated by Abs study (Chapter 3). This would suggest that the role of Phe23 in
heme degradation mechanism for IsdG/I may be distinct, and that the dioxygenation
mechanism by IsdG/I may be fundamentally different than that of MhuD.
Role of Phe23 in IsdG. The heme substrate makes extensive hydrophobic
interactions with Leu9, Phe23, Phe64, Trp67, Leu68 and Val80 in IsdG. It has been
suggested that Phe23 located on the distal side of the heme along with proximal Trp67
may induce observed heme ruffling in heme bound IsdG.19 However, increasing the steric
bulk of Phe23 did not significantly alter the heme ruffling or the heme degradation
mechanism by IsdG. Similar to this study, substitution of Phe23 to Ala did not
significantly alter the heme degradation by IsdG as well.18 The Phe23 substitution
resulted in change in the heme conformation and the enzymatic activity in MhuD, but not
in IsdG. Therefore, it is interesting to point out that the role of conserved Phe23 residue
in MhuD and IsdG are very different. The data collected from this study point towards
the fact that Phe23 doesn’t change the IsdG or the heme substrate structure, and thus,
does not play a significant role in enzymatic mechanism of IsdG/I.
5.5 CONCLUSION
In conclusion, the effect of F23W substitution on heme ruffling and heme
degradation of Staphylococcus aureus IsdG is investigated using Abs spectroscopy and
LC-MS. The heme ruffling study performed using Abs spectroscopy also showed no
change in ruffling of heme by F23W substitution. The Abs and LC-MS study on the
enzymatic activity of F23W IsdG suggested that the F23W substitution did not
significantly affect the heme degradation mechanism. The observation from these studies
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are consistent with the fact that Phe23 may not play a significant role in heme
degradation mechanism by IsdG.
5.6 CHAPTER 4 REFERENCES
1.

van Hal, S. J.; Jensen, S. O.; Vaska, V. L.; Espedido, B. A.; Paterson, D. L.;
Gosbell, I. B., Predictors of Mortality in Staphylococcus aureus Bacteremia. Clin.
Microbiol. Rev., 2012, 25 (2), 362-386.

2.

Klein, E. Y.; Mojica, N.; Jiang, W. D.; Cosgrove, S. E.; Septimus, E.; Morgan,
D. J.; Laxminarayan, R., Trends in Methicillin-Resistant Staphylococcus aureus
Hospitalizations in the United States, 2010-2014. Clin. Infect. Dis., 2017, 65 (11),
1921-1923.

3.

Turner, N. A.; Sharma-Kuinkel, B. K.; Maskarinec, S. A.; Eichenberger, E. M.;
Shah, P. P.; Carugati, M.; Holland, T. L.; Fowler, V. G., Methicillin-resistant
Staphylococcus aureus: an overview of basic and clinical research. Nat. Rev.
Microbiol., 2019, 17 (4), 203-218.

4.

Skaar, E. P.; Humayun, M.; Bae, T.; DeBord, K. L.; Schneewind, O., Ironsource preference of Staphylococcus aureus infections. Science, 2004, 305 (5690),
1626-1628.

5.

Mazmanian, S. K.; Skaar, E. P.; Gaspar, A. H.; Humayun, M.; Gornicki, P.;
Jelenska, J.; Joachmiak, A.; Missiakas, D. M.; Schneewind, O., Passage of
heme-iron across the envelope of Staphylococcus aureus. Science, 2003, 299
(5608), 906-909.

6.

Grigg, J. C.; Vermeiren, C. L.; Heinrichs, D. E.; Murphy, M. E. P., Haem
recognition by a Staphylococcus aureus NEAT domain. Mol. Microbiol., 2007, 63
(1), 139-149.

7.

Torres, V. J.; Pishchany, G.; Humayun, M.; Schneewind, O.; Skaar, E. P.,
Staphylococcus aureus IsdB is a hemoglobin receptor required for heme iron
utilization. J. Bacteriol., 2006, 188 (24), 8421-8429.

127

8.

Tiedemann, M. T.; Muryoi, N.; Heinrichs, D. E.; Stillman, M. J., Iron acquisition
by the haem-binding Isd proteins in Staphylococcus aureus: studies of the
mechanism using magnetic circular dichroism. Biochem. Soc. Trans., 2008, 36,
1138-1143.

9.

Skaar, E. P.; Gaspar, A. H.; Schneewind, O., IsdG and IsdI, heme-degrading
enzymes in the cytoplasm of Staphylococcus aureus. J. Biol. Chem., 2004, 279
(1), 436-43.

10.

Matsui, T.; Nambu, S.; Ono, Y.; Goulding, C. W.; Tsumoto, K.; Ikeda-Saito,
M., Heme degradation by Staphylococcus aureus IsdG and IsdI liberates
formaldehyde rather than carbon monoxide. Biochemistry, 2013, 52 (18), 3025-7.

11.

Reniere, M. L.; Ukpabi, G. N.; Harry, S. R.; Stec, D. F.; Krull, R.; Wright, D.
W.; Bachmann, B. O.; Murphy, M. E.; Skaar, E. P., The IsdG-family of haem
oxygenases degrades haem to a novel chromophore. Mol. Microbiol., 2010, 75
(6), 1529-38.

12.

Tenhunen, R.; Marver, H. S.; Schmid, R., Microsomal heme oxygenase.
Characterization of the enzyme. J. Biol. Chem., 1969, 244 (23), 6388-94.

13.

Matsui, T.; Unno, M.; Ikeda-Saito, M., Heme oxygenase reveals its strategy for
catalyzing three successive oxygenation reactions. Acc. Chem. Res., 2010, 43 (2),
240-7.

14.

Schmitt, M. P., Utilization of host iron sources by Corynebacterium diphtheriae:
identification of a gene whose product is homologous to eukaryotic heme
oxygenases and is required for acquisition of iron from heme and hemoglobin. J.
Bacteriol., 1997, 179 (3), 838-45.

15.

Zhu, W.; Wilks, A.; Stojiljkovic, I., Degradation of heme in gram-negative
bacteria: the product of the hemO gene of Neisseriae is a heme oxygenase. J.
Bacteriol., 2000, 182 (23), 6783-90.

16.

Chen, H.; Moreau, Y.; Derat, E.; Shaik, S., Quantum mechanical/molecular
mechanical study of mechanisms of heme degradation by the enzyme heme
128

oxygenase: the strategic function of the water cluster. J. Am. Chem. Soc., 2008,
130 (6), 1953-65.
17.

Wilks, A.; Heinzl, G., Heme oxygenation and the widening paradigm of heme
degradation. Arch. Biochem. Biophys., 2014, 544, 87-95.

18.

Wu, R. Y.; Skaar, E. P.; Zhang, R. G.; Joachimiak, G.; Gornicki, P.;
Schneewind, O.; Joachimiak, A., Staphylococcus aureus IsdG and IsdI, hemedegrading enzymes with structural similarity to monooxygenases. J. Biol. Chem.,
2005, 280 (4), 2840-2846.

19.

Lee, W. C.; Reniere, M. L.; Skaar, E. P.; Murphy, M. E., Ruffling of
metalloporphyrins bound to IsdG and IsdI, two heme-degrading enzymes in
Staphylococcus aureus. J. Biol. Chem., 2008, 283 (45), 30957-63.

20.

Takayama, S. J.; Ukpabi, G.; Murphy, M. E.; Mauk, A. G., Electronic properties
of the highly ruffled heme bound to the heme degrading enzyme IsdI. Proc. Natl.
Acad. Sci., 2011, 108 (32), 13071-6.

21.

Graves, A. B.; Morse, R. P.; Chao, A.; Iniguez, A.; Goulding, C. W.; Liptak,
M. D., Crystallographic and spectroscopic insights into heme degradation by
Mycobacterium tuberculosis MhuD. Inorg. Chem., 2014, 53 (12), 5931-40.

22.

Chim, N.; Iniguez, A.; Nguyen, T. Q.; Goulding, C. W., Unusual diheme
conformation of the heme-degrading protein from Mycobacterium tuberculosis. J.
Mol. Bio., 2010, 395 (3), 595-608.

23.

Graves, A. B.; Horak, E. H.; Liptak, M. D., Dynamic ruffling distortion of the
heme substrate in non-canonical heme oxygenase enzymes. Dalton Trans., 2016,
45 (24), 10058-67.

24.

Ukpabi, G.; Takayama, S. J.; Mauk, A. G.; Murphy, M. E., Inactivation of the
heme degrading enzyme IsdI by an active site substitution that diminishes heme
ruffling. J. Biol. Chem., 2012, 287 (41), 34179-88.

129

25.

Lockhart, C. L.; Conger, M. A.; Pittman, D. S.; Liptak, M. D., Hydrogen bond
donation to the heme distal ligand of Staphylococcus aureus IsdG tunes the
electronic structure. J. Biol. Inorg. Chem., 2015, 20 (5), 757-70.

26.

Conger, M. A.; Cornetta, A. R.; Liptak, M. D., Spectroscopic Evidence for
Electronic Control of Heme Hydroxylation by IsdG. Inorg. Chem., 2019, 58 (22),
15455-15465.

27.

Conger, M. A.; Pokhrel, D.; Liptak, M. D., Tight binding of heme to
Staphylococcus aureus IsdG and IsdI precludes design of a competitive inhibitor.
Metallomics, 2017, 9 (5), 556-563.

28.

Kapust, R. B.; Tozser, J.; Fox, J. D.; Anderson, D. E.; Cherry, S.; Copeland, T.
D.; Waugh, D. S., Tobacco etch virus protease: mechanism of autolysis and
rational design of stable mutants with wild-type catalytic proficiency. Protein
Eng, 2001, 14 (12), 993-1000.

29.

Nallamsetty, S.; Kapust, R. B.; Tozser, J.; Cherry, S.; Tropea, J. E.; Copeland,
T. D.; Waugh, D. S., Efficient site-specific processing of fusion proteins by
tobacco vein mottling virus protease in vivo and in vitro. Protein Expression
Purif., 2004, 38 (1), 108-15.

30.

Berry, E. A.; Trumpower, B. L., Simultaneous determination of hemes a, b, and c
from pyridine hemochrome spectra. Anal. Biochem., 1987, 161 (1), 1-15.

31.

Lobley, A.; Whitmore, L.; Wallace, B. A., DICHROWEB: an interactive website
for the analysis of protein secondary structure from circular dichroism spectra.
Bioinformatics, 2002, 18 (1), 211-2.

32.

Whitmore, L.; Wallace, B. A., DICHROWEB, an online server for protein
secondary structure analyses from circular dichroism spectroscopic data. Nucleic
Acids Res., 2004, 32 (Web Server issue), W668-73.

33.

Compton, L. A.; Johnson, W. C., Jr., Analysis of protein circular dichroism
spectra for secondary structure using a simple matrix multiplication. Anal.
Biochem., 1986, 155 (1), 155-67.
130

34.

Sreerama, N.; Woody, R. W., Estimation of protein secondary structure from
circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR
methods with an expanded reference set. Anal. Biochem., 2000, 287 (2), 252-60.

35.

Schuelke-Sanchez, A. E. Spectroscopic Study of the Formation and Degradation
of Metalated Tetrapyrroles by the Enzymes CfbA, IsdG, and MhuD. Dissertation
and Theses, University of Vermont, 2019.

36.

Gouterman, M., Study of the Effects of Substitution on the Absorption Spectra of
Porphin. J. Chem. Phys., 1959, 30, 1139 - 1161.

37.

Graves, A. B.; Graves, M. T.; Liptak, M. D., Measurement of Heme Ruffling
Changes in MhuD Using UV-vis Spectroscopy. J. Phys. Chem. B, 2016, 120 (16),
3844-53.

38.

Falk, J. E., Porphyrins and Metalloporphyrins. Elsevier Publishing Co. :
Amsterdam, 1964.

39.

Jones, P.; Prudhoe, K.; Robson, T., Oxidation of deuteroferrihaem by hydrogen
peroxide. Biochem. J., 1973, 135 (2), 361-5.

40.

Streit, B. R.; Kant, R.; Tokmina-Lukaszewska, M.; Celis, A. I.; Machovina, M.
M.; Skaar, E. P.; Bothner, B.; DuBois, J. L., Time-resolved Studies of IsdG
Protein Identify Molecular Signposts along the Non-canonical Heme Oxygenase
Pathway. J. Biol. Chem., 2016, 291 (2), 862-871.

131

CHAPTER 6: SYNTHESIS OF MESO–HYDROXYHEME: TO UNDERSTAND THE
ENZYMATIC MECHANISM OF MHUD FOR CONVERSION OF -MESO–
HYDROXYHEME TO MYCOBILIN.
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6.1 INTRODUCTION
Heme oxygenases (HOs) are a family of enzymes found in mammals, bacteria and
plants, that are involved in the biological process of heme degradation, where heme is
oxidatively cleaved to form biliverdin, with the release of carbon monoxide (CO) and
free iron.1-3 During the heme degradation by HO, heme is first hydroxylated at the meso position to form -meso-hydroxyheme.4 Next, -meso-hydroxyheme is converted
to form verdoheme, by the release of meso-carbon as CO.4, 5 Finally, verdoheme is
converted to biliverdin through the oxidative cleavage at the -meso position and the iron
is released (Figure 6.1).6, 7
In bacterial pathogens, HO predominantly catalyzes heme to produce biliverdin,8,
9

however, several bacterial pathogens such as Mycobacterium tuberculosis and

Figure 6. 1. Proposed heme degradation mechanism by HO, MhuD and IsdG/I. The first
monooxygenation step on forming meso-hydroxyheme is common for all three. The
subsequent degradation by HO (top), MhuD (middle) and IsdG/I (bottom) produces
different side and final products by releasing iron.
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In bacterial pathogens, HO predominantly catalyzes heme to produce biliverdin,8,
9

however, several bacterial pathogens such as Mycobacterium tuberculosis and

Staphylococcus aureus consists of non-canonical HO that degrades heme to produce
different organic byproducts than biliverdin.10-12 M. tuberculosis MhuD has been shown
to degrade heme to mycobilin, with the release of free iron and the meso-carbon is
retained as an aldehyde group.11 On the other hand, S. aureus IsdG/I catalyzes heme to
produce staphylobilin, with the release of free iron and formaldehyde (Figure 6.1).10 Like
canonical HO, the heme degradation by IsdG/I and MhuD has been proposed to go
through a meso-hydroxyheme intermediate,13, 14 and this is also where the similarities end
between them. Moreover, unlike the canonical HO, the initial hydroxylation by IsdG/I
and MhuD has been shown to happen at the /-meso position (Figure 6.1).10, 13, 14 Thus,
these non-canonical HO follow distinct heme degradation mechanism than what has been
known for canonical HO.
Previous studies have synthesized -meso-hydroxyheme to help understand the
nature of the -meso-hydroxyheme-HO complex, as well as to help understand the
underlying mechanism behind the conversion of -meso-hydroxyheme to verdoheme5, 7,
15, 16

because the reactive meso-hydroxyheme intermediate is hard to isolate and

characterize. The meso-hydroxyheme is proposed to exist in a resonance structure of a
keto form, a phenolate form, and a ferrous neutral radical form.15 The spectroscopic study
on the -meso-hydroxyheme-HO complex has helped to understand its coordination
chemistry.15 More importantly, the verdoheme formation from -meso-hydroxyheme-HO
was suggested to go through either Fe(III) and Fe(II) state.15 An Electron Paramagnetic
Resonance study later revealed that an equilibrium between a Fe(III) and a Fe(II) with an
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organic radical exists for -meso-hydroxyheme-HO complex.4 The studies involving the
need of an oxygen and an electron for the conversion of -meso-hydroxyheme to
verdoheme using a synthetic meso-hydroxyheme has been controversial.5, 15, 16
Nevertheless, a kinetic study has suggested that the more favorable path involves
conversion of Fe(III) -meso-hydroxyheme to Fe(III) verdoheme, which then gets
reduced to Fe(II) verdoheme.17
Similarly, artificially synthesized meso-hydroxyheme can be complexed to MhuD
in order to investigate the nature of meso-hydroxyheme-MhuD via spectroscopy, and to
understand the mechanism on conversion of -meso-hydroxyheme to mycobilin.
Previous study using artificial meso-hydroxyheme has showed that heme degradation by
MhuD proceeds via -meso-hydroxyheme.13 In addition, it also revealed that -mesohydroxyheme gets converted to a dioxetane intermediate on the way to mycobilin
formation (Figure 6.1).13 Likewise, other spectroscopic techniques such as Magnetic
Circular Dichroism can be utilized to understand the electronic ground state of the mesohydroxyheme-MhuD, similar to what has been studied for MhuD−heme complex.18-20
This can help understand any electronic driving force behind the dioxygenation reaction
of -meso-hydroxyheme to mycobilin. Similarly, the synthetic meso-hydroxyheme can
be complexed to R26S and W66F variants of MhuD in understanding the mechanism
behind their role in formation of biliverdin instead of mycobilin (Chapter 3).21 Therefore,
the synthesis of meso-hydroxyheme will help answer lot of the questions regarding the
second step of the heme degradation by MhuD (Figure 6.1).
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The full synthetic steps on formation of meso-hydroxyheme from heme is shown
in the Figure 6.2. However, in this study, synthesis of meso-benzoyloxyprotoporphyrin
IX dimethyl ester from heme, using previously described methods is performed. Next
step on the conversion of meso-benzoyloxyprotoporphyrin IX dimethyl ester to meso-

Figure 6. 2. Synthetic steps on formation of meso-hydroxyheme from heme.The products
at each synthetic step are labelled from (1) to (7). They correspond to: heme (1), heme
dimethyl ester (2), u-oxo-bis(heme dimethyl ester) (3), meso-benzoyloxy heme dimethyl
ester isomers (4), meso-benzoyloxyprotoporphyrin IX dimethyl ester isomers (5), benzoyloxyprotoporphyrin IX dimethyl ester (6) and -meso-hydroxyheme (7).
hydroxyheme is describe in the following chapter (Chapter 7). For the synthesis,
previous methods were slightly modified, and are described below. The UV/Vis
absorbance (Abs) spectroscopy along with the Mass Spectrometry (MS) were used to
characterize the products at various synthetic steps. The results and some interesting
observations during the synthesis has been reported and discussed in detail below.

136

6.2 EXPERIMENTAL
Unless otherwise noted, all materials in this work were purchased from Fisher Scientific
and used without further purification.
Conversion of heme to heme dimethyl ester (hDME). The process of
esterifying the acid groups of heme is well known and has been described previously.22, 23
However, the method was adjusted slightly and described as follows. 0.5 g of hemin
chloride was esterified using 50 mL sulfuric acid/methanol (5%, v/v) acid at room
temperature while stirring overnight (~20 hrs). The resulting reaction mixture was
washed with diethyl ether and hydrochloric acid/water (5%, w/v). The middle precipitate
layer (hDME) was collected, filtered through a filter paper, and dried. The final yield was
~99%.
Conversion of hDME to -oxo-bis(heme dimethyl ester) [-oxo-bis(hDME)].
The dimerization reactions of hDME to -oxo-bis(hDME) has been previously been
described.24, 25 A modification was made during the alumina chromatography, where the
dimer band was eluted with acetonitrile/chloroform (5%, v/v). Also, the crystallization of
-oxo-bis(hDME) was modified using hexane-chloroform mixture. The final yield was
~25%.
Addition of meso-benzoyloxo group and demetallation to prepare isomeric
mixture of meso-benzoyloxyprotoporphyrin IX dimethyl ester (meso-bPPIX-DME).
The preparation of isomeric mixture of meso-benzoyloxyheme dimethyl ester and mesobPPIX-DME was performed as described previously with some modifications.7 The
elution of isomeric mixture of meso-benzoyloxyheme dimethyl ester using alumina
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chromatography was performed using chloroform/methanol (100:1, v/v). Likewise, after
the demetallation, the elution of the isomeric mixture of meso-bPPIX-DME using
alumina chromatography was performed using a mixture of acetonitrile/chloroform (5%,
v/v).
Spectral Characterization. UV/Vis Absorbance (Abs) spectroscopy was utilized
to analyze the spectra of hDME, -oxo-bis(hDME) and meso-bPPIX-DME in
chloroform. The Abs spectra was collected on a Cary 100 Bio spectrophotometer with a
scan rate of 600 nm/min, 0.1 s digital integration time, 2 nm bandwidth, and 1.0 nm data
interval.
Mass Spectrometry (MS). Two different ionization techniques were utilized:
Electrospray ionization (ESI-MS) and Atmospheric pressure chemical ionization (APCIMS) for the sample analysis using ABI Sciex 4000 QTrap Pro hybrid triple-quadrupole
mass spectrometer. Sample of hDME and -oxo-bis(hDME) was injected into the MS
using ESI, equilibrated with 98% acetonitrile with 0.1% formic acid (v/v) in water (v/v).
In addition, APCI was also used to inject the -oxo-bis(hDME) sample into the MS,
equilibrated with 100% acetonitrile as the mobile phase. MS Data was analyzed using
BioAnalyst 1.5.
6.3 RESULTS AND DISCUSSION
Spectral Characterization of hDME: The Abs spectra of the esterified product
in chloroform was taken to make sure the esterification reaction was successful (Figure
6.3). The Abs spectrum of the esterified product in chloroform had a Soret band at 387
nm and Q-bands at 510, 541, and 641 nm. This is similar to the Abs spectrum reported
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for the heme dimethyl ester in previous study.26 Next, ESI-MS was also performed on the
esterified product to confirm this result. During the extraction procedure, three different
layers were observed in the separatory funnel. The top was an organic layer, middle was
a precipitate, and the bottom layer was an aqueous mixture. Using ESI-MS organic, and

Figure 6. 3. Abs spectrum of esterified product in chloroform with Soret band at 387 nm
and Q-bands at 510, 541, and 641 nm. It matches the Abs spectra of hDME. Inset: the
zoomed in Abs spectrum from 450 to 675 nm.
the precipitate layer was analyzed to identify the formation of hDME. ESI-MS spectra of
the precipitate dissolved in chloroform showed a defined peak of m/z 644.3 (Figure 6.4).
This matches the theoretical mass of hDME (644.5 g/mol). However, the MS of the
organic layer suggests that it may be a mixture of hDME and other impurities (Figure
E.1). Qualitatively, the esterified heme is dark reddish in color when dissolved in
chloroform. Therefore, Abs and MS data suggests that the esterification of heme was
successful.
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Figure 6. 4. ESI-MS spectrum of the esterified product (extracted precipitate). The m/z
644.3 is consistent with the theoretical mass of hDME (644.2 g/mol).

Figure 6. 5. Abs spectrum of dimerized product of the esterified heme (hDME) in
chloroform with Soret band at 396 nm and Q-bands at 571 and 599 nm. Inset: the zoomed
in Abs spectrum from 520 to 690 nm.
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Spectral Characterization of -oxo-bis(hDME). After the dimerization, Abs
spectra was taken to confirm the formation of -oxo-bis(hDME). The Abs spectrum is a
match to the previously reported -oxo-bis(hDME),27 with a Soret band at 396 nm and
the Q-bands at 571 and 599 nm (Figure 6.5). Qualitatively, after the dimerization
reaction, a change from reddish to a distinct green solution is observed. But the ESI-MS
taken on the dimerized product revealed m/z of 644.3 (data no shown). Careful
observations during the dimer synthesis pointed out that the dimer was not very stable in
the acidic environment or in an organic solvent with a proton source. In the previous
studies involving -oxo-bis(Fe(III)porphyrin) polymer28, 29 and -oxo-bis(Fe(III)TPP)30,
the presence of Bronsted acid readily broke the -oxo bridge to give their respective
monomers. This is shown to be a reversible phenomenon, where it reverts to -oxo
bridged dimer upon addition of a base. Thus, the dimer formation seems to be acid-base
controlled. Another study has determined that the dimerization of Iron(III)
protoporphyrin IX is controlled by solvent identity.31The study revealed that the -oxo
dimer does not form in the presence of a protic solvent. Instead – dimerization or
monomer formation was observed when methanol, ethanol, 2-propanol, etc., was used.31
Thus, it is plausible that the ESI-MS process that is used to identify the -oxobis(hDME) in this study is breaking apart the -oxo bridge, because a small amount of
formic acid [98% acetonitrile with 0.1% formic acid (v/v) in water (v/v)] is being used as
a mobile phase (Figure E.2). Therefore, the mobile phase was changed to 100%
acetonitrile and the ESI-MS was performed on the dimerized product (Figure E.3).
Removing the proton source resulted in a peak at m/z 1343.7 and m/z 718.4. These peaks
may be arising from the presence of potassium adduct ions (+K, m/z 38 for m/z 1343.7
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peak and +2K-H, m/z 76 for m/z 718.4 peak). Changing the ionization source from ESI to
APCI may get rid of the metal adduct ion problem. Unlike, ESI where the ionization
occurs in the liquid-phase32, the ionization in APCI occurs in the gas-phase33. Thus, the
metal ions such as sodium and potassium cannot be easily vaporized as ions,
consequently their corresponding adduct ions would be absent when APCI is used as an
ionization source. APCI-MS of the dimerized sample showed a peak at m/z 1305.6 and
m/z 644.2 (Figure E.4), corresponding to -oxo-bis(hDME) and hDME, respectively.
Since APCI-MS is used for identification purposes only, it is impossible to quantify the
amount of dimer species in solution because the ionization efficiency of the -oxobis(hDME) and hDME is not known. This data does, however, show that the dimerization
reaction was successful. Thus, the crystallized dimer was used as a starting material for
the next step in synthesis.
Spectral Characterization of meso-bPPIX-DME. During the alumina
chromatography of the demetallated meso-benzoyloxyheme dimethyl ester, two distinct
bands were observed; green top band and bright red bottom band. The bright red band
was eluted using acetonitrile/chloroform (5%, v/v), while the green band did not travel.
The green band may be the unreacted meso-benzoyloxyheme dimethyl ester. Abs spectra
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for the bright red band in chloroform was taken (Figure 6.6). The Abs spectra of the
bright red solution has a Soret band at 408 nm and the Q-bands at 506, 540, 578 and 630

Figure 6. 6. UV/Vis absorbance spectra alumina eluted bright red band (solid red). The
Soret band is observed at 408 nm and the Q-bands are observed at 506, 540, 578 and 630
nm. This is like the Abs spectra reported for meso-benzoyloxyprotoporphyrin IX
dimethyl ester.7, 34
nm. This is consistent with the Abs spectra of -benzoyloxoprotoporphyrin IX dimethyl
ester7, 34, however the Abs spectra for other meso-bPPIX-DME isomers (  and ) are
also very similar34. Also, without the separation of these isomers, it is likely that the
resulting Abs spectra is due to the combination of all four isomers in solution.
Nonetheless, this suggests that meso-bPPIX-DME isomers were successfully synthesized.
Several attempts to separate the isomers using a High Pressure Liquid Chromatography
(HPLC) method as described previously, has been unsuccessful.35 Careful qualitative
inspection suggested that the color of the isomeric mixture of meso-bPPIX-DME was
changing with time. Abs spectra was taken to check the changes in the color (Figure E.5).
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In the old sample, a new peak at 666 nm is observed compared to the fresh sample. This
may be due to the photooxidation of the meso-bPPIX-DME isomers. Previous studies
have shown that photooxidation of protoporphyrin IX dimethyl ester in an aprotic solvent
yielded a mixture of hydroxyaldehydes (photoprotoporphyrins), which is evidenced by
the growth of a band at 670 nm.36 Thus, it is likely that the meso-bPPIX-DME isomers
has been photooxidized. The eluted isomeric mixture of meso-bPPIX-DME was not
protected from light while performing HPLC separation. Along with mixtures of mesobPPIX-DME isomers, photooxidized mixtures of these isomers could also be present in
the solution, which can make HPLC separation quite difficult. Thus, the separation must
be performed in the absence of light. Even though the separation of the isomers weren’t
completed, the data shows that the formation of the meso-bPPIX-DME isomers from oxo-bis(hDME) was successful. It is worth noting that the Abs spectra of protoporphyrin
IX dimethyl ester in chloroform is also very similar to the spectra of meso-bPPIX-DME
isomers (Figure 6.3).37 However, this seems unlikely and the 1H NMR spectra on the
separated meso-bPPIX-DME isomers can provide evidence regarding this issue.

6.4 CONCLUSION
In conclusion, hemin chloride has been successfully esterified to heme dimethyl
ester and confirmed with Abs spectroscopy. Next, the ester was dimerized to form -oxobis(heme dimethyl ester) and confirmed with Abs spectroscopy and Mass Spectrometry.
Finally, the addition of benzoyl-oxo protecting group onto the meso carbons of the dimer,
followed by its demetallation, resulted in the formation of mesohenzoyloxyprotoporphyrin IX dimethyl ester isomers. The formation meso-bPPIX-DME
was suggested by the Abs spectroscopy, however, more work needs to be done to confirm
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this. The final goal for this project is to synthesize meso-hydroxyheme, thus its future
directions are discussed in the following chapter (Chapter 7).
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CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS
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7.1 CONCLUSIONS
A spectroscopic and chromatographic study of MhuD and its variants has
provided insights into the heme binding and degradation by MhuD. Also, a spectroscopic
investigation of the F23W variant of IsdG provided detailed understanding on the role of
Phe23 residue in the heme degradation mechanism. Heme binding affinity studied using
fluorescence spectroscopy showed that MhuD binds the first heme with nanomolar
dissociation constant, making it a competent HO in vivo. An Abs assay was developed to
investigate the second dissociation constant. The micromolar binding affinity was
extracted from the fitted Abs data for binding of a second heme by MhuD. This led us to
propose that MhuD–diheme is a preferred state in a heme replete condition, and to
speculate that MhuD may have a secondary function of heme storage or a regulatory
protein. Next, the influence of second-sphere amino acids on the heme degradation
mechanism was studied.
An Abs and MS study of WT, F23W and W66F MhuD was performed to
investigate the role of active site induced heme ruffling on the heme degradation
mechanism by MhuD. The heme substrate is more ruffled in F23W MhuD,1 and less
ruffled in W66F compared to WT MhuD.2 Abs and MS monitored heme degradation by
F23W MhuD showed decreased heme degradation activity. Furthermore, tandem LC-MS
and Abs spectra identified the presence of a meso-hydroxyheme intermediate. Thus, the
Abs monitored assay was used to determine the rate formation and destruction of the
meso-hydroxyheme. The data suggested that the rate of formation of the intermediate is
considerably faster than its rate of conversion to the final product. Thus, increased heme
ruffling seems to alter the heme degradation pathway by slowing down the second step of
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the mechanism. This would also suggest that planar heme conformation may be
important for the conversion of meso-hydroxyheme to mycobilin. On the other hand,
heme degradation by W66F MhuD was studied as a function of time using Abs and MS.
The study confirmed the alteration of the product identity, as −biliverdin is observed as
the major product of heme degradation by W66F MhuD. This suggests that the active site
of MhuD incorporating less ruffled heme dramatically changes the heme degradation
mechanism in a way to accommodate different organic byproduct. These data suggest
that the heme substrate ruffling deformation induced by the active site of MhuD is
responsible for the unique heme degradation products. Therefore, it is important to have a
dynamic heme in the active site of MhuD for its activity, because the absence of either of
the heme conformation (planar or ruffled) completely alters the heme degradation
mechanism.
A combination of Abs, NMR and MCD spectroscopy was utilized to study
cyanide inhibited R26S MhuD–heme–CN to understand the role of Arg26 in heme
degradation mechanism of MhuD. A recent study has shown that R26S MhuD degrades
heme to biliverdin by the release of formaldehyde.3 NMR spectroscopy confirmed the
presence of two different species: one with 2Eg [(dxz, dyz )3 (dxy)2] electronic ground state
(planar heme) and another with a mixture of 2Eg and 2B2g [(dxz, dyz )4 (dxy)1] electronic
states (dynamic heme). The Abs spectrum of R26S showed lack of change in the Soret
and the Q-band compared to WT MhuD–heme–CN, however, it is likely that the Abs
spectroscopy may not be sensitive enough to distinguish between the two species.
Moreover, VTVH MCD spectroscopy showed 2B2g as the electronic ground state of the
dynamic species. Based on the crystal structure of MhuD–heme–CN4 and MhuD–
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diheme,5 Arg26 forms a salt bridge interaction with a propionate group of heme in
MhuD–heme, and with a propionate group of the solvent exposed heme in MhuD–
diheme structure. Thus, losing this interaction would lead to lack of control on guiding
heme into the correct binding pocket, which may result in binding of heme at different
binding site inducing separate heme conformations. A heme degradation study performed
using MS and a previous study3 has shown that biliverdin and mycobilin are formed as
the major and the minor product, respectively. Previous studies have shown, MhuD
degrades dynamic heme in its active site to mycobilin and canonical HO degrades planar
heme in its active site to biliverdin.4, 6, 7 Thus, the presence of planar or dynamic heme in
the active site may control the identity of heme degradation product by R26S MhuD.
Therefore, these data led us to propose that the loss of Arg26 involved in stabilizing the
monoheme binding site, changes the dynamics of the active site of R26S MhuD in a way
to accommodate either planar or dynamic heme.
Besides MhuD, heme degradation of IsdG was also examined. Spectroscopic and
chromatographic investigation on Phe23 substituted Staphylococcus Aureus IsdG was
performed using a combination of Abs, CD and MS to gain insights on the role of Phe23
in the heme degradation mechanism by IsdG. CD spectroscopy showed a lack of
structural changes in IsdG due to F23W substitution. Furthermore, the Abs spectrum of
F23W IsdG confirmed that the bulkier amino acid substitution at the 23-residue position
did not alter the heme conformation. The MS and the Abs monitored activity assays
confirmed the presence of formyl-oxo-bilin and staphylobin, suggesting that the heme is
being degraded efficiently by F23W IsdG. These data showed that the F23W substitution
did not affect the heme degradation activity by IsdG, which is consistent with the CD and
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the Abs data. Phe23 is a conserved residue in IsdG and MhuD, however, the data
presented in this study strongly suggest that its role is distinct in each of these enzymes.
Therefore, the Phe23 is not involved in the heme degradation mechanism by IsdG.
Finally, the synthesis of meso-hydroxyheme was initiated to investigate the
electronic structure of the meso-hydroxyheme complexed with MhuD, and subsequently
understand the mechanism behind the conversion meso-hydroxyheme to mycobilin. MS
and Abs spectroscopy were utilized, which confirmed the identity of synthesized
intermediates along the meso-hydroxyheme conversion process. Hemin chloride was used
as a starting product and successfully converted to isomeric mixture of mesobenzoyloxoprotoporphyrin dimethyl ester (meso-bPPIX DME) using previously
described methods with several modifications, as described in Chapter 6. However, the
separation of these isomers along with their hydrolysis to form meso-hydroxyheme will
be discussed below (Future direction).
7.2 FUTURE DIRECTIONS
A thorough investigation on heme degradation by F23W MhuD suggested that the
second step of the heme degradation mechanism is significantly slowed down. This is the
first instance where an intermediate; meso-hydroxyheme, has been observed during heme
degradation by MhuD. The meso-hydroxyheme in canonical HO has been proposed to
have a resonance structure of a ferric keto form, a ferric phenolate form, and a ferrous
neutral radical form. Electron Paramagnetic Resonance (EPR) is a great tool to elucidate
local environment, structure, and oxidation states of the paramagnetic center. Thus, EPR
spectroscopy could be utilized to investigate meso-hydroxyheme. Previously, the
reconstituted MhuD–-meso-hydroxyheme study has identified the intermediate as a
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ferrous neutral radical form using EPR spectroscopy.8 However, past studies have shown
that the experimentally observed meso-hydroxyheme complexed with the HO-19 had
different structure than the one observed from the reconstituted HO1–-mesohydroxyheme.10 Therefore, the intermediate observed during the heme degradation by
F23W MhuD should be analyzed by EPR to characterize the intermediate.
Next, the meso-hydroxyheme synthesis can be completed from an isomeric
mixture of meso-bPPIX DME. The separation of these isomers with Normal Phase HPLC
has been unsuccessful. A previous method which uses 250 x 4 mm Hypersil 5 Silica
column with Acetone :1,2-dichloroethane (1:99) as mobile phase has been successful in
separating the isomers.11 The method describes that the alumina chromatography for the
collection of isomeric mixtures were performed in the dark and were collected in 50 mL
batch and these batches were analyzed by HPLC at 400 nm. It should also be noted that
the silica column is hygroscopic in nature and to maintain a consistent retention time and
better separation, a 50% water-saturated mobile phase should be used.12 Therefore, these
changes can be done to the current HPLC method to separate the meso-bPPIX DME
isomers. After the separation of the isomers, the separated meso-bPPIX DME can be
metallated and hydrolyzed to give their respective meso-hydroxyheme isomer, as
described previously.13 It has been proposed that heme ruffling may alter the electronic
structure and the reactivity of IsdG/I– and MhuD–meso-hydroxyheme complex, however,
this remains untested experimentally. Therefore, Magnetic Circular Dichroism (MCD)
spectroscopy can be used to characterize the electronic structure of MhuD–mesohydroxyheme and the IsdG/I–meso-hydroxyheme complex.
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A.1 SUPPLEMENTAL EXPERIMENTAL
The fluorescence-detected titrations of heme into MhuD and MhuDCH were analyzed in
order to determine Kd1 for MhuD and MhuDCH. The Trp66 fluorescence intensity for a
mixture of MhuD, MhuD–heme, and heme depends upon equation (A.1):

𝐹=

([𝑀ℎ𝑢𝐷]𝑇 +[ℎ𝑒𝑚𝑒]𝑇 +𝐾𝑑1 )−√([𝑀ℎ𝑢𝐷]𝑇 +[ℎ𝑒𝑚𝑒]𝑇 +𝐾𝑑1 )2 −4[𝑀ℎ𝑢𝐷]𝑇 [ℎ𝑒𝑚𝑒]𝑇
2

𝐹𝑚𝑖𝑛 −𝐹𝑚𝑎𝑥

X(

[𝑀ℎ𝑢𝐷]𝑇

)+

(A.1)

𝐹𝑚𝑎𝑥

The Abs-detected titrations were analyzed to extract Kd2 for MhuD and MhuDCH. The
Abs intensity at 410 nm for a mixture of MhuD, MhuD–diheme, MhuD–heme, and heme
depends upon equation (A.2):

𝐴410 =

𝜀𝑀ℎ𝑢𝐷−𝑑𝑖ℎ𝑒𝑚𝑒 [𝑀ℎ𝑢𝐷𝑇 ][ℎ𝑒𝑚𝑒]2 +𝜀𝑀ℎ𝑢𝐷−ℎ𝑒𝑚𝑒 𝐾𝑑2 [𝑀ℎ𝑢𝐷𝑇 ][ℎ𝑒𝑚𝑒]
+
[ℎ𝑒𝑚𝑒]2 +𝐾𝑑2 [ℎ𝑒𝑚𝑒]+𝐾𝑑1 𝐾𝑑2

𝜀ℎ𝑒𝑚𝑒 ([ℎ𝑒𝑚𝑒]3 +𝐾𝑑2 [ℎ𝑒𝑚𝑒]2 +𝐾𝑑1 𝐾𝑑2 [ℎ𝑒𝑚𝑒])

(A.2)

[ℎ𝑒𝑚𝑒]2 +𝐾𝑑2 [ℎ𝑒𝑚𝑒]+𝐾𝑑1 𝐾𝑑2

where εMhuD–diheme, εMhuD–heme, and εheme are the molar extinction coefficients for
MhuD–diheme, MhuD–heme, and heme, respectively, at 410 nm. The Abs-detected
heme titrations intoWT MhuD were performed to extract the dissociation constant (Kd2)
of binding for the second heme substrate. The Abs intensity at 410 nm for a mixture
containing MhuD–diheme, MhuD–heme, MhuD and heme depends on equation (A.3):
𝐴410 = 𝜀𝑀ℎ𝑢𝐷−𝑑𝑖ℎ𝑒𝑚𝑒 [𝑀ℎ𝑢𝐷 − 𝑑𝑖ℎ𝑒𝑚𝑒] + 𝜀𝑀ℎ𝑢𝐷−ℎ𝑒𝑚𝑒 [𝑀ℎ𝑢𝐷 − ℎ𝑒𝑚𝑒] +
(A.3)

𝜀ℎ𝑒𝑚𝑒 [ℎ𝑒𝑚𝑒]

where, MhuD-diheme, MhuD–heme, and heme are the extinction coefficients of these species at
410 nm. The Kd1 for the first heme binding to MhuD is given by equation (A.4):
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𝐾𝑑1 =

[𝑀ℎ𝑢𝐷][𝐻𝑒𝑚𝑒]
[𝑀ℎ𝑢𝐷 − ℎ𝑒𝑚𝑒]

(𝐴. 4)

The Kd2 for the second heme binding to MhuD is given by equation (A.5):

𝐾𝑑2 =

[𝑀ℎ𝑢𝐷 − ℎ𝑒𝑚𝑒][𝐻𝑒𝑚𝑒]
[𝑀ℎ𝑢𝐷 − 𝑑𝑖ℎ𝑒𝑚𝑒]

(𝐴. 5)

The total amount of MhuD (MhuDT) is defined by equation (A.6):
[𝑀ℎ𝑢𝐷𝑇 ] = [𝑀ℎ𝑢𝐷] + [𝑀ℎ𝑢𝐷 − 𝑑𝑖ℎ𝑒𝑚𝑒] + [𝑀ℎ𝑢𝐷 − ℎ𝑒𝑚𝑒]

(A.6)

Rearranging equation (A.6):
[𝑀ℎ𝑢𝐷] = [𝑀ℎ𝑢𝐷𝑇 ] − [𝑀ℎ𝑢𝐷 − 𝑑𝑖ℎ𝑒𝑚𝑒] − [𝑀ℎ𝑢𝐷 − ℎ𝑒𝑚𝑒]

(A.7)

The total amount of heme (hemeT) is defined by equation (A.8):
[ℎ𝑒𝑚𝑒𝑇 ] = [ℎ𝑒𝑚𝑒] + 2[𝑀ℎ𝑢𝐷 − 𝑑𝑖ℎ𝑒𝑚𝑒] + [𝑀ℎ𝑢𝐷 − ℎ𝑒𝑚𝑒]

(A.8)

This equation can be rearranged to give equation (A.9)
[ℎ𝑒𝑚𝑒] = [ℎ𝑒𝑚𝑒𝑇 ] − 2[𝑀ℎ𝑢𝐷 − 𝑑𝑖ℎ𝑒𝑚𝑒] − [𝑀ℎ𝑢𝐷 − ℎ𝑒𝑚𝑒]

(A.9)

Next, we have introduced a dummy variable, α, which is given by equation (A.10) 1
Let 𝛼 =

[𝑀ℎ𝑢𝐷−𝑑𝑖ℎ𝑒𝑚𝑒]

(A.10)

[ℎ𝑒𝑚𝑒]2

By dividing [MhuD–diheme], [MhuD–heme] and [MhuD] by α, we get equations (A.11) (A.13) respectively:
[𝑀ℎ𝑢𝐷 − 𝑑𝑖ℎ𝑒𝑚𝑒]
= [ℎ𝑒𝑚𝑒]2
𝛼

(𝐴. 11)

[𝑀ℎ𝑢𝐷 − ℎ𝑒𝑚𝑒]
= 𝐾𝑑2 [ℎ𝑒𝑚𝑒]
𝛼

(𝐴. 12)
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[𝑀ℎ𝑢𝐷]
= 𝐾𝑑1 𝐾𝑑2
𝛼

(𝐴. 13)

Dividing equation (A.6) by α using equations (A.11), (A.12) and (A.13) results in
equation (A.14):
[𝑀ℎ𝑢𝐷𝑇 ]
= [ℎ𝑒𝑚𝑒]2 + 𝐾𝑑2 [ℎ𝑒𝑚𝑒] + 𝐾𝑑1 𝐾𝑑2
𝛼

(𝐴. 14)

Dividing equation (A.9) by α and substituting with equations (A.11) and (A.12) gives
equation (A.15):
[ℎ𝑒𝑚𝑒]
[ℎ𝑒𝑚𝑒𝑇 ]
= 2[ℎ𝑒𝑚𝑒]2 + 𝐾𝑑2 [ℎ𝑒𝑚𝑒] +
𝛼
𝛼

(A. 15)

Dividing equation (A.13) by equation (A.14) gives equation (A.16):

[𝑀ℎ𝑢𝐷] =

[𝑀ℎ𝑢𝐷𝑇 ]𝐾𝑑1 𝐾𝑑2
+ 𝐾𝑑2 [ℎ𝑒𝑚𝑒] + 𝐾𝑑1 𝐾𝑑2

[ℎ𝑒𝑚𝑒]2

(A. 16)

Dividing [heme] by α and using equation (A.10), we get equation (A.17):
[ℎ𝑒𝑚𝑒]3
[ℎ𝑒𝑚𝑒]
=
[𝑀ℎ𝑢𝐷 − 𝑑𝑖ℎ𝑒𝑚𝑒]
𝛼

(A. 17)

Multiplying equation (A.4) and (A.5), we get equation (A.18):

𝐾𝑑1 𝐾𝑑2

[ℎ𝑒𝑚𝑒]2 [𝑀ℎ𝑢𝐷]
=
[𝑀ℎ𝑢𝐷 − 𝑑𝑖ℎ𝑒𝑚𝑒]

(A. 18)

Rearranging equation (A.18) results in equation (A.19):
[ℎ𝑒𝑚𝑒]2 [𝑀ℎ𝑢𝐷]
[𝑀ℎ𝑢𝐷 − 𝑑𝑖ℎ𝑒𝑚𝑒] =
𝐾𝑑1 𝐾𝑑2

(A. 19)

Substitution of equation (A.19) into equation (A.17) gives equation (A.20):
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[ℎ𝑒𝑚𝑒] [ℎ𝑒𝑚𝑒]𝐾𝑑1 𝐾𝑑2
=
[𝑀ℎ𝑢𝐷]
𝛼

(A. 20)

Substitution of equation (A.16) into equation (A.20) gives equation (A.21):
[ℎ𝑒𝑚𝑒] [ℎ𝑒𝑚𝑒]3 + [ℎ𝑒𝑚𝑒]2 𝐾𝑑2 + [ℎ𝑒𝑚𝑒]𝐾𝑑1 𝐾𝑑2
=
[𝑀ℎ𝑢𝐷𝑇 ]
𝛼

(A. 21)

Substitution of equation (A.21) in equation (A.15), gives equation (A.22)
2[𝑀ℎ𝑢𝐷𝑇 ][ℎ𝑒𝑚𝑒]2 + [𝑀ℎ𝑢𝐷𝑇 ][ℎ𝑒𝑚𝑒]𝐾𝑑2 + [ℎ𝑒𝑚𝑒]3 + [ℎ𝑒𝑚𝑒]2 𝐾𝑑2 +
[ℎ𝑒𝑚𝑒𝑇 ]
[ℎ𝑒𝑚𝑒]𝐾𝑑1 𝐾𝑑2
=
[𝑀ℎ𝑢𝐷𝑇 ]
𝛼
(A. 22)
Dividing equation (A.22) by equation (A.14) and solving, gives cubic equation (A.23):
[ℎ𝑒𝑚𝑒]3 + [ℎ𝑒𝑚𝑒]2 (2[𝑀ℎ𝑢𝐷𝑇 ] + 𝐾𝑑2 − [ℎ𝑒𝑚𝑒𝑇 ]) + [ℎ𝑒𝑚𝑒]([𝑀ℎ𝑢𝐷𝑇 ]𝐾𝑑2 +
𝐾𝑑1 𝐾𝑑2 − [ℎ𝑒𝑚𝑒𝑇 ]𝐾𝑑2 ) − [ℎ𝑒𝑚𝑒𝑇 ]𝐾𝑑1 𝐾𝑑2 = 0

(A.23)

The above equation (A.23) is in the form x3 + ax2 + bx + c = 0, where:
a = 2[𝑀ℎ𝑢𝐷𝑇 ] + 𝐾𝑑2 − [ℎ𝑒𝑚𝑒𝑇 ]
b = ([𝑀ℎ𝑢𝐷𝑇 ]𝐾𝑑2 + 𝐾𝑑1 𝐾𝑑2 − [ℎ𝑒𝑚𝑒𝑇 ]𝐾𝑑2 )
c = −[ℎ𝑒𝑚𝑒𝑇 ]𝐾𝑑1 𝐾𝑑2
x = [ℎ𝑒𝑚𝑒]
Solving and simplifying the cubic equation for x gives three real roots which is given by
equation (A.24.a), (A.24.b) and (A.24.c).2
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∅
𝑎
𝑥 = 2√−𝑄 cos ( ) −
3
3

(A. 24. 𝑎)

∅
𝑎
𝑥 = 2√−𝑄 cos ( + 120𝑜 ) −
3
3

(A. 24. 𝑏)

∅
𝑎
𝑥 = 2√−𝑄 cos ( + 240𝑜 ) −
3
3

(A. 24. 𝑐)

where,

𝑄=

3𝑏 − 𝑎2
9

(A. 25. 𝑎)

𝑅
∅ = 𝑐𝑜𝑠 −1 (
)
√−𝑄 3

(A. 25. 𝑏)

9𝑎𝑏 − 27𝑐 − 2𝑎3
𝑅=
54

(A. 25. 𝑐)

Equation (A.24.a) is the relevant solution of the cubic equation for this expreiment. Other
solutions: (A.24.b) and (A.24.c) did not provide best fits for the experiment and hence
would no
t be used to fit the data to calculate Kd2. Therefore, equation (A.24.a) will be used for rest
of the analysis. Dividing equation (1) by  yields equation (A.26):
𝐴410
𝜀𝑀ℎ𝑢𝐷−𝑑𝑖ℎ𝑒𝑚𝑒 [𝑀ℎ𝑢𝐷 − 𝑑𝑖ℎ𝑒𝑚𝑒] 𝜀𝑀ℎ𝑢𝐷−ℎ𝑒𝑚𝑒 [𝑀ℎ𝑢𝐷 − ℎ𝑒𝑚𝑒]
=
+
𝛼
𝛼
𝛼
+

𝜀ℎ𝑒𝑚𝑒 [ℎ𝑒𝑚𝑒]
𝛼
(A.26)
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Substituting the values from equation (A.11), (A.12) and (A.21) to equation (A.26) gives
equation (A.27):
𝐴410
= 𝜀𝑀ℎ𝑢𝐷−𝑑𝑖ℎ𝑒𝑚𝑒 [ℎ𝑒𝑚𝑒]2 + 𝜀𝑀ℎ𝑢𝐷−ℎ𝑒𝑚𝑒 𝐾𝑑2 [ℎ𝑒𝑚𝑒]
𝛼
[ℎ𝑒𝑚𝑒]3 + [ℎ𝑒𝑚𝑒]2 𝐾𝑑2 + [ℎ𝑒𝑚𝑒]𝐾𝑑1 𝐾𝑑2
+ 𝜀ℎ𝑒𝑚𝑒 (
)
[𝑀ℎ𝑢𝐷𝑇 ]
(A.27)
Dividing equation (A.27) by equation (A.14) and solving for A410 gives equation (A.28):
𝐴410
[𝑀ℎ𝑢𝐷𝑇 ]𝜀𝑀ℎ𝑢𝐷−𝑑𝑖ℎ𝑒𝑚𝑒 [ℎ𝑒𝑚𝑒]2 + [𝑀ℎ𝑢𝐷𝑇 ]𝜀𝑀ℎ𝑢𝐷−ℎ𝑒𝑚𝑒 𝐾𝑑2 [ℎ𝑒𝑚𝑒]
=
[ℎ𝑒𝑚𝑒]2 + 𝐾𝑑2 [ℎ𝑒𝑚𝑒] + 𝐾𝑑1 𝐾𝑑2
+

𝜀ℎ𝑒𝑚𝑒 ([ℎ𝑒𝑚𝑒]3 + [ℎ𝑒𝑚𝑒]2 𝐾𝑑2 + [ℎ𝑒𝑚𝑒]𝐾𝑑1 𝐾𝑑2 )
[ℎ𝑒𝑚𝑒]2 + 𝐾𝑑2 [ℎ𝑒𝑚𝑒] + 𝐾𝑑1 𝐾𝑑2

(A. 28)

Equation (A.28) and equation (A.24.a) was rewritten in Graph Pad Prism 7.0 to fit the
data collected from UV/Vis spectrophotometer and extract Kd2 as equation (A.29):
𝐴 = 2 ∗ 𝑃 + 𝐾𝑑2 − 𝑋
𝐵 = (𝑃 ∗ 𝐾𝑑2) + (𝐾𝑑1 ∗ 𝐾𝑑2) − (𝑋 ∗ 𝐾𝑑2)
𝐶 = −(𝑋 ∗ 𝐾𝑑1 ∗ 𝐾𝑑2)
𝑄 = ((3 ∗ 𝐵) − (𝐴 ∗ 𝐴))/9
𝑅 = ((9 ∗ 𝐴 ∗ 𝐵) − (27 ∗ 𝐶) − (2 ∗ 𝐴 ∗ 𝐴 ∗ 𝐴))/54
𝑇 = 𝑎𝑟𝑐𝑐𝑜𝑠(

𝑅
𝑠𝑞𝑟𝑡(−(𝑄 ∗ 𝑄 ∗ 𝑄))

)

𝑇
𝐴
𝐻 = ((2 ∗ (𝑠𝑞𝑟𝑡(−𝑄)) ∗ cos ( ))) − ( )
3
3
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(𝑃 ∗ 𝐸 ∗ 𝐻 ∗ 𝐻) + (𝐹 ∗ 𝑃 ∗ 𝐾𝑑2 ∗ 𝐻) +
𝑌=

(𝐺 ∗ ((𝐻 ∗ 𝐻 ∗ 𝐻) + (𝐾𝑑2 ∗ 𝐻 ∗ 𝐻) + (𝐻 ∗ 𝐾𝑑1 ∗ 𝐾𝑑2)))
(𝐻 ∗ 𝐻) + (𝐾𝑑2 ∗ 𝐻) + (𝐾𝑑1 ∗ 𝐾𝑑2)
(A.29)

where, E, F and G are extinction coefficient of MhuD–diheme, MhuD–heme and heme, P
is the total concentration of the protein. Abs data was used to plot abosrobance at 410 nm
(A410) as a function of total heme concentration (hemeT).

185

Table A. 1. MhuDCH gene sequence.
M-46

H-45

H-44

H-43

H-42

H-41

H-40

S-39

S-38

G-37

L-36

V-35

ATG

CAC

CAT

CAT

CAT

CAT

CAT

TCT

TCT

GGT

CTG

GTG

P-34

R-33

G-32

S-31

G-30

M-29

K-28

E-27

T-26

A-25

A-24

A-23

CCA

CGC

GGT

TCT

GGT

ATG

AAA

GAA

ACC

GCT

GCT

GCT

K-22

F-21

E-20

R-19

Q-18

H-17

M-16

D-15

S-14

P-13

D-12

L-11

AAA

TTC

GAA

CGC

CAG

CAC

ATG

GAC

AGC

CCA

GAT

CTG

G-10

T-9

D-8

D-7

D-6

D-5

K-4

A-3

M-2

A-1

P2

V3

GGT

ACC

GAC

GAC

GAC

GAC

AAG

GCC

ATG

GCC

CCA

GTG

V4

K5

I56

N7

A8

I9

E10

V11

P12

A13

G14

A15

GTG

AAG

ATC

AAC

GCA

ATC

GAG

GTG

CCC

GCC

GGC

GCT

G16

P17

E18

L19

E20

K21

R22

F23

A24

H25

R26

A27

GGC

CCC

GAG

CTG

GAG

AAG

CGG

TTC

GCT

CAC

CGC

GCG

H28

A29

V30

E31

N32

S33

P34

G35

F36

L37

G38

F39

CAC

GCG

GTC

GAG

AAC

TCC

CCG

GGT

TTC

CTC

GGC

TTT

Q40

L41

L42

R43

P44

V45

K46

G47

E48

E49

R50

Y51

CAG

CTG

TTA

CGT

CCG

GTC

AAG

GGT

GAA

GAA

CGC

TAC

F52

V53

V54

T55

H56

W57

E58

S59

D60

E61

A62

F63

TTC

GTG

GTG

ACA

CAC

TGG

GAG

TCC

GAT

GAA

GCA

TTC

Q64

A65

W66

A67

N68

G69

P70

A71

I72

A73

A74

H75

CAG

GCG

TGG

GCA

AAC

GGG

CCC

GCC

ATC

GCA

GCC

CAT

A76

G77

H78

R79

A80

N81

P82

V83

A84

T85

G86

A87

GCC

GGA

CAC

CGG

GCC

AAC

CCC

GTG

GCG

ACC

GGT

GCT

S88

L89

L90

E91

F92

E93

V94

V95

L96

D97

V98

G99

TCG

CTG

CTG

GAA

TTC

GAG

GTC

GTG

CTT

GAC

GTC

GGT

G100

T101

G102

K103

T104

A105

GGG

ACC

GGC

AAG

ACT

GCA
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Figure A. 1. FPLC chromatograph for purification of MhuD. The 280 nm absorbance
(black trace) and percentage of Buffer B (50 mM Tris, 350 mM NaCl, 500 mM
Imidazole pH 7.8, red trace) are plotted as function of buffer run through the column.
Numbers in boxes on top of the x-axis refer to fractions collected during FPLC.

A

B

C

D

Figure A. 2. MhuD was obtained as assessed by SDS-PAGE gel electrophoresis. From
left to right, the lanes correspond to: (A) FPLC fraction 2, (B) FPLC fraction 4, (C) FPLC
fractions 7-9, and (D) PageRuler Plus prestained protein ladder (Pierce).
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A

B

C

D

Figure A. 3. Purity of MhuD assessed by SDS-PAGE. (A) MhuD, (B) 1/10 dilution of
MhuD, (C) 1/100, dilution of MhuD, and (D) PageRuler Plus prestained protein ladder
(Pierce)

Figure A. 4. FPLC chromatograph for purification of uncleaved MhuDCH. The 280 nm
absorbance (black trace) and percentage of Buffer B (50 mM Tris, 350 mM NaCl, 500
mM Imidazole pH 7.8, red trace) are plotted as a function of buffer run through the
column. Numbers in boxes on top of the x-axis refer to fractions collected during FPLC.
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A

B

C

D

Figure A. 5. Uncleaved MhuDCH was obtained as assessed by SDS-PAGE gel
electrophoresis. From left to right, the lanes represent: (A) FPLC fraction 2, (B) FPLC
fraction 3, (C) FPLC fractions 5-7, and (D) PageRuler Plus prestained protein ladder
(Pierce).

Figure A. 6. FPLC chromatograph for purification of cleaved MhuDCH (Black Trace).
The 280 nm absorbance (black trace) and percentage buffer B (20 mM Tris, 500 mM
NaCl pH 8.0, red trace). Numbers in boxes on top of the x-axis refer to fractions collected
during FPLC.
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A

B

C

D

E

Figure A. 7. Cleaved MhuDCH was obtained as assessed by SDS-PAGE gel
electrophoresis. From left to right, the lanes correspond to: (A) FPLC fractions 3-5, (B)
FPLC fractions 8-11, (C) PageRuler Plus prestained protein ladder (Pierce), (D) FPLC
fractions 20-22, and (E) MhuDCH enterokinase reaction mixture prior to anion-exchange
chromatography.
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A

B

C

D

E

Figure A. 8. Purity of MhuDCH assessed by SDS-PAGE. (A) 1/100 dilultion of MhuDCH,
(B) 1/20 dilution of MhuDCH, (C) 1/10 dilution of MhuDCH, (D) Cleaved MhuDCH, and
(E) PageRuler Plus prestained protein ladder (Pierce)

Figure A. 9. ESI-MS of 30 uM cleaved MhuDCH in 50 mM Tris pH 7.4, 150 mM NaCl.
The observed molecular weight of 11,327 Da is in excellent aggrement with the expected
molecular weight 11,327 Da.
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Table A. 2. Soret band wavelength upon addition of 0.2, 1, 2 and 3 equivalents of heme
to MhuD.
Soret band, max (nm)
Heme Equivalents

Trial 1

Trial 2

Trial 3

Average

0.2

407

408

407

407

1

401

401

402

401

2

401

403

400

401

3

409

410

410

410

Table A. 3. Soret band wavelength upon addition of 0.2, 1, 2 and 3 equivalents of heme
to MhuDCH.
Soret band, max (nm)
Heme Equivalents

Trial 1

Trial 2

Trial 3

Average

0.2

408

408

408

408

1

401

399

399

400

2

395

395

395

395

3

394

393

394

394
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APPENDIX B: SUPPORTING INFORMATION FOR CHAPTER 3
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B.1 SUPPLEMENTAL EXPERIMENTAL
Spectral Analysis. The Abs-detected heme degradation by F23W MhuD was
analyzed at 412 nm to extract the rate of breakdown of heme to meso-hydroxyheme (k1)
using equation (B.1):1
𝐴𝑆𝑜𝑟𝑒𝑡 = (𝐴𝑆𝑜𝑟𝑒𝑡,0 − 𝐴𝑆𝑜𝑟𝑒𝑡,∞ )𝑒 −𝑘1𝑡 + 𝐴𝑆𝑜𝑟𝑒𝑡,∞

(B.1)

where, ASoret,0 is the absorbance at 0 min, ASoret,∞ is the final absorbance intensity at at ∞
min and k1 is the constant for heme monooxygenation. The decrease of the Soret band
absorption intensity versus time was fit to equation B.1 using GraphPad Prism 8.0 in
order to extract k1 and its standard error for each MhuD variant. For F23W MhuD, the
increase of 620 nm UV/Vis Abs feature was described by the following kinetic model:
𝜀𝑚ℎ

𝐴620 = 𝐴620,0 ∗ [𝑒 −𝑘1𝑡 + (

𝜀ℎ

) ∗ (𝑘

𝑘1
2 −𝑘1

) ∗ (𝑒 −𝑘1𝑡 − 𝑒 −𝑘2𝑡 )]

(B.2)
where A620,0 is the absorbance at 0 min, k1 is the rate constant for F23W MhuD-catalyze
heme monooxygenation determined from fitting the Soret band decrease to equation 1,
εmh is the molar extinction coefficient for meso-hydroxyheme, εh is the molar extinction
coefficient for heme, and k2 is the rate constant for heme dioxygenation. εh was
determined based upon the pyridine hemochrome assay.2 The change in absorbance at
620 nm versus time was fit to equation B.2 using GraphPad Prism 8.0 to extract k2, εmh,
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and their standard errors. Complete derivations of equations B.1 and B.2 are shown
below.
The heme degradation of heme to its final product can be given by equation (B.3):
𝑘1

𝑘2

𝐻𝑒𝑚𝑒 → 𝑀𝑒𝑠𝑜 − ℎ𝑦𝑑𝑟𝑜𝑥𝑦ℎ𝑒𝑚𝑒 → 𝑀𝑦𝑐𝑜𝑏𝑖𝑙𝑖𝑛

(B.3)

Simplifying equation (B.3) to express in terms of A, B and C, we get equation (B.4):
𝑘1

𝑘2

(B.4)

𝐴→ 𝐵 →𝐶

Derivation of equation (B.1). The rate of heme monoxygenation is given by a
psuedo-first order kinetics, because the rate is only proportional to the heme
concentration. The differential equation of A can be given by equation (B.5):
𝑑𝐴
𝑑𝑡

(B.5)

= −𝑘1 [𝐴]

Equation (B.5) can be organized as equation (B.6):
𝑑𝐴
[𝐴]

(B.6)

= −𝑘1 𝑑𝑡

Upon integration and simplification, equation (B.6) becomes equation (B.7):
[𝐴] = [𝐴]0 𝑒 −𝑘1𝑡

(B.7)

where [A]0 is the F23W MhuD-heme concentration at 0 min. As explained in the previous
paper1, in this situation, [A] does not react completely and does not reach zero, instead it
approaches a nonzero baseline at an infinite time (∞). For this the concentration of A can
be written as [A]∞. Thus equation (B.7) can be written as equation (B.8):
[𝐴] − [𝐴]∞ = ([𝐴]0 − [𝐴]∞ )𝑒 −𝑘1𝑡

(B.8)
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Using Beer’s law, equation (B.8) can be written in terms of Abs as given by equation
(B.9):
𝐴𝑆𝑜𝑟𝑒𝑡 = (𝐴𝑆𝑜𝑟𝑒𝑡,0 − 𝐴𝑆𝑜𝑟𝑒𝑡,∞ )𝑒 −𝑘1𝑡 + 𝐴𝑆𝑜𝑟𝑒𝑡,∞

(B.9)

Equation (B.9) was rewritten in GraphPad Prism 8.0 as equation (B.10) to fit the data
collected from Abs monitored heme degradation assay to extract k1.
(B.10)

Y = ((I − F) ∗ exp(−k1 ∗ X)) + F
where I and F are the Soret absorbance at 0 and ∞ min. Abs data was used to plot
absorbance at 412 nm (Y) as a function of time (X).

Derivation of equation (B.2). The differential equation for B from equation (B.4)
can be also written as equation (B.11):
𝑑𝐵
𝑑𝑡

(B.11)

= 𝑘1 𝐴 − 𝑘2 𝐵

The concentration of B from equation (B.4) can then be expressed as shown in equation
(B.12):3, 4
[𝐵] =

𝑘1 [𝐴0 ]
𝑘2 −𝑘1

(𝑒 −𝑘1𝑡 − 𝑒 −𝑘2𝑡 )

(B.12)

Using the Beer’s law, [B] and [Ao] can be expressed in terms of Abs as be given by
equation (B.13) and (B.14):
[𝐴] =

𝐴620,0

[𝐵] =

𝐴620,𝐵

(B.13)

𝜀ℎ

(B.14)

𝜀𝑚ℎ

Pluggin (B.13) and (B.14) into equation gives equation (B.15):
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𝜀𝑚ℎ

𝐴620,𝐵 = 𝐴620,0 (

𝜀ℎ

𝑘1

)(

𝑘2 −𝑘1

) (𝑒 −𝑘1𝑡 − 𝑒 −𝑘2𝑡 )

(B.15)

Also, equation (B.7) can be written in terms of equation (B.16):
𝐴620,𝐴 = 𝐴620,0 𝑒 −𝑘1𝑡

(B.16)

As the Abs spectra at 620 nm would have contribution from both A and B species,
equation (B.15) and (B.16) can be written in terms of A620, as given by equation (B.17):
𝐴620 = 𝐴620,0 [𝑒 −𝑘1𝑡 + (

𝜀𝑚ℎ
𝜀ℎ

) (𝑘

𝑘1
2 −𝑘1

) (𝑒 −𝑘1𝑡 − 𝑒 −𝑘2𝑡 )]

(B.17)

Equation (B.17) was rewritten in GraphPad Prism 8.0 as equation (B.18) to fit the data
collected from Abs monitored heme degradation assay to extract k2 and mh.
Y = A * ( exp (-k1 * X) ) + ( ( E / F) * (k1 / (k2 – k1) ) * ( exp (-k2 * X) – exp (-k2 * X) )
))

(B.18)

where, E and F are the molar extinction coefficients for F23W MhuD–mesohydroxyheme and MhuD–heme at 620 nm respectively, and A is the initial Abs intensity
at 620 nm. Abs data was used to plot absorbance at 620 nm (Y) as a function of time (X).
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Figure B. 1. FPLC chromatograph for purification of F23W MhuD. The 280 nm
absorbance (black trace) and percentage of Buffer B (50 mM Tris, 350 mM NaCl, 500
mM Imidazole pH 7.8, red trace) are plotted as a function of buffer run through the
column. Numbers in boxes on top of the x-axis refer to fractions collected during FPLC.
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Figure B. 2. F23W MhuD assessed by SDS-PAGE gel electrophoresis. From left to right,
the lanes represent: (A) FPLC fraction 2, (B) FPLC fraction 3, (C) PageRuler Plus
prestained protein ladder (Pierce), (D) FPLC fractions 4-6, (E) 1/100 dilution of fractions
4-6, (F) 1/20 dilution of fractions 4-6.

Figure B. 3. FPLC chromatograph for purification of W66F MhuD. The 280 nm
absorbance (black trace) and percentage of Buffer B (50 mM Tris, 350 mM NaCl, 500
mM Imidazole pH 7.8, red trace) are plotted as a function of buffer run through the
column. Numbers in boxes on top of the x-axis refer to fractions collected during FPLC.
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Figure B. 4. W66F MhuD assessed by SDS-PAGE gel electrophoresis. From left to right,
the lanes represent: (A) Lysate, (B) FPLC fraction 7, (C) FPLC fraction 10-11, (D)
PageRuler Plus prestained protein ladder (Pierce), (E) FPLC fractions 14-16, (E) 1/100
dilution of fractions 14-16, (F) 1/20 dilution of fractions 14-16.
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Figure B. 5. UV/Vis Assay of heme degradation by WT MhuD. Heme degradation by
WT MhuD (50 M WT MhuD‒heme, 50 mM KPi pH 6.0, 37oC) monitored at 0 (red
trace), 5 - 60 (Dotted gray) and 120 mins (blue trace).
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Figure B. 6. ESI-MS spectra of heme degradation by WT MhuD. Extracted Ion
chromatogram of 30 min sample from heme degradation by WT MhuD (50 M WT
MhuD‒heme, 50 mM Potassium Phosphate pH 6.0, 150 mM NaCl, 37oC). Peaks with
m/z 583, 611 and 616 were observed, likely corresponding to formation of biliverdin,
mycobilin and heme respectively.
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Figure B. 7. MS/MS spectrum of hemin chloride. Two major daughter fragments of m/z
557 and m/z 498 is observed corresponding to loss of CH2COOH (red dotted line) and
(CH2COOH)2 (blue dotted line) respectively.

Figure B. 8. MS/MS spectrum of m/z 611 peak. The fragment ions observed during
MS/MS of m/z 611 parent ion are color matched to their corresponding fragments and
can be traced back to mycobilin.
204

Figure B. 9. MS/MS spectrum of m/z 583 peak. The fragment ion of m/z 297 matches up
with the loss of the fragment denoted by a red dotted line in the biliverdin structure
above.

Figure B. 10. ESI-MS spectrum of hemin chloride degradation. Control assay of 50 M
hemin chloride, 50 mM Potassium Phosphate pH 6.0, 150 mM NaCl, 37oC performed in
the presence of 5 mM ascorbate, 10 mM EDTA, 840 U/mL of catalase and 167 U/mL of
Superoxide Dismutase (SOD).
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Figure B. 11. WT MhuD MS/MS chromatogram of m/z 583. Four peaks corresponding
to parent ion of m/z 583 is observed when the heme degradation sample at 120 min by
WT MhuD was analyzed by LC-MS/MS. MS2 fragments (Figure 6) were used to identify
each peak, where the isomers of biliverdin eluted in following order:  (38.7
min)  (39.0 min)  (39.4 min) and  (40.2 min) (as shown above).
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Figure B. 12. F23W and W66F MhuD MS/MS chromatogram of m/z 583. Peaks
corresponding to parent ion of m/z 583 observed when heme degradation sample at 120
min by F23W (top) and W66F (bottom) MhuD were analyzed by LC-MS/MS. MS2
fragments of m/z 583 were used to identify the peaks.  (39.2 min)  (39.6 min) and biliverdin (40.0 min) isomers were identified for F23W MhuD, whereas,  (39.1 min)
and -biliverdin (39.9 min) isomers were identified for W66F MhuD.
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Figure B. 13. Rate of heme degradation by F23W MhuD. 412 nm peak was monitored
during the heme degradation by F23W MhuD as a function of time and fitted using a
pseudo first order kinetic model described in equation (1). The fitting gave a rate 0.0253
± 0.0002 min-1 for heme monoxygenation reaction (k1), with a R2 of 0.9927. Black dots
represent the experimental data and the purple line represents the fitted data.
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Figure B. 144. Rate of heme monooxygenation by F23W, WT and W66F MhuD.
Decrease of Soret band at 37oC was monitored during the heme degradation by F23W,
WT and W66F MhuD as a function of time and fitted using a pseudo first order kinetic
model described in equation (1). The fitting gave a rate 0.15072 ± 0.01882 min-1 for
F23W, 0.07956 ± 0.00520 min-1 for WT and 0.00481 ± 0.00362 min-1 for W66F MhuD
(Table 2.1). The solid line represents the fitted data for the respective variants.
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C.1 SUPPLEMENTAL EXPERIMENTAL
Table C. 1. R26S MhuD gene sequence.
M1
ATG

P2
CCA

V3
GTG

V4
GTG

K5
AAG

I-6
ATC

N7
AAC

A8
GCA

I9
ATC

E10
GAG

V11
GTG

P12
CCC

A13
GCC

G14
GGC

A15
GCT

G16
GGC

P17
CCC

E18
GAG

L19
CTG

E20
GAG

K21
AAG

R22
CGG

F23
TTC

A24
GCT

H25
CAC

S26
AGC

A27
GCG

H28
CAC

A29
GCG

V30
GTC

E31
GAG

N32
AAC

S33
TCC

P34
CCG

G35
GGT

F36
TTC

L37
CTC

G38
GGC

F39
TTT

Q40
CAG

L41
CTG

L42
TTA

R43
CGT

P44
CCG

V45
GTC

K46
AAG

G47
GGT

E48
GAA

E49
GAA

R50
CGC

Y51
TAC

F52
TTC

V53
GTG

V54
GTG

T55
ACA

H56
CAC

W57
TGG

E58
GAG

S59
TCC

D60
GAT

E61
GAA

A62
GCA

F63
TTC

Q64
CAG

A65
GCG

W66
TGG

A67
GCA

N68
AAC

G69
GGG

P70
CCC

A71
GCC

I72
ATC

A73
GCA

A74
GCC

H75
CAT

A76
GCC

G77
GGA

H78
CAC

R79
CGG

A80
GCC

N81
AAC

P82
CCC

V83
GTG

A84
GCG

T85
ACC

G86
GGT

A87
GCT

S88
TCG

L89
CTG

L90
CTG

E91
GAA

F92
TTC

E93
GAG

V94
GTC

V95
GTG

L96
CTT

D97
GAC

V98
GTC

G99
GGT

G100
GGG

T101
ACC

G102
GGC

K103
AAG

T104
ACT

A105 TE106 G107
GCA TAA GGT

V108
GTA

P109
CCA

R110
CGA

G111
GGT

K112
AAG

L113
CTT

A114
GCG

A115
GCC

A116
GCA

L117
CTC

H120
CAC

H121
CAC

H122 H123
CAC CAC

H124
CAC
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E118
GAG

H119
CAC

Figure C. 1. FPLC Chromatograph for purification of R26S MhuD. The 280 nm
absorbance (black trace) and percentage of Buffer B (20 mM Tris, 200 mM NaCl pH 8.0,
red trace) are plotted as function of buffer run through the column. Number in boxes on
top of the x-axis refer to fractions collected during FPLC.
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A

B

C

D

E

F

Figure C. 2. R26S MhuD was obtained as assessed by SDS-PAGE gel electrophoresis.
From left to right, the lanes represent: (A) Fraction 8 and 9 pooled, (B) 1/10 dilution of
R26S MhuD, (C) 1/100 dilution of R26S MhuD, (D) Fraction 10, (E) Fraction 12, (F)
PageRuler Plus pre-stained protein ladder (Pierce).
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Table C. 2. Gaussian fit results of the Soret band for WT, F23W, F23A and R26S
MhuD-heme-CN.
Variant of

Area

MhuD

Height (M-1

FWHM

cm-1)

(cm-1)

WT

-5.4015 X 106

-6650.91

+/- 0.06

763

+/- 50

F23W

-1.2902 X 106

-1486.93

+/- 0.06

820

+/- 50

R26S

-5.6514X 106

-8006.30

+/- 0.06

663

+/- 50
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D.1 SUPPLEMENTAL EXPERIMENTAL
Table D. 1. F23W IsdG primer sequence
Primer

Sequence

Forward

5'-aatcccatgtctcgtgtaccatcgttctataatatcttttgctgttcctttt-3'

Backward

5'-aaaaggaacagcaaaagatattatagaacgatggtacacgagacatgggatt-3'

Table D. 2. F23W IsdG gene sequence.
M-22
ATG
D-12
GAT
Q-2
CAG
R8
AGG
D18
GAT
G28
GGG
M38
ATG
D48
GAT
W58
TGG
L68
TTA
K78
AAA
S88
AGT
T98
ACA

G-21
GGT
I-11
ATC
S-1
TCG
L9
CTG
I19
ATT
I29
ATT
F39
TTT
F49
TTT
K59
AAA
K69
AAA
H79
CAT
S89
AGC
Y99
TAT

H-20
CAT
P-10
CCA
T-0
ACC
T10
ACG
I20
ATA
E30
GAA
V40
GTT
D50
GAT
S60
TCA
S70
TCT
V80
GTT
P90
CCG
D100
GAT

H-19
CAT
T-9
ACG
M1
ATG
L11
TTA
E21
GAA
T31
ACA
T41
ACA
E51
GAA
K61
AAG
D71
GAT
R81
AGA
I91
ATT
I101
ATA

H-18
CAT
T-8
ACC
K2
AAA
T12
ACA
R22
CGA
L32
TTA
Q42
CAA
V52
GTG
Q62
CAA
V72
GTC
S82
AGT
I92
ATA
G102
GGC

H-17
CAT
E-7
GAA
F3
TTT
K13
AAA
W23
TGG
E33
GAA
T43
ACT
K53
AAA
A63
GCT
F73
TTT
K83
AAA
N93
AAT
Y103
TAT
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H-16
CAT
N-6
AAC
M4
ATG
G14
GGA
Y24
TAC
G34
GGC
L44
TTA
I54
ATT
F64
TTT
K74
AAA
N84
AAT
N94
AAC
S104
AGT

H-15
CAC
L-5
CTG
A5
GCA
T15
ACA
T25
ACG
F35
TTT
E45
GAA
L55
TTA
T65
ACG
A75
GCA
E85
GAA
K95
AAA
Y105
TAC

D-14
GAT
Y-4
TAT
E6
GAA
A16
GCA
R26
AGA
D36
GAT
Q46
CAA
T56
ACA
D66
GAT
A76
GCG
D86
GAT
V96
GTA
M106
ATG

Y-13
TAC
F-3
TTT
N7
AAT
K17
AAA
H27
CAT
G37
GGC
E47
GAA
V57
GTT
W67
TGG
H77
CAT
E87
GAA
I97
ATT
K107
AAA

Figure D. 1. FPLC chromatograph for purification of F23W IsdG. The 280 nm
absorbance (black trace) and percentage of Buffer B (50 mM Tris pH 7.4, 150 mM NaCl,
500 mM Imidazole, red trace) are plotted as function of buffer run through the column.
Number in boxes on top of the x-axis refer to fractions collected during FPLC.
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E
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H

Figure D. 2. F23W IsdG was obtained as assessed by SDS-PAGE gel electrophoresis.
From left to right, the lanes represent: (A) FPLC fractions 3-4, (B) FPLC fractions 9-12
(uncleaved F23W IsdG), (C) Cleavage reaction of uncleaved F23W IsdG with TEV, (D)
PageRuler Plus pre-stained protein ladder (Pierce), (E) Cleaved F23W IsdG, (F) 1/100
dilution of E, (G) 5/100 dilution of E, (H) 1/10 dilution of E.
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Figure D. 3. ESI-MS of uncleaved F23W IsdG in 50 mM Tris pH 7.4, 50 mM NaCl. The
observed molecular weight of 15,258 g/mol is consisted with the calculated molecular
weight of 15,257 g/mol.

Figure D. 4. ESI-MS of cleaved F23W IsdG in 50 mM Tris pH 7.4, 50 mM NaCl. The
observed molecular weight of 12776 g/mol for cleaved F23W IsdG is consistent the His6
tag cleaved F23W IsdG.
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Figure D. 5. UV CD spectra of apo F23W IsdG (solid green with star) in 10 mM
potassium phosphate buffer pH 7.4. The UV CD spectra of apo F23W IsdG is fitted using
DichroWeb CDSSTR (reference set 4) algorithm.1-4

Table D. 3. Secondary structure analysis by UV CD for F23W IsdG using the fitting
method in Figure D.5. and compared that to WT IsdG.
Species

Percent −helices

Percent −sheets

WT IsdG

9.0

35.0

F23W IsdG

10.0

35.0
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Figure E. 1. ESI-MS spectrum of the top organic layer. The m/z 644 (heme dimethyl
ester) along with other impurities are observed.
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Figure E. 2. ESI-MS spectrum ESI-MS spectrum of the dimerized sample collected in
the mobile phase of 98% acetonitrile with 0.1% formic acid (v/v) in water (v/v). The m/z
644.3 corresponding to heme dimethyl ester is observed, along with a possible adduct ion
at m/z 712.3. But peak of m/z ~1305 corresponding to –oxo–bis(heme dimethyl ester) is
missing.
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Figure E. 3. ESI-MS spectrum of dimerized sample with no proton source (100%
acetonitrile used as a mobile phase). Peaks of m/z 1343 and m/z 718 are observed. The
m/z 1343 may be the –oxo–bis(heme dimethyl ester) with a potassium adduct ion (+K,
m/z 38) and the m/z 718 may be heme dimethyl ester with two potassium adduct ions
(2K-H, m/z 76).
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Figure E. 4. APCI-MS spectrum of dimerized sample with no proton source (100%
acetonitrile used as a mobile phase). Peaks of m/z 1305.6 and m/z 644.2 are observed,
corresponding to –oxo–bis(heme dimethyl ester) and heme dimethyl ester, respectively.
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Figure E. 5. UV/Vis absorbance spectra of freshly eluted isomeric mixture of mesobenzoyloxyprotoporphyrin IX dimethyl ester (solid red) and a week old eluted isomeric
mixture of meso-benzoyloxyprotoporphyrin IX dimethyl ester (dashed blue). Emergence
of a peak at 666 nm is observed in the old sample.
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